annual report proud work respiratory portfolio know important medicine live patient julie gsk respiratory packaging operator ware ukoverview significant year gsk challenge reflect trading performance pleased group respond standout event year propose threepart transaction novartis accelerate strategy make gsk simple strong balanced platform longterm growth sir andrew witty chief executive officer read ceo statement performance summary group turnover core operate profitb total operating profit return shareholder cera cera cer dividend share buyback core earning shareb total earning share new molecular new product sale primarily reflect entity phase iii noncash adjustment access medicine index country fully company file regulatory dow jones sustainability index implement new sale approval malaria vaccine score put force compensation model candidate pharmaceutical sector xcluding divestment complete reconciliation number adjust measure report performance core result exclude divestment complete total result business measure define reconciliation set core result total result set cover story julie picture gsk deliver medicine lead year work respiratory training programme cover quality packaging operator manufacture safety patient impact help site ware year employee appreciate importance role help ensure gsk respiratory medicine million lifesave medicine copd adult child asthma ventolin seretide julie people recently new medicine gsk help remain leader administer ellipta inhaler respiratory medicine year relvarbreo anoro incruse arnuity continuously strive generate high quality scientific insight help develop new available patient world medicine inhaler meet need need patient launch new julie gsk respiratory key julie role help colleague respiratory medicine past year packaging operator gsk understand patient previous year combine ware end supply chain offer great choice healthcare critical contribution employee professional patient gsk annual report mission gsk mission content strategic report improve quality human chairman statement ceo statement life enable people global marketplace feel well live long business model strategic priority perform risk management business develop innovative responsible business group financial review product improve access healthcare governance remuneration patient world board corporate executive team chairman letter board report shareholder committee report remuneration report chairman annual statement annual report remuneration remuneration policy report financial statement director statement responsibility independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap investor information quarterly trend year record product development pipeline product competition intellectual property risk factor share capital share price dividend tax information shareholder annual general meeting law regulation shareholder service contact glossary term cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result accordance legal regulatory obligation include list rule disclosure transparency rule financial conduct authority group undertake obligation update forwardlooke statement result new information future event reader consult additional disclosure group document publish andor file sec reader locate note disclosure accordingly assurance give particular expectation meet shareholder caution place undue reliance forwardlooke statement forwardlooke statement subject assumption inherent risk uncertaintie relate factor group control precise estimate group caution investor number important factor include document cause actual result differ materially express imply forwardlooke statement factor include limit discuss risk factor page annual report forwardlooke statement behalf group speak date base knowledge information available director date annual report find wwwgskcom number adjust measure report performance business measure define reconciliation core result total result set gsk annual report gsk annual report strategic report governance remuneration financial statement investor information chairman statement behalf board please risk management commitment return report see good progress ethical behaviour group strategy building board aim assure integrity shareholder diversify business deliver gsk business operation product value simplify rigorous process system remain key operating model year risk management key board discussion notwithstanding recognise priority fundamental change trading audit risk committee play critical environment group operate role oversee issue challenge board particularly face management team include impact performance resolution investigation set dividend board continue believe chinese authority business management team place illegal activity gsk china share appropriate strategy respond clear breach gsk governance challenge compliance procedure wholly contrary value standard increase board particularly pleased expect gsk employee approve propose threepart implement substantial change transaction novartis chinese business consequence transform future shape group make balanced provide board expect group remain well opportunity broadly base sale vigilant compliance issue fully growth delight shareholder support management effort overwhelmingly vote favour encourage employee concern transaction december speak investigate allegation continue invest return shareholder remain key improved procedure priority board management team despite challenge trading doubt commercial success environment focus cost financial directly link operate responsible efficiency allow board way meet change expectation set dividend share society respect board increase year expect support action management maintain dividend share take delink compensation sale return billion net proceed representative number propose novartis transaction prescription write board appropriate approval gain recognise industry lead work group fundamentally total billion change relationship return shareholder doctor customer remove dividend share buyback perception conflict interest forward look approach exemplify work world malaria vaccine await news regulator effort global response ebola crisis example dedication skill expertise gsk real difference people live worldwidegsk annual report strategic report governance remuneration financial statement investor information board diversity male female year effort improve succeed nomination prospect corporate reporting incorporate committee chairman january closing behalf board information responsible lead refreshment board like thank sir andrew executive business approach performance reflect requirement future team continue commitment annual report reshape group continue challenge year align principle provide sir philip committee demonstrate ability integrate reporting addition support continuity stand deliver group strategy responsible business supplement board agm report chairman publish march provide detail welcome sir philip gsk like thank topic set progress board please announce shareholder support group october urs rohner join tenure time chairman responsible business commitment board nonexecutive director see change governance remuneration effect january progress delivery chairman commit gsk bring great value board company organisation effort seek operate high standard experience chairman credit suisse improve access medicine corporate governance independent group broad business evolution commercial model evaluation undertaken board background couple strong committee pleased commitment shareholder return like thank sir deryck maughan result positive agreeing remain board look forward integration confirm board operate additional year senior independent new element follow completion effective manner director assist transition role propose threepart novartis remuneration committee chairman sir philip transaction restructuring operate accordance bind utilise considerable experience innovation come pipeline remuneration policy receive knowledge gsk business provide remain confident gsk deliver overwhelming shareholder support continuity balance considerable longterm value agm report find return shareholder thank je ulrich dedicated service board jing board change composition decide seek reelection agm number change finally tom swaan stand board year agm year valuable follow extensive rigorous committed service include search sir philip hampton appoint exemplary chairmanship audit risk successor sir philip join remuneration committee sir christopher gent board nonexecutive director like thank tom advice chairman start january deputy support year wish chairman april chairman future end agm sir philip bring enormous expertise board include chair number global company operate complex highly regulate environment gsk annual report strategic report governance remuneration financial statement investor information ceo statement reshape trading performance challenge propose gsk help deliver sustainable pharmaceutical vaccine sale sale earning performance grow emerge market threepart increase innovation product japan europe flat well access medicine offset sale decline transaction patient worldwide result continue pricing contracting pressure particularly mark progress novartis respiratory business objective notably propose innovative threepart transaction work hard improve fundamentally novartis fundamentally formulary position coverage reshape company major step reshape group fulfil strategy create starting early encourage simple strong balanced sign help regain market major step platform longterm growth share deliver improve performance respiratory addition continue trading condition continue good progress transition fulfil challenge particularly primary new portfolio respiratory medicine care market lead sale year recently launch new product strategy decline cer billion incruse ellipta copd arnuity core earning share cer ellipta asthma await regulatory sale pressure decision mepolizumab potentially mitigate delivery cost important product financial efficiency continue return shareholder priority hiv viiv healthcare grow year increase dividend sale tivicay triumeq reach share expect hold million launch level product good class future success group underpin organisation performance consumer healthcare continue productive business impact supply addition substantial advanced issue sale year fall pipeline large number increase quarter exciting early phase asset key follow progress remediation therapeutic area rapidly issue expect increase benefit move forward clinic improve supply situation remain confident keep pace outlook business innovation business model continue evolve relationship reshape company doctor customer ensure sustainable future meet societys expectation april announce propose global pharmaceutical company innovative threepart transaction novartis acquire vaccine business form joint consumer healthcare company sell novartis market oncology product exclude divestment complete gsk annual report strategic report governance remuneration financial statement investor information propose transaction addition organic programme operate emerge market substantial global scale consumer propose novartis transaction especially challenging give issue healthcare business allow target synergie billion country face fund market leader country year fifth year follow maturity respective healthcare number company completion identify system continue believe worldwide overthecounter medicine billion annual cost saving robust compliance system deliver year work closely local government currently world lead reshape pharmaceutical presence market help vaccine manufacturer propose organisation improve access medicine broad transaction strengthen position healthcare allow expand portfolio business remain cash generative notably meningitis build net cash inflow operation broaden access medicine geographic reach particularly billion enable broad possible access bring expertise virology impact global currency fluctuation medicine remain priority bacterial infection research particularly strength sterling delight top half access medicine index selling market oncology asset fourth consecutive time well novartis billion realise evolution business model demonstrate commitment innovation attractive price make financial saving access business fast grow restructure programme work vaccine malaria subscale benefit seek modernise way work file rapid establish oncology company continue response ebola crisis working challenge expect complete propose candidate ebola vaccine agenda transaction week commence able achieve month march substantial progress rolling take year change compensate pay tribute gsk involve sustainable pipeline sale representative change build project support future growth reform start year outlook year ago please organisation exceptional look focused recent healthcare practitioner period productivity successful execution strategic satisfaction research showing gsk achieve fda approval priority close propose novartis rank new molecular entity nme transaction clearly key alongside peer group value bring company consolidate build early practitioner work progress see respiratory follow approval receive add fully successfully launch new respiratory product breo ellipta implement commitment stop product need ensure anoro ellipta tafinlar mekinist pay doctor speak behalf consumer healthcare business continue oncology tivicay hiv instead deliver new multichannel recover supply issue receive approval system transform doctor incruse ellipta arnuity ellipta sale headwind face receive information respiratory triumeq hiv tanzeum group continue adversely type diabetes undertake reform affect performance ensure patient great impact half year await fda decision breo eliminate perception annualisation ellipta use asthma mepolizumab conflict interest believe factor successful execution firstinclass antiil treatment change right thing priority expect strong performance severe eosinophilic asthma continue competitive second half year significant organic pipeline delivery advantage follow initiative year expect phase make decision clinical trial datum transparency iii start undertake minority initial company make public offering viiv healthcare advanced pipeline significant clinical study result available potential example vaccine addition follow closure operating value prevent shingle triple combination propose novartis transaction plan operate important therapy copd new long act hold investor day issue deliver financial performance hiv treatment cabotegravir addition specific earning guidance year issue see china year number exciting profile medium longterm shape wholly disappointing cause early stage asset therapy area opportunities gsk harm group reputation immunoinflammation immunooncology take significant step rectify issue finally like thank cardiovascular disease number identify chinese business employee partner supplier prophylactic therapeutic vaccine apply appropriate lesson operation continue commitment support candidate give complexity cost control financial efficiency sector challenge work remain focused cost control global healthcare continue improve financial efficiency face risk year deliver million incremental saving compare restructuring initiative ongoing cost reduction effort sir andrew witty chief executive officer gsk annual report strategic report governance remuneration financial statement investor information business sciencele global healthcare company research develop innovative pharmaceutical vaccine consumer healthcare product global reach structure significant global commercial turnover region primary area presence market business commercial operation network manufacturing site structure combination country large centre regional unit area focus usa belgium china business benefit gsk global commercial infrastructure reshaped global international supply network innovative footprint improve access high growth significant scale potential market include usa asia pacific latin america japan pharmaceuticals vaccine operate europe emerge market combine business geographical japan segment consumer healthcare global unit viiv healthcare specialist hiv company majority pfizer shionogi group turnover cera employee region shareholder trading turnover include canada puerto rico australasia central vaccine tender sale contract manufacturing sale employee turnover segment exclude divestment complete usa pharmaceuticals vaccines europe emerge market japan europe emerge market japan viiv healthcare establish product trading consumer healthcare research sustain grow business consumer healthcare business investment people underpin science development work role group innovation launch spend billion new market product include noncoreb item billion total sensodyne true white horlick search develop innovative medicine variation vaccine consumer product core expenditure pharmaceutical allocation new molecular entity phase core expenditure phase iii therapeutic area pharmaceutical respiratory immunoinflammation vaccine hiv cardiovascular disease consumer healthcare vaccine currently phase iiii calculation core result noncore item set preclinical phase nmes prevent shingle hepatitis novel mechanism action respiratory syncytial virus exacerbation copd malaria ebolagsk annual report strategic report governance remuneration financial statement investor information pharmaceutical pharmaceutical business develop make medicine treat broad range acute chronic disease portfolio innovative establish medicine lead global position respiratory disease hiv read sale therapy area respiratory oncology cardiovascular metabolic urology total turnover immunoinflammation pharmaceutical viiv healthcare hiv establish product group turnover vaccine vaccine business large world broad portfolio paediatric adolescent adult travel vaccine distribute approximately million dose country read sale product line infanrixpediarix boostrix cervarix total turnover fluarix flulaval hepatitis rotarix synflorix group turnover consumer consumer healthcare business large world drive science value develop market product category healthcare wellness oral health nutrition skin health brand available country read sale category wellness oral health nutrition total turnover skin health group turnover gsk annual report strategic report governance remuneration financial statement investor information global marketplace opportunity challenge demand medicine healthcare treatment remain strong coming year global economic review consumer healthcare market emphasis cost lead increase global economy grow gsk operate estimate pricing pressure competitive intensity slightly worth billion project private marketplace grow annum public programme make recovery uneven yearsc essential manufacturer region growth major demonstrate value medicine economy strong grow global trend impact healthcare vaccine bring patient market economic growth change healthcare system usa grow demographic emerge market develop innovative product offer growth weak euro area increase demand healthcare product significant improvement exist japan demand expect grow option access healthcare remain significantly fast market key priority evidence initiative long term mature emerge market show strong new health insurance marketplace market country rich economic growth develop market expansion medicaid programme increase consumption food alcohol continue longterm trend financial penalty people tobacco combine exercise china show robust growth purchase insurance lead growth chronic disease compare americans access respiratory cardiovascular low income country continue grow healthcare coverage access medicine disease europe rise public debt robust pace example growth continue challenge government austerity programme continue subsaharan africa patient healthcare system create pressure healthcare spending include private marketplace focus cost value global healthcare market lead payer reduce price restrict europe global pharmaceutical market access demand differentiate europe european medicine agency continue grow sale product manufacturer develop ema regulate new medicine billion jansep innovative product offer significant issue positive opinion billion jansep cera improvement exist option recommend marketing authorisation medicine contain new active north america remain large globally population age take substance pharmaceutical market share increasingly active role manage global sale health create demand give public funding healthcare europe show slight decline healthcare product rise individual country continue pressure period empowerment grow expectation government budget lead flat emerge market asia pacific society mean patient reduce investment healthcare continue represent global consumer want healthcare company pharmaceutical europe spending sale japan represent operate high standard order hospital medicine increase previous yeara build trust drive increase use oncology biological product decrease global vaccine market pricing regulation primary care highpriced medicine increase billionb prescription medicine vaccine generate significant public debate market expect continue highly regulated ensure patient user particular focus oncology grow represent billion access safe effective medicine treatment hepatitis individual government determine product market country inequality access medicine stateregulate system european country total global sale medicine govern product pricing patient population remain significant regiona concern despite debate usa new pricing approach reduce food drug administration fda approve new medicine inequality concrete progress limit practical challenge approve novel medicine parallel trade international reference increase pricing remain year ema healthcare landscape usa launch adaptive pathway pilot undergo substantial change help accelerate patient access valuable strong focus improve quality new medicine country include control cost impact france consider particularly significant issue unilaterally usa create challenging condition europe industry emerge market asia pacific japan footnote reference im datum jansep reference evaluatepharma reference ims evaluatepharma internal analysismacroeconomic social trend population growth ageing population rapid technological advance rise individual empowerment rise public debt western market economic growth emerge market climate change resource depletion lifestyle change global competition talent opportunity challenge healthcare sector strategic response gsk annual report strategic report governance remuneration financial statement investor information respond longterm global opportunity challenge change lifestyle lead new disease burden rise public debt lead pressure healthcare spend grow demand emerge market payer focus value lead demand differentiate product age population lead increase demand rise individual empowerment meeting healthcare societys grow expectation emerge market key focus create innovative product reshape business enhance commit develop innovative new product access highgrowth market asia pacific offer significant improvement exist treatment latin america japan emerge market sale focus research effort area grow turnover today science present good opportunity address unmet medical need preclinical phase nmes novel mechanism action address affordability change work healthcare professional commit tackle affordability barrier modernise work healthcare develop country cap price professional hcp ensure action patent medicine vaccine price interest patient sale staff directly charge develop country develop market interact prescribing hcp incentivise pioneer novel reimbursement approach knowledge expertise business performance widen access new medicine price individual sale target stop current treatment direct payment hcp speak medicine vaccine gsk annual report strategic report governance remuneration financial statement investor information global marketplace opportunity challenge continue adoption new vaccine remain intellectual property consumer healthcare product slow country coverage patent protection development timeline consumer rate vary significantly journey scientific breakthrough healthcare product shorter approve new medicine vaccine pharmaceutical vaccine japan take year incur significant intellectual property protection japan pharmaceutical medical cost ensure reasonable return available importance device agency pmda regulate new investment researchbase healthcare effectiveness different consumer medicine approve april company rely protection healthcare product cover december intellectual property patent national regulation test april japanese ministry right approval manufacturing labelling health labour welfare conduct marketing advertising patent generally year term biyearly review pricing medicine filing challenge consumer healthcare product strong result reduction exclude expire case legal reliance brand loyalty trade mark impact consumption tax increase proceeding legal proceeding protection create value especially national health note financial statement emerge market brand play important insurance pricing scheme base role business lead government market price survey patent expiry early loss patent brand include sensodyne panadol lead availability generic premium new drug development horlick polident paradontax tum version product introduce trial eno niquitinnicorette abreva zovirax cheap generic manufacturer basis remain place aquafresh brand typically incur significant cost distinct heritage horlick emerge market develop market generic rapidly year old eno year old emerge market prescription capture large share market market medicine regulate variety erosion emerge market competition way approval process automatic substitution method competition prescription product continue evolve align develop patient come company research closely usa europe japan quality safety concern make patentprotected medicine term format content prefer establish medicine brand indication treat similar disease country china india medicine principal research market operate russia vietnam nigeria require base pharmaceutical vaccine intellectual property right particularly local clinical datum order fulfil competitor include abbvie amgen patent datum protection regulatory requirement astra zeneca bayer bristolmyers squibb enforceable government seek eli lilly johnson johnson merck economic growth change control price increase access novartis novo nordisk pfizer roche demographic market medicine limit right holding sanofi takeda increase demand healthcare product example india brazil argentina demand expect grow significantly implement consider main consumer healthcare fast market long practice restrict availability competitor include colgatepalmolive term mature market patent addition country johnson johnson procter gamble consider widespread use reckitt benckiser novartis government region compulsory license individual list continue seek way improve access company use another patent healthcare time addition locally operate consent pay patent manage healthcare expenditure include company compete gsk owner set fee licence spending medicine country certain market indonesia china india look vaccine biological product expand population cover currently face degree governmentfunde health scheme generic competition partly increase opportunitie high complex research manufacturing volume tender impact pricing process compare medicinesgsk annual report strategic report governance remuneration financial statement investor information business model create value success depend ability research develop innovative healthcare product accessible people possible resource business operate output model mission pharmaceutical benefit patient underpin discover customer develop innovative value healthcare product financial return people vaccine manufacture profit cashflow financial resource make shipping quality product strategic priority world shareholder value partnership consumer healthcare commercialisation expertise distribution wide benefit society improve access product reinvestment mission improve quality operating model output human life enable people innovation key success develop innovative product feel well live long transform organisation maximise access deliver direct recent year agile benefit patient consumer resource medicine approve deliver mission align successfully lead healthcare company resource strategic priority profitable sustainable performance development turn allow generate value depend expertise implement different way return shareholder enable enthusiasm employee support example open reinv business patient embrace new way work forge access expertise facility consumer continue benefit partnership offer fresh insight intellectual property good combat world collaborate external wide society benefit healthcare challenge organisation healthy people communitie essential building strong sustainable expect value bring innovation patient society create value make heart decision make consumer manufacture billion direct indirect economic social mean act transparently respectfully product highquality standard contribution country integrity put supply country operate tax employment interest patient consumer worldwide charitable support deliver success commercial success depend important achieve market presence customer understanding good progress expand access seek strategic priority establish product accessible country grow diversified global business level income development deliver product value develop country simplify operating model include cap price develop market level reduce business price highvolume contract sciencele healthcare develop market pioneer company operate main area novel reimbursement approach widen pharmaceutical vaccine access new medicine price consumer healthcare current treatment gsk annual report strategic report governance remuneration financial statement investor information strategic priority deliver strategy design increase growth reduce risk improve longterm financial performance strategic priority progress progress key challenge key performance priority grow total group sale broadly stable propose major threepart transaction increase pricing pressure implement propose transaction despite significant sale loss novartis bolster vaccine consumer market change competitor novartis diversify business generic competition healthcare business announce dynamic contracting improve commercialisation new aim create balanced diversification deliver organic growth transition new respiratory portfolio continue pricing pressure europe group turnover respiratory hiv consumer business product portfolio emerge market sale underway launch relvarbreo government austerity programme healthcare product capable deliver sustainable turnover today ellipta anoro ellipta incruse ellipta unanticipated supply continuity drive growth emerge market sale growth centre billion return pay shareholder arnuity ellipta challenge consumer healthcare business business area pharmaceutical include billion dividend viiv healthcare sale vaccine consumer healthcare billion buyback dividend successful launches tivicay triumeq core earning share capitalise product supply resumption consumer healthcare business reconciliation core result total result set deliver create agile productive significant new product approval disappointing phase iii result continue progress midstage pipeline organisation product respiratory disease hiv diabete mage darapladib programme phase iiiii start expect product value approval healthcare malaria candidate vaccine rtss integrate propose novartis vaccine company aim research develop submit regulatory approval new product approval major market pipeline high quality product offer improve investment rate return valuable improvement treatment positive phase iii study result patient consumer shingle candidate vaccine hzsu healthcare provider pharmaceutical vaccine new molecular entity phase iii simplify billion cumulative annual cost million incremental saving unanticipate supply continuity execute pharmaceutical restructuring saving deliver range deliver restructuring initiative challenge consumer healthcare programme save billion annum operating model restructure programme ongoing cost reduction year complexity roll new system aim reflect reduce complexity dispose global enterprise resource planning scale market day increase work capital continue streamline product portfolio business change transform noncore brand integrate supply system erp roll market embed common process operate reduce complexity chain business continue rollout erp system efficient introduce new workplace efficiency speed decision make execute restructure programme free resource reinvest business cumulative annual saving related propose novartis transaction restructuring programme save billion annum fifth year close adjusted exclude divestment complete impact intangible asset impairment responsible relentless focus access healthcare collaborate partner accelerate rebuilding business china follow continue enhance governance business access medicine index development ebola vaccine candidate criminal conviction china affiliate compliance quality proactive violation chinese law risk management qualityled culture deliver global rollout new sale force responsible business evolve commercial model compensation approach meeting value chain carbon emission deliver new commercial model globally central strategy change way work target sale product change way work hcp launch new africa strategy reach deliver success important healthcare professional incentive high carbon footprint ventolin subsaharan african improve leadership effectiveness achieve sale force increase develop country population quality talent ensure value embed lead increase transparency clinical early extend price continue progress development culture decision make trial datum company sign freeze commitment year ebola vaccine candidate help well meet alltrial campaign gavigraduate country expectation societygsk annual report strategic report governance remuneration financial statement investor information strategic priority progress progress key challenge key performance prioritie total group sale broadly stable propose major threepart transaction increase pricing pressure implement propose transaction despite significant sale loss novartis bolster vaccine consumer market change competitor novartis generic competition healthcare business announce dynamic contracting improve commercialisation new diversification deliver organic growth transition new respiratory portfolio continue pricing pressure europe group turnover respiratory hiv consumer emerge market sale underway launch relvarbreo government austerity programme healthcare product turnover today ellipta anoro ellipta incruse ellipta unanticipated supply continuity drive growth emerge market billion return pay shareholder arnuity ellipta challenge consumer healthcare business include billion dividend viiv healthcare sale billion buyback dividend successful launches tivicay triumeq core earning share capitalise product supply resumption consumer healthcare business reconciliation core result total result set create agile productive significant new product approval disappointing phase iii result continue progress midstage pipeline organisation product respiratory disease hiv diabete mage darapladib programme phase iiiii start expect approval healthcare malaria candidate vaccine rtss integrate propose novartis vaccine company submit regulatory approval new product approval major market pipeline improve investment rate return positive phase iii study result shingles candidate vaccine hzsu pharmaceutical vaccine new molecular entity phase iii billion cumulative annual cost million incremental saving unanticipate supply continuity execute pharmaceutical restructuring saving deliver range deliver restructuring initiative challenge consumer healthcare programme save billion annum restructure programme ongoing cost reduction year complexity roll new system reduce complexity dispose global enterprise resource planning scale market day increase work capital continue streamline product portfolio noncore brand integrate supply system erp roll market embed common process chain business continue rollout erp system introduce new workplace efficiency speed decision make execute restructure programme cumulative annual saving related propose novartis transaction restructuring programme save billion annum fifth year close adjusted exclude divestment complete impact intangible asset impairment relentless focus access healthcare collaborate partner accelerate rebuilding business china follow continue enhance governance access medicine index development ebola vaccine candidate criminal conviction china affiliate compliance quality proactive violation chinese law risk management qualityled culture deliver global rollout new sale force evolve commercial model compensation approach meeting value chain carbon emission access medicine index deliver new commercial model globally change way work target sale product change way work hcp launch new africa strategy reach healthcare professional incentive high carbon footprint ventolin subsaharan african improve leadership effectiveness sale force increase develop country population quality talent lead increase transparency clinical trial datum company sign early extend price dow jones sustainability index score continue progress development alltrial campaign freeze commitment year place sector ebola vaccine candidate gavigraduate country gsk annual report strategic report governance remuneration financial statement investor information new pharmaceutical vaccine group turnover turnover major growth areasb new product approval major market product performanceb perform definition approval definition definition turnover exclude measure focus major growth major market define usa new product launch divestment prior year low area vaccine consumer healthcare andor japan year rolling basis pharmaceutical vaccine emerge market japan follow product long perform sale establish perform regulatory approval include calculation arzerra product partly offset growth lamictal potiga prolia votrient emerge market japan viiv groe eon mti ind mha kea dic als eta lln ipz rir mse llipta arnuity perform healthcare consumer healthcare kle eys eme ivow ere oar strategy inaa rec ira smyd ato dou thre orhh gisy nmit nrp ssr light rio nth rod uct nle oos rew nree dpr int sil lion deliver sustainable broadlysource drive growth group important important sale growth highlight progress deliver measure show delivery strategy create broadbase sale year product sale growth resilient launch prior year volatility roll basis create incentive improve performance report growth cer share total turnover report growth cer report growth total operating profit margin free cash flowb cash return shareholder perform definition perform total operating profit billion calculation free cash flow gsk return billion exclude currency effect describe shareholder dividend share total operating margin decline reconciliation provide buyback percentage point primarily calculation cer important reflect high sga cost lower describe profit disposal business perform dive roe veu loe nli teri product noncash adjustment free cash flow billion return free cash flow shareholder contingent consideration relation decline reflect impact share buyback viiv healthcare result high strength sterling low profit offer attractive return sale outlook tivicay triumeq include impact divestment alternative investment important measure show cash generate available return shareholder reinvest business effectiveness convert earning cash effective work capital control investment discipline report growth cer report growth sdnedivid sdnedivid sdnedivid perform key performance indicator measure performance number key performance indicator exclude divestment complete exclude divestment complete core operating profit margina perform core operating profit billion exclude currency effect core operating margin decline percentage point primarily reflect increase sga percentage sale despite decline actual sale important opu tinje leiv rre agm rep ate profit growth perform ahead sale performance margin indicate cost manage percentage sale report growth cer report growth report growth exclude divestment complete core earning sharea total earning share definition perform core result exclude number item total earning share total result definition compare primarily core result find reflect noncash adjustment reconciliation core contingent consideration relation result total result provide viiv healthcare result high sale outlook tivicay triumeq unfavourable comparison perform product asset disposal gain core eps decrease cer compared cer decline turnover result cost financial efficiency important earning share key indicator performance return generate shareholder report growth cer report growth cer report growth exclude divestment complete report growth gsk annual report strategic report governance remuneration financial statement investor information new pharmaceutical vaccine group turnover turnover major growth areasb new product approval major market product performanceb perform definition approval definition definition turnover exclude measure focus major growth major market define usa new product launch divestment prior year low area vaccine consumer healthcare andor japan year rolling basis pharmaceutical vaccine emerge market japan follow product long perform sale establish perform regulatory approval include calculation arzerra product partly offset growth lamictal potiga prolia votrient emerge market japan viiv groe eon mti ind mha kea dic als lln ipz rir mse llipta arnuity perform healthcare consumer healthcare kle eys eme ivow ere oar strategy inaa rec ira smyd ato dou thre orhh gisy nmit nrp ssr light rio nth rod uct nle oos rew nree dpr int sil lion deliver sustainable broadlysource drive growth group important important sale growth highlight progress deliver measure show delivery strategy create broadbase sale year product sale growth resilient launch prior year volatility roll basis create incentive improve performance report growth cer share total turnover report growth cer report growth total operating profit margin free cash flowb cash return shareholder perform definition perform total operating profit billion calculation free cash flow gsk return billion exclude currency effect describe shareholder dividend share total operating margin decline reconciliation provide buyback percentage point primarily calculation cer important reflect high sga cost lower describe profit disposal business perform dive roe veu loe nli teri product noncash adjustment free cash flow billion return free cash flow shareholder contingent consideration relation decline reflect impact share buyback viiv healthcare result high strength sterling low profit offer attractive return sale outlook tivicay triumeq include impact divestment alternative investment important measure show cash generate available return shareholder reinvest business effectiveness convert earning cash effective work capital control investment discipline report growth cer report growth sdnedivid sdnedivid sdnedivid report growth report growth growth exclude legal settlement total earning share footnote perform use number adjust measure report performance remuneration executive link marked key indicator total earning share business include core result management information executive pay policy find compare primarily plan reporting purpose directly comparable remuneration policy report reflect noncash adjustment similarly describe measure company reconciliation contingent consideration relation core result total result set viiv healthcare result high sale outlook tivicay triumeq unfavourable comparison product asset disposal gain relative total shareholder return table responsible business external benchmarking access medicine retain position cdps member ftsegood score dow index top biannual ftse climate disclosure jones sustainability index report growth cer index begin leadership index seventh year put gsk report growth sector gsk annual report strategic report governance remuneration financial statement investor information risk management approach risk rigorous risk management process system help assure integrity business operation commit conduct business europe emerge market review implement accordance applicable law initiate widerange review require improvement plan address regulation manner internal control confirm risk strengthen control consistent value company standard local law continue satisfy corporate integrity establish risk management framework regulation understand adhere agreement obligation office address operational legal compliance country region take inspector general north america risk inherent nature business specific internal control framework strategic ambition risk management heo ath tau foa ora uce ork nterprise oversight internal control quality safety sustainability independent assurance wra itm uro vrk uin eju lpn vanoo ledn ear sop ega dmn biph nwr tasi eos eoa iuc lad ea oik rar sbn eel disi epn fond eap ede ntnden seu csn nai tnt rodwo lsar dti sten ear cge enh deia edtc ntc tct responsible embed business party include regulatory suu ilc toi nuk dai aitg tyo work blem ser nding activity train trc kns eae pin loe ree ccountable work itg ine gnt communication eiv athl oed par rce iat tvs tfi cien osd eng establish standard identify action improve escalate encounter risk internal control appropriately manage group company comprehensive learning programme ensure employee gsk value suitably train include mandatory key training gsk code conduct individual accountability antibribery corruption policy line management accountability compliance business management accountability compliance progress audit assurance learn lesson compliance board responsible system corporate issue experience recent year director governance strategy risk management financial performance continue look way strengthen internal control framework proactively manage audit risk responsible reviewing approve principal risk example committee adequacy effectiveness risk china implement new management internal control governance model increase dedicated compliance resource place corporate support ceo manage business additional control monitor local executive team activity way work financial transaction central dedicated antibribery corruption team provide external risk oversight authorise board assist audit risk insight standard training expertise compliance committee oversee risk management business globally council internal control activity group strengthen internal investigation team create regional hub provide consistent approach investigation business unit responsible identifying assess group allow respond manage risk business quickly consistently emerge issue enhance approach risk management ensure appropriate internal control independent business monitoring detect compliance effective risk management implement abnormal inappropriate financial flow board complement country executive risk board well europe emerge market ensure consistent approach risk management local geography gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser governance structure risk managementgsk annual report strategic report governance remuneration financial statement investor information principal risk principal risk list believe cause result differ materially expect historical result list order significance description definition context potential impact mitigate activity principal risk set page principal risk definition manage risk patient safety failure appropriately collect review follow chief medical officer lead large global report adverse event potential source safety pharmacovigilance team maintain act relevant finding timely applicable global policy guide staff worldwide manner intellectual property failure appropriately secure protect global patent group continually analyse intellectual property right ensure change patent law regulation incorporate process obtain maintain enforce global patent protection product quality failure comply current good manufacture chief product quality officer lead practice inadequate control governance global network quality council implement quality applicable policy assure single quality management system define quality business supply chain continuity failure deliver continuous supply compliant closely monitor inventory status finish product delivery product help ensure customer medicine vaccine consumer product need supply chain governance committees financial reporting failure report accurate financial information internal control financial information disclosure compliance accounting standard report oversee regional management applicable legislation review financial controller chief financial officer cfo external auditor tax treasury failure comply current tax law incur tax risk managed set policy significant loss treasury activity procedure help ensure consistency compliance tax legislation appropriate engage advisor legal counsel review tax legislation applicability business antibribery failure comply applicable local extensive global abac programme corruption abac international abac legislation policy procedure oversee toplevel abac oversight committee programme significant training provide employee globally antibribery corruption compliance group abac policy commercial practice failure engage commercial andor scientific harmonise policy standard scientific engagement activity consistent letter govern promotional activity scientific spirit legal industry group requirement engagement undertaken group relate marketing communication behalf employee worldwide train medicine therapeutic area policy implication failure comply policy research practice failure protect inform patient involve implement system governance human clinical trial research generally control oversee clinical trial research conduct clinical trial compliance law use biological sample data integrity key system environment health failure manage ehss consistent global ehss standard support safety sustainability group objective policy relevant law ehss policy oversee members ehss regulations cet employee globally routinely train group ehss policie information protection failure protect maintain access critical chief information security officer oversee sensitive computer system information global information policy programme regularly assess change closely monitor system external briefing crisis continuity inability recover sustain critical operation establish crisis continuity management follow disruption respond crisis management ccm governance board incident timely manner team ccm expert ensure critical business operation crisis continuity plan place thirdparty oversight failure maintain adequate governance chief procurement officer oversee policy oversight thirdparty relationship framework govern buy good service management thirdparty relationship gsk annual report strategic report governance remuneration financial statement investor information business lead capability pharmaceutical vaccine consumer healthcare drive sciencele innovation innovative science forefront investigate potential new treatment respiratory patient conduct research develop world malaria vaccine rhiannon picture work laboratory ware research potential treatment leishmaniasis disease currently affect million people world poor countriesgsk annual report strategic report governance remuneration financial statement investor information gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine growth emerge market japan viiv healthcare offset challenging environment usa leading pharmaceutical hiv business manage vaccine vaccine business underpin viiv healthcare global specialist vaccine business large substantial organisation company hiv majority world broad portfolio significant commercial presence pfizer shionogi paediatric adolescent adult usa europe japan emerge shareholder viiv healthcare travel vaccine large vaccine market increase lead global company hiv sale infanrix diphtheria investment emerge market significant recent success tetanus hepatitis rotarix rotavirus account group turnover regulatory approval industry lead synflorix pneumonia recent year launch dolutegravirbase vaccine business particularly launch important new medicine medicine tivicay singlepill strong develop world vaccine respiratory hiv oncology treatment triumeq viiv healthcare vaccine produce diabete influenza number antiretroviral medicine distribute develop country clinical development include pharmaceutical includes develop low cabotegravir detail pharmaceutical business develop middle income country viiv healthcare make medicine treat broad tiere pricing approach base range acute chronic disease respiratory hiv country gross national income enable portfolio innovative portfolio pharmaceutical country maintain expand establish medicine product treatment condition commitment immunisation lead global position respiratory lupus benlysta benign prostatic economy grow gsk disease hiv hyperplasia avodartjalyn type diabete large contributor gavi vaccine recently launch tanzeumeperzan leader respiratory alliance publicprivate partnership bacterial infection augmentin disease year improve access vaccine develop portfolio mature product past year build country country seretideadvair ventolin flovent significant oncology business recent grow economy graduate recent year strengthen year multiple regulatory gavi support january broaden respiratory portfolio approval global product launch announce year price freeze addition new medicine relvarbreo include tykerbtyverb votrient gavi graduating country ellipta inhale corticosteroid ics promactarevolade arzerra tafinlar propose novartis transaction longacte beta agonist laba mekinist strengthen vaccine portfolio combination anoro ellipta longacte propose novartis acquisition novartiss muscarinic antagonist lama laba transaction agree div vaccine business exclude influenza dual bronchodilator incruse ellipta lama market oncology portfolio relate add number vaccine meningitis arnuity ellipta ics activity right akt inhibitor travel vaccine number respiratory currently development billion strengthen manufacturing network product pipeline include represent unique opportunity combine business benefit mepolizumab investigational antiil crystallise value shareholder increase exposure key market monoclonal antibody treat severe leverage global scale novartis usa novartis eosinophilic asthma close therapy area improve strong presence track record triple combination treatment treat patient outcome regulatory approval propose copd remain confident novartis transaction enhance addition establish maintain leadership respiratory gsk vaccine pipeline bring product portfolio epp include disease decade expertise virology bacterial offpatent product infection different adjuvant platform brand generics business local product product important emerge market business gsk brand important differentiatorgsk annual report strategic report governance remuneration financial statement investor information sale hepatitis vaccine vaccine sales europe fall grow million supply low sale infanrix cervarix constraint boostrix flu vaccine reflect increase strategy remain grow business million competitor competitive pressure broadly base sale challenge return market year partly offset sale growth trading condition notably supply constraint rotarix product boostrix mean group turnover decline sale decline million competitor billion positive result cdc stockpile withdrawal supply issue half year performance year emerge market japan europe flat emerge market pharmaceutical europe pharmaceutical vaccine turnover increase regional performance vaccine turnover flat million pharmaceutical global sale pharmaceutical million pharmaceutical sale flat vaccine market vaccine fall million strong growth outside asia show strong growth million pharmaceutical oncology sale million notable performance brazil turnover decline growth lead votrient promacta newly million rest emerge market japan viiv launch tafinlar avodart latin america million healthcare offset franchise million sale china fall effect low sale establish offset fall respiratory sale government investigation product pharmaceutical sales europe million newly launch year continue growth flat global vaccine sale relvar ellipta record sale million respiratory oncology product decline lower report sale year seretide sale decline respectively europe japan despite million result avodart franchise grow positive performance emerge increase competitive pressure vaccine growth strong tender market vaccine sale flat transition respiratory portfolio sale boostrix rotarix synflorix year new product particularly largely offset low sale pharmaceutical vaccine year cervarix result lose tender turnover million supply constraint pharmaceutical vaccine flat pharmaceutical sale impact continue price contracting pressure primary care market primarily affect respiratory sale put patient customer sale advair decline volume decline price mix fundamentally transform invest continue increase access modernising way sell market healthcare professional stop new portfolio respiratory medicine medicine meet information pay external expert speak january medicare need healthcare professional behalf prescription medicine coverage breo ellipta ensure patient interest medical science liaison anoro ellipta starting believe change msls step early indication right thing deliver talk physicians increase coverage new portfolio competitive advantage recently launch medicine help regain market share deliver benefit new way work improve performance respiratory gsk lead industry internal expert change way reward oncology product strong sale representative focus direct knowledge clinical contribution performance sale quality information trial lead approval million benefit sharing healthcare professional medicine customer attend good performance votrient overall business performance talk anoro ellipta deliver promacta recent launch individual sale target gsk medical staff give tafinlar mekinist sale immuno approach rolledout presentation high mark time rate inflammation treatment benlysta grow country operate effective million generic competition usa lead external speaker far continue impact sale healthcare professional survey programme attract dermatology product rank gsk number attendee externalle million mepron report major pharmaceutical company presentation past sale decline million value bring change allow continue sale infanrixpediarix vaccine well meet need healthcare grow million benefit customer tell valuable professional patient favourable cdc stockpile compare source information want absence competitor provide information way particularly half year well meet need explore digital realtime channel provide information way customer want want gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine continue japan pharmaceutical vaccine turnover grow million pharmaceutical sale vaccine pharmaceutical sale benefit strong growth oncology product avodart respectively partially offset low sale respiratory portfolio turn affect weak allergy season beginning year increase competitive pressure new prescription share increase follow substantial increase new prescription relvar ellipta lift ryotan prescribing restriction sale year relvar ellipta million overall respiratory sale fall million low vaccine sale reflect impact cervarix continue suspension recommendation use hpv vaccine high sale rotarix partly compensate respiratory continue develop enhance lead way respiratory respiratory portfolio new product launch await fda decision gsk forefront year previous year breo ellipta use asthma advance respiratory disease combine offer great choice mepolizumab firstinclass antiil launch ventolin year ago healthcare professional patient treatment severe asthma overall continue expect total sale broad portfolio medicine add strength respiratory portfolio return growth market respiratory medicine globally respiratory portfolio potential add number asset currently late stage firstinclass medicine development confident respiratory sale fall come year respiratory pipeline continue million year deliver new treatment option seretideadvair sale transform respiratory able meet evolve need million flixotideflovent sale pipeline year scientific research patient decade fall million ventolin sale approve medicine grow million xyzal sale potential benefit million continue work hard exclusively japan patient live asthma copd ensure mainstay treatment year gain approval seretide ventolin remain million incruse ellipta usa europe important treatments millions usa respiratory sale fall arnuity ellipta usa patient world want face continue price contracting gain approval anoro ellipta ensure access pressure market sale advair europe follow approval broad number patient million fall success build approval example reduce pack size volume decline price relvarellipta enable small amount mix flovent sale medicine deliver ellipta purchase create lowcost ventolin sale newly inhal achievement formulation launch product breo ellipta record significant give amass sale million anoro ellipta recognise unprecedented regulatory approval sell million year achieve overcome relvar ellipta global burden respiratory disease commit help people ongoing commitment respiratory disease optimise investment scientific research treatment achieve well possible working collaboration external clinical outcome expert remain forefront expand portfolio respiratory respiratory medicine medicine enable clinician commitment scientific tailor treatment patient individual leadership help transform need fact recent approval live patient enable mean launch new feel well live long respiratory medicine past twogsk annual report strategic report governance remuneration financial statement investor information european respiratory sale decline category vaccine largely increase competition sale cardiovascular metabolic vaccine sale seretide sale fall million urology category million year decrease volume negative million year avodart decline europe japan impact price result increase franchise grow million partly offset growth competitive pressure transition increase sale duodartjalyn emerge market sale respiratory portfolio newer avodart sale decline usa flat emerge market product year sale levitra fall million help strong performance relvar ellipta record sale million year sale prolia synflorix boostrix rotarix year million follow infanrixpediarix grow million agreement amgen terminate joint respiratory sale emerge market growth usa offset sale commercialisation select market grow sale seretide decline europe emerge market million help improve regionally sale usa boostrix sale increase performance china sale growth million million growth region ventolin million emerge market grow sale fall largely veramyst million million japan grow sale return competitor product offset flixonase sale fall million europe flat rotarix sale grow million largely sale decline million drive tender shipment europe china sale immunoinflammation emerge market japan respiratory sale fall product grow million help decrease usa impact million sale million sale increase benlysta cdc stockpile withdrawal fourth relvar ellipta offset impact million year therapy quarter synflorix sale increase competitor action adoair area million million mainly strong fall million growth largely reflect generic competition tender performance emerge market xyzal million dermatology product sale hepatitis vaccine fall offset low sale establish product million partly supply respiratory portfolio new sale establish product fall constraint affect emerge prescription share increase million generic competition market fluarix flulaval sale follow substantial increase new lovaza million million low prescription relvar lift seroxatpaxil million production level increase ryotan prescribing restriction valtrex million competition cervarix sale decline oncology contribute fall category million largely fall oncology sale grow million sale emerge market japan regionally sale usa year contribution increase competitive pressure million sale europe votrient sale million japan fall million promacta sale million million respectively sale arzerra fall million emerge market performance tykerbtyverb sale decline category decline million million new launch compensate generic competition hycamtin argatroban tafinlar mekinist recording sale million million respectively oncology grow million contribution votrient million promacta million tafinlar million mekinist million europe oncology sale grow million lead votrient sale million emerge market sale million japan sale grow million gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine continue new indication approve darapladib investigational deliver regulator exist oncology medicine cardiovascular medicine arzerra firstline treatment chronic successful phase iii study organisation deliver lymphocytic leukaemia combination development terminate number new medicine vaccine chemotherapy treatments usa patient expand treatment partner mmv start europe promacta usa option additional indication phase iii study investigate safety treatment severe aplastic anaemia exist product file efficacy tafenoquine singledose number latestage asset regulator hivaid investigational radical cure plasmodium significant new asset progress viiv healthcare gain approval vivax malaria form disease final stage development tivicay dolutegravir integrase inhibitor occur primarily south south east follow approval usa asia latin america horn africa progress give continue confidence approval give triumeq pipeline potential new medicine continue pursue usa europe triumeq remain strong sustainable new indication exist medicine singlepill regimen treatment continue deliver value patient oncology phase iii study begin hiv combine dolutegravir gsk pharmaceutical vaccine evaluate promactarevolade patient nucleoside reverse transcriptase inhibitor currently new molecular myelodysplastic syndrome mds nrtis abacavir lamivudine entity nme phase iiiii clinical type cancer bone marrow development diabete healthy blood cell tanzeum new glp treatment type submit regulatory file seek product approval diabetes receive approval usa additional indication medicine respiratory offer onceweekly injectable option severe aplastic anaemia europe respiratory anoro ellipta patient product chronic immune idiopathic oncedaily medicine combine eperzan approve thrombocytopenia itp paediatric bronchodilator longacte muscarinic europe set usa phase iii study antagonist lama longacte beta agonist laba single inhaler pipeline newsflow subcutaneous ofatumumab patient pemphigus vulgaris rare autoimmune approve europe chronic obstructive pharmaceutical skin disorder begin pulmonary disease copd follow regulatory file submit approval usa end usa europe biologic submit regulatory file incruse ellipta monotherapy lama respiratory mepolizumab investigational ema variation marketing approve oncedaily treatment antiil monoclonal antibody administer authorisation volibris medicine copd include chronic bronchitis andor week treat patient pulmonary arterial hypertension pah emphysema usa europe severe eosinophilic asthma asset include use initial combination launch usa quarter evaluate phase iii therapy pah patient finally arnuity ellipta oncedaily study treatment eosinophilic alongside advance late inhale corticosteroid medicine treat granulomatosis polyangiitis egpa stage pipeline significant asthma approve usa rare disease characterise widespread potential cabotegravir hiv asthma treatment new respiratory inflammation wall small blood information sirukumab portfolio gain approval vessel vasculitis adjunctive antiil monoclonal antibody respiratory medicine therapy adult severe copd rheumatoid arthritis prolyl administer innovative breo ellipta oncedaily fix dose hydroxylase inhibitor anaemia patent dry powder inhaler ellipta combination inhale corticosteroid exvivo stem cell gene therapy treatment oncology ic longacte beta agonist potential cure adascid rare mekinist mek inhibitor gain approve usa copd disease affect child european approval treatment file usa treatment gsk product cell gene braf mutant metastatic melanoma asthma announce start therapy technology fastmoving area medicine class license phase iii programme evaluate science believe europe oral target therapy efficacy safety close triple potential deliver number receive approval usa combination treatment icslama transformational medicine fda accelerate approval process laba patient copd vaccine use combination tafinlar evaluate oncedaily triple combination vaccine business previously approve oral target therapy treatment inhale corticosteroid announce pivotal phase iii study result accelerate approval contingent longacte bronchodilator shingles candidate vaccine hzsu result phase iii trial single inhaler show reduce risk shingle design evaluate clinical benefit phase iii study begin evaluate adult aged year combination positive overall survival effect losmapimod acute coronary old compare placebo study result announce february syndrome losmapimod inhibitor start august ongoing phase iii combid study mitogen activate protein map country involve result submit regulatory kinase enzyme understand play individual evaluate authority review central role acute inflammation filing strategy vaccine occur heart attack develop shortterm treatment administer quickly possible heart attack reduce risk subsequent cardiac eventgsk annual report strategic report governance remuneration financial statement investor information reach major milestone development programme malaria candidate vaccine rtss submission regulatory file july european medicines agency case study ebola crisis begin march gsk work closely world health organization regulator partner respond outbreak accelerate development investigational ebola vaccine contribute overall humanitarian effort take step support small number employee region phase study investigational ebola vaccine demonstrate acceptable safety profile produce immunological response healthy adult volunteer test large phase iii clinical trial sponsor national institutes health nih liberia april announce decision stop development investigational magea antigenspecific cancer immunotherapeutic treatment nonsmall cell lung cancer phase iii study fail meet efficacy endpoint follow strategic review vaccine submit regulatory application candidate immunotherapeutic unit include malaria vaccine available datum development current environment investigation additional technology decide july reach major milestone rtsss development involve pursue new research effort submission regulatory big vaccine trial antigen specific immunotherapy application candidate malaria conduct africa number vaccine rtss european additional step need earlystage pipeline medicine agency ema key complete anticipate pharmaceutical continue moment gsk year journey vaccine available substantial improvement novelty develop world malaria vaccine implementation early adopter earlystage pharmaceutical research submission follow ssa country programme announcement phase iii datum show preclinical phase nme project gsk invest hundred million rtss halve number novel mechanism action dollar date rtss case clinical malaria young develop multiple earlystage programme receive funding child aged month asset therapeutic area bill melinda gates vaccination month significant opportunity immuno foundation international vaccination inflammation specifically disease nonprofit organisation path rheumatoid arthritis inflammatory rtss intend exclusively use contribute financial scientific bowel disease psoriatic arthritis plasmodium falciparum managerial field expertise multiple asset development malaria parasite prevalent development rtss include gmcsf monoclonal antibody subsaharan africa ssa committed price rtss number rip kinase inhibitor estimate death malaria cover cost manufacturing receptor monoclonal antibody occur ssa vaccine small return immunooncology range child age reinveste asset target haematological second generation malaria date license vaccine cancer solid tumour include vaccine vaccine available prevention malaria icos tlr tropical disease positive opinion cell therapy partnership ema grant world health biotechnology company adaptimmune organization indicate cancer epigenetic policy recommendation clinical programme address beti possible end ezh lsd target positive opinion ema basis marketing authorisation application nras ssa gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine continue vaccine continue integrate collaborate external partner core pharmaceutical investment earlystage asset follow acquisition critical component biotechnology company okairos strategy recent year novel adenovector platform involve partnership external show potential disease ebola company individual academic hepatitis respiratory syncytial virus enable access rsv rsv remain increase understand new paediatric infectious disease area science share risk vaccine exist recent development phase datum vaccine candidate pharmaceutical business demonstrate value employ approximately people exploratory work pharmaceutical core discovery pharmaceutical approach expenditure billion decline development pharmaceutical business compare previous year facility central support dynamic organisation believe result execution change lead build sustainable pipeline innovative continued efficiency improvement nimble personalise unit new medicine focus earlystage research fundamental step away traditional cuttingedge science earlystage research drug discovery hierarchical business model help highly selective crucial step explore new maintain flexibility research investment concentrate area medicine great investment focus believe science present challenge identify biological promising scientific opportunity opportunity likely deliver mechanism involve development budget great significant medical advance essential disease create small accountability project progress continue challenge area molecule biopharmaceutical dpu business plan regularly work recognise interact disease target review discovery investment announce programme ultimately lead new medicine board dib group senior sharpen focus activity research work commercial management alongside eliminate area low probability external scientist make external individual life science success announce plan progress improve understand investment expertise understand change geographical footprint disease target believe payer perspective bring significant operation improve success rate discover latestage development global centre new medicine case study compound demonstrate philadelphia usa discovery performance unit potential proof concept work stevenage area believe dpus responsible discovery decide advance vital enable scientist work development potential new laterstage development portfolio worldclass facility medicine earlystage clinical investment board pib assess trial completion phase iia technical commercial investment dpus case project progress scientist work particular development disease pathway area science timeline development stage pharmaceutical research drug regulatory approval postmarkete preclinical clinical trial discovery review launch surveillance phase phase phase compound compound compound number patient approve new medicine year year yearsgsk annual report strategic report governance remuneration financial statement investor information stage call commit medicine development typically take place harness advance technology drive phase iia trial compound test small number patient drug discovery development particular condition disease phase iii study largerscale study patient continue build scientific currently estimate examine compound efficacy technical capability enable compound enter clinical trial safety different therapeutic dose well decision early drug reach patient medicine determine appropriate discovery development increase biological target stage successful use probability success reduce drug understand result study combine attrition rate significantly great challenge drug discovery key scientific information submit improve proportion high quality need understand well regulatory file review possible drug candidate progress clinical mechanism body relate approval regulatory agency development ensure select disease improve develop good candidate prioritise effective medicine time work optimise resource progress compound physical property promise potential medicine cttv scientist combine formulation produce expertise explore interpret large efficiently sufficient quantity capitalise major volume datum aim improve manufacturing process technology advance help ability define biological target case research include researcher crucial step range disease wellcome develop new inhaler device explore new medicine find trust sanger institute contributing deliver medicine start launch unique understanding role centre therapeutic target genetic health disease responsibility guide validation cttv european european bioinformatics institute investigational medicine later bioinformatics institute integrate huge stream experimental stage development filing rest wellcome trust sanger institute data create bioinformatics insight medicine development team mdts pioneer research initiative contribute expertise disease small unit people harness big data genome biology translational medicine drug pharmaceutical new sequence improve success discovery molecular entity nme phase iiiii rate discover new medicine multimillion pound contribution clinical development fund initial wave project governance length time cost involve drug discovery development investment essential highly selective inv focus resource executive team oversight focus productivity continue improve financial strategic issue overall budget remain committed improve efficiency february management number productivity develop announce estimate irr governance board manage investment innovative new product continue target decision life cycle great efficiency longerterm basis early commercialisation investment decision begin discovery investment decision estimate irr important phase dib continue base good measure financial discipline pib describe early opportunity consider patient strategic progress improve need market opportunity economic underpin pib cochaire president scientific understanding believe strategy create flexibility pharmaceutical president effective determine price new medicine global pharmaceutical investment requirement basis include head pharmaceutical calculation recent irr fix proportion sale region head global include product launch manufacture legal counsel productivity key challenge january december industry believe compound phase iib additional governance committee important provide great level iii development process assess technical scientific commercial transparency decision yearend calculation investment decision project make return base actual sale development commercial forecast sale operation new medicine rate return determine adjusted reflect expect failure rate launch assess cost involve broadly line standard discover develop latestage industry failure rate cost base pipeline project profit calculation comprise medicine vaccine estimate attributable cost approve launch actual project milestone payment calculate appropriate estimate internal rate return irr state longterm aim increase gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine continue vaccine approach discovery development oversight key decision rest vaccine work focus discovery development new body vaccine development discover develop new vaccine complex process typically commercial board vdcb prophylactic therapeutic vaccine take year vaccine vaccine investment board vib help protect treat people discovery begin identify new vdcb review research infectious disease cancer chronic antigen specific structure development project strategy advise disorder look life cycle pathogen viruse bacteria parasite scientific technical commercial management maximise potential cancer cell recognise opportunity assessment overall exist vaccine broaden immune system produce view early advanced life cycle geographic availability advance pathogen yeast bacteria development project vdcb formulation approach allow mammalian cell genetically manipulate recommendation progress project increase value product bring purify stage submit extend reach adapt formulate vaccine antigen vib ensure meet need patient create bodys immune response vib cochaire president manage prioritise investment case formulation vaccine vaccine chairman global decision well meet need involve mix antigen gsk vaccine board make final customer help address proprietary adjuvant system use decision invest project remain global health challenge adjuvant improve immune system evaluate vdcbs recommendation core vaccine investment response antigen contain vaccine alongside public health benefit business million innovate area opportunity development cost risk reflect decision stop development adjuvant system year project time overall evolution magea formulation candidate vaccine portfolio vaccine scientist work usually combination antigen vaccine organisation currently final composition vaccine vaccine development antigen adjuvant change range disease time continue explore potential governance early stage asset acquire key decision point okairos novel adenovector vaccine development process commit platform complement exist vaccine research decide initiate research adjuvant technology expertise enable programme commit candidate continue work develop development decide invest resource generation vaccine allow explore potential vaccine tackle new disease number clinical trial commit early clinical development phase commit phase iii commit registration launch vaccine research development cycle registration identify produce preclinical phase phase proof phase iii file postmarkete antigen antigen test concept surveillance research include immunology preclinical development clinical development include postmarkete surveillance transfer process manufacturing year year year yeargsk annual report strategic report governance remuneration financial statement investor information latestage pipeline pipeline remain extensive summary pharmaceutical vaccine phase iii regulatory set comprehensive list medicine vaccine phase iii development available page compound indication respiratory relvarbreo ellipta ffvi asthma file june approve nov vilanterol copd iii iii mepolizumab severe eosinophilic asthma file nov file nov copd iii iii ffumecvi copd iii iii vaccine nimenrix menacwy menacwy prophylaxis approve apr magea melanoma iii iii herpe zoster shingle prophylaxis iii iii mosquirix rtss malaria prophylaxis file july oncology arzerra ofatumumab cll relapsedrelapse maintenance iii iii nhl iii iii mekinist trametinib tafinlar metastatic melanoma approve jan iii dabrafenib combination use adjuvant melanoma iii iii promactarevolade myelodysplastic syndrome mds iii iii severe aplastic anaemia approve aug file nov cardiovascular metabolic retosiban threaten preterm labour iii iii losmapimod acute coronary syndrome acs iii iii immunoinflammation benlysta systemic lupus erythematosus iii iii benlysta vasculitis iii iii sirukumab rheumatoid arthritis iii iii rare disease adenosine deaminase severe combine immune deficiency iiiii iiiii exvivo stem cell gene therapy adascid mepolizumab eosinophilic granulomatosis polyangiitis egpa iii iii infectious disease tafenoquine treatment relapse prevention plasmodium vivax malaria iii dermatology ofatumumab pemphigus vulgaris iii iii gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine continue manufacture supply common process simplify gsk pharmaceutical pharmaceutical vaccine vaccine site country make business continue streamline core commit reduce complexity pharmaceutical vaccine product process boost efficiency key step business help people involve establishment core efficient allow respond manufacture supply activity commercial cycle programme key need patient consumer enterprisewide planning decision quickly effectively pharmaceutical vaccine make process bring manufacture organisation aim year commercial finance supply chain consistently deliver outstanding quality undertake broad range restructuring ensure meet expect service value patient simplification programme demand product customer group reduce consolidation supply base operational complexity deliver total sale performance helps simplify pharmaceutical billion annual saving date certain pharmaceutical vaccine manufacturing supply chain operation impact supply constraint reshape business reduce number identify significant simplification manufacture network thirdparty supplier manufacture synergy opportunity continue review global medicine behalf gsk consumer healthcare vaccine pharmaceutical manufacturing compare business propose novartis supply network ensure effectiveness continue reduce complexity transaction complete target efficiency supply base standardise specification total annual saving transaction good material buy year continue invest billion fifth year closing pursuing integrate source process network ensure capacity key include related oncology area example respiratory continued initiative reduce expect approximately commit build new manufacturing complexity pharmaceutical product deliver year facility montrose scotland provide portfolio allow simplify undertake restructure additional capacity new supply chain commercial operation programme refocus global product relvarbreo ellipta anoro reduce risk complexity pharmaceutical business follow ellipta incruse ellipta arnuity ellipta increase service level divestment oncology product antibiotic continue invest achieve reduction change dynamic manufacturing capacity active baseline equate respiratory market cost base ingredient finish product discontinue pack rescale commercial operation global site notre dame commitment quality support function relevant bondeville france leave network strongly commit meeting manufacture pharmaceutical change announce high quality standard stringent intend improve performance quality control quality insurance establish streamline agile endtoend supply chain process medicine vaccine business expect deliver annual endtoend supply chain programme manufacture accord current cost saving billion year begin design good manufacturing practice cgmp expect reform simplify supply chain regulation approve file introduce process programme reshape include commitment authority improve coordination stage global pharmaceutical operation internal quality standard production source create franchise respiratory procedure gsk site cork manufacture efficient delivery speciality pharmaceutical ireland ste foy canada receive product patient consumer sit alongside establish product warn letter food portfolio global business introduce gsk production drug administration fda year respiratory franchise continue system gps pharmaceutical taking comprehensive action focus exist emerge manufacturing site gps standard resolve issue respiratory portfolio newly way working identify eliminate procurement create specialty pharmaceutical root cause accident defect procurement organisation continue business comprise latestage waste standardise way work support delivery great value pipeline asset newly launch improve process performance external expenditure global medicine cardiovascular example site cairo egypt procurement saving performance core metabolic neuroscience cvmn deployment programme result external operating expenditure increase immuno inflammation infectious increase production additionally disease iiid oncology discovery decrease manufacturing interruption september launch category dermatology create lean council comprise business finance commercial operation simplify process procurement leader eliminate duplication enhance procurement process accelerate performance drive right rigour buying decision help strengthen relationship external partner critical business modify process cause inefficiencieserachtlaeh viiv drawyah ytak otohp gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine viiv healthcare grow dolutegravirbase hiv portfolio include tivicay triumeq contribute strong year viiv healthcare viiv healthcare specialist global hiv company deliver advance treatment care people live hiv establish majority own gsk pfizer shionogi shareholder company focus hiv viiv healthcare deliver strong performance prove ability deliver standalone company gsk announce intention explore potential undertake initial public offering minority share viiv healthcare business million people worldwide live hiv accord late available figure unaid million die aidsrelated cause global effort help reduce rate new hiv infection aidsrelated death today disease prevalent subsaharan africa adult population infect nearly people infect hiv live lowincome country subsaharan africa increase access treatment increase access hiv treatment priority access hiv treatment major adult mpp collaboration grow focus viiv healthcare include approach viiv company support people live healthcare apply establish viiv healthcare turnover hiv country royaltyfree voluntary licensing billion growth generate variety approach address dolutegravir second specific tivicay epzicomkivexa need people live hiv middleincome country include newly launch triumeq different part world india company establish offset impact generic competition firstever mpp licence tiere old viiv healthcare product include company offer royaltyfree royalty structure country pay combivir trizivir core operating profit voluntary licence access price small percentage sale grow viiv healthcare growth lowincome leastdevelope price base gdp outpace hiv global market growth country subsaharan africa viiv healthcare core operating country people child viiv healthcare profit include cost exclude hiv currently live middleincome grant mpp voluntary licence noncore item contingent country viiv healthcare take country generic manufacturer consideration payable shionogi casebycase approach base develop paediatric formulation relation sale tivicay triumeq burden disease gdp dolutegravir pay royalty person medicine include tivicay record sale million pipeline new treatment company continue uptake tivicay lead tivicay triumeq support community industry usa market cover access policy project worldwide positive include germany japan compare action positive action child recent hiv medicine launch april month approval fund positive action southern initiative sale triumeq new singlepill tivicay usa paediatric innovation seed fund treatment launch usa viiv healthcare announce new august european country collaboration medicine september million patent pool mpp increase access epzicomkivexa abacavir lamivudine dolutegravir country grow million child adult celsentriselzentry maraviroc hiv develop world live flat million gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine viiv healthcare continue regionally sale north america grow hiv treatment regimen combine simplify drive strong performance different antiretroviral improve tivicay triumeq continue convenience patient triumeq decision create viiv healthcare growth epzicom tivicay triumeq drug combine dolutegravir company focus hiv perform strongly dynamic nrtis abacavir lamivudine allow company totally segment patient initiate switch singlepill regimen dedicate innovate make therapy achieve joint share viiv healthcare enter collaboration difference people live hiv treatment naive patient janssen develop switch patient viiv healthcare maintain drug single tablet combine dolutegravir nimble model europe time viiv janssen rilpivirine nonnucleoside specialist organisation focus healthcare creation sale grow reverse transcriptase inhibitor core capability rely relationship fast market result research compare efficacy shareholder particular excellent performance tivicay twodrug regimen compare gsk allow operate approve january achieve threedrug regimen maintain viral simplified operating model reimbursement european market suppression patient virally successful initial uptake triumeq suppress threedrug regimen combine model lean country launch management structure globally locally begin phase study continue growth kivexa company reduce complexity experimental longacting injectable maximise efficiency viiv healthcare pay international region sale grow integrase inhibitor cabotegravir previously service provide owe growth portfolio celsentri know gsk study shareholder armslength contract kivexa tivicay contribute investigate potential cabotegravir twothird region revenue prevention hiv negative man model extend organisation japan australia launch combination longacting conduct research partnership tivicay second half year rilpivirine treatment people live gsk hiv discovery performance unit see particularly impressive sale hiv cabotegravir offer possibility pharmaceutical biotech company performance treatment injection allow academic researcher people switch daily oral use monthly potentially frequent form deliver treatment important regulatory approval dolutegravirbase portfolio year tivicay dolutegravir approve follow approval triumeq combine dolutegravir nucleoside reverse transcriptase inhibitor nrtis approve usa innovative antiretroviral treatment tivicay integrase inhibitor antiretroviral medicine treatment adult adolescent live hiv tivicay clinical development programme include people live hiv new treatment naive treat hiv medicine experience infect virus develop resistance previously available integrase inhibitor cite dolutegravir longterm developmental priority child antiretroviral treatmentsgsk annual report strategic report governance remuneration financial statement investor information consumer healthcare strong innovation focus geographic expansion new route market lead continued growth key category gsk consumer healthcare business april announce propose major new gsk consumer healthcare large world threepart transaction novartis business geographically product reach million people complete create new joint match strong presence day country venture consumer healthcare company emerge market topselle brand include sensodyne significant scale reach make cis central eastern europe panadol horlick world large consumer combine business world healthcare company operate lead consumer healthcare company category wellness market estimate grow approximately number position specialist oral health nutrition skin health annum year oral health otc market brand exist help people feel well live long wellness category focus pain management respiratory health gastrointestinal health smoker health panadol topselle paracetamol brand globally tum antacid brand usa global leader specialist oral health leading position sensitivity sensodyne acid erosion pronamel denture care gum health nutrition horlick brand year old lead nutritional supplement indian subcontinent finally skin health brand abreva zovirax hold leading position flonase allergy relief world large market expand access prove medicine focus combine good pharmaceutical fast move consumer healthcare business flonase contain prescribed consumer good fmcg capability focus help people allergy treatment ingredient otc world good world improve everyday health treatment temporary relief fast move consumer healthcare symptom hay fever upper fmch company drive science way make respiratory allergy value realise vision prescription medication otc nasal spray provide relief implement strategy easily available consumer nasal ocular symptom key growth lever switch overthecounter otc flonase inhibit key substance product otc switch building category define brand allergic response unlike remove need people consumer love mean build common otc allergy pill healthcare professional order strong global brand leadership target histamine medicine need switch position reduce overall cost healthcare usa million people improve live scientific addition otc switch suffer nasal allergy innovation strong pipeline enable people manage variety estimate treat new product everyday health condition symptom prescription otc treatment half choice shopper past year draw sufferer report completely retail partner expert specialist knowledge scientist satisfy current method researcher consumer deliver high quality product treatment present significant healthcare pharmaceutical right time cost opportunity gsk provide business switch additional new option consumer live value develop possible expand access widely people high performance culture product smoker health expect flonase allergy relief weight loss skin condition pain growth driver consumer healthcare business strong heritage provide wellestablished allergy scientific strength discover treatment consumer continue develop respiratory product launch brand otc product patient worldwide bring prescription market flonase consumer usa overthecounter medicine gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare continue lead position skin health wellness sale deliver family nutrition key brand like million impact significantly sensodyne parodontax polident voltaren supply particularly smoker health innovation portfolio comprise theraflu panadol otrivin horlick zovirax gastrointestinal product grow new product unique line extension abreva total new company impact launch year critical major brand annual supply constraint eno see growth consumer healthcare revenue excess million strong growth emerge market business especially india brazil pain approximately half business management grew drive double focused create continue otc medicine create world digit growth fenbid china offset pipeline new scientifically differentiate otc business half new supply interruption bactroban product category company comprise fmcg brand china launch newtomarket product area oral health nutrition year innovation skin health increase speed skin health sale portfolio account market investment new product million drive primarily bactroban consumer healthcare global sale business great supply interruption china physiogel invest million core consumer opportunity deliver revenue growth sale healthcare consistently market rate regional performance key innovation launch regional level business grow decline million impact include horlick kesar badam sensodyne true white sensodyne supply disruption primarily wellness complete pronamel multiaction overall consumer healthcare turnover oral health grew lead strong sale fenbid sustain release million sensodyne successful launch primarily result supply pronamel multiaction sensodyne major contributor innovation disruption begin repair protect sale include sensodyne repair protect early sign supply recovery fourth niquitin flash strip panadol extra europe sale fall quarter growth generate panadol advance zovirax duo million combination positive momentum business factor include supply competitive continue benefit scientific pressure particularly oral health strength pharmaceutical business category performance political disruption central fda approval flonase allergy oral health sale grow million eastern europe market growth relief allergy spray otc use base drive strong growth rate slow year new drug application nda sensodyne sensitivity acid erosion include datum clinical study rest world market include india gum health global postmarketing experience china latin america middle east grow sensodyne maintain prescription nonprescription market africa million despite lead position sensitive tooth overall slowdown emerge market focus ensure category consumption grow ahead particular note india business consumer heart business market region growth see grow year year invest rollout emerge develop execute successful restage horlick new fullyintegrated platform single market notable success focus increase nutritional benefit point consumer contact phone china north america sensodyne consume day improve social medium digital allow repair protect sensodyne formula dissolve easily hot listen well interact complete key driver growth cold milk launch new consumer gather insight combination strong brand innovation variant horlick kesar badam saffron ultimately drive product improvement successful marketing approach almond india specifically design marketing strategy innovation dentist testimonial continue drive meet unique taste indian deploy new platform brand success consumer continue focus new country collect nearly million datum nutrition category grow route market expand distribution point lead creation multiple million lead horlick boost model well reach rural consumer new marketing promotional campaign grow respectively product brand portfolio year begin process reflect strong innovationdriven helping maintain horlick position add gsk branding performance continue focus india lead nutritional supplement consumer healthcare product expand rural distribution india latin america sales strong advertising promotional material lead protein brand maxinutrition performance oral health wellness research show work prove drive strong innovation value brand expect increase distribution majority product packaging carry gsk brand end gsk annual report strategic report governance remuneration financial statement investor information simplify face challenge year consumer healthcare manufacturing site primarily north america affect supply line fully operational expect increase benefit resumption supply undertake comprehensive operational review supply network invest heavily multiyear programme ensure future sustainable supply include improvement system capacity training people addition new role particularly key area quality engineering work reduce exposure single source supply continue rollout gsk commercial enterprise resource planning erp system consumer healthcare business new platform allow well commercial decision drive financial efficiency standardise consolidate datum innovative approach rural distribution india forecast plan system save time money system maintenance upgrade consumer healthcare short span year efficient business constantly innovate build huge distribution network customer consumer consumer access widest today cover village directly healthcare market add available range high quality healthcare supply product range global consumer healthcare revenue product commit wellness oral health nutritional system expect fully expand geographic reach product right size price complete rollout achieve great flexibility small mediumsize village product offer format price order deliver high quality product retail outlet order reach consumer customer right time create network rural cost focus reduce traditional distribution model subdistributor regularly number pack product build business india work deliver gsk product portfolio provide shopper rural hardtoreach village village retailer small simple easy choice base currently represent indias village population clear brand proposition billion population retail outlet create distribution channel go simplify supply chain result goal build strong directly home easier well forecast infrastructure time train local woman set inventory result low warehousing improve consumer awareness distribution business selling directly cost increase capacity factory health nutrition information household helping build low cost good market build sustainable income source achieve net pack reduction sustainable business end woman go forward expect deliver want exist train programme estimate total annual cost save direct distribution network cover million result propose village previously novartis transaction delivery service distributor give little saving phase year insight product purchase achieve year retailer communication customer receive gsk annual report strategic report governance remuneration financial statement investor information responsible business success depend ability research develop innovative medicine vaccine consumer healthcare product accessible people worldwide responsible way partnership save child aim help save life million child programme democratic republic congo health worker like head nurse jacqueline mankenda picture directly reach thousand child include hard reach communitiesnerdlihc eht evasedaw yerbua otohp gsk annual report nerdlihc eht evas nohal yvi otohp strategic report governance remuneration financial statement investor informationtax business increasingly challenge ensure contribute tax system society operate provide information tax management principle policy understand responsibility pay appropriate tax fully support effort ensure company appropriately transparent tax affair manage substantial business employment presence country globe pay significant tax include corporation business taxis tax associate employee time responsibility shareholder financially efficient deliver sustainable tax rate approach look align investment strategy country substantial economic activity government policy promote tax regime attractive business investment pay considerable tax significant proportion global corporate function manufacturing activity locate include corporation tax profit generate indirect tax employment taxis precise amount fluctuate year year gsk annual report strategic report governance remuneration financial statement investor information responsible business approach conduct business important financial performance responsible business central responsible business priority strategy conduct prioritie responsible business business important approach sit context macro financial result achieve strive economic social trend value heart impact wide society company decision meet exceed trend present opportunity expectation society challenge global healthcare company like gsk commitment start ceo corporate executive team report progress area dedicate boardlevel corporate health behaviour people responsibility committee crc lead planet responsible business chairman priority identify report crc understanding issue important business success create value society stakeholder detail develop innovative product analysis responsible business maximise access deliver direct supplement gskcomresponsibility benefit patient consumer successfully deliver profitable develop longerterm sustainable business performance commitment area turn allow generate value reflect global health need return shareholder reinvest align strategic priority business wide value transparency respect society benefit healthy people people integrity patient focus community essential building report detailed progress strong sustainable society commitment responsible contribute significant value business supplement available make direct indirect economic gskcomresponsibility contribution country assess commitment community operate progress track tax box employment work people charitable support total review charitable contribution year set detail corporate tax charge year publish detail position taxnerdlihc eht evasedaw yerbua otohp gsk annual report strategic report governance remuneration financial statement investor information access healthcare ensure access determine drive access product reach patient consumer matter live ability pay medicine vaccine consumer health product improve quality life patient consumer world million people get vaccine treatment need afford disease impact poor treatment exist play tackle global health challenge drive access product people pioneer new business model collaborate strengthen healthcare infrastructure innovate tackle disease disproportionately affect poor affordability availability improve access healthcare central business evolve approach increase access patient consumer tackle affordability availability barrier maximise patient benefit sustain business develop country ldc low pricehigher volume approach cap price product develop market level respond ebola outbreak seek regulatory approval establish product develop ebola crisis begin march protect volunteer hope country catch gsk work closely contribute significantly programme bridge gap access world health organization control outbreak future compare develop country regulator partner use mass vaccination campaign investment local manufacturing respond outbreak depend capability building increase accelerate development regulator stakeholder availability locally relevant vaccine investigational ebola vaccine satisfied vaccine candidate medicine contribute overall provide protection ebola supply vaccine gavi vaccine humanitarian effort take step cause significant effect alliance significantly reduce price support small number quickly large quantity use world poor country employee region vaccine committed provide gavi phase study investigational actively explore million vaccine dose ebola vaccine demonstrate relevant organisation partner reduce price help protect million acceptable safety profile produce opportunity accelerate child develop world immunological response healthy development manufacturing commit year adult volunteer test industrial scale trial price freeze gavi graduating country large phase iii clinical trial sponsor successful position country grow national institute health nih significantly rampup production economy graduate gavi support begin liberia february vaccine candidate help combat trial expect involve future ebola outbreak people onethird receive gsk candidate ebola vaccine compare candidate vaccine control vaccine assess immune response see phase trial actually translate meaningful protection ebola nerdlihc eht evasedaw yerbua otohp gsk annual report strategic report governance remuneration financial statement investor information access healthcare continue invest new formulation take consider small pack different distribution approach pricing relvar ellipta model product affordable anoro ellipta incruse ellipta available introduce price line singledose capsule help respiratory alternative gsk top access medicine index patient spread cost inhaler strengthen healthcare system fourth consecutive time index ventolin rotacap world poor country lack measure performance widely distribute gsk product train healthcare worker diagnose pharmaceutical company effort philippine disease administer treatment improve access medicine tiere pricing approach prevent patient access healthcare develop country prescription medicine vaccine lifesave medicine vaccine index country pay different price base regardless cost take step help widen access ability pay determined reinvesting profit ldc medicine include file gross national income gni person enable broad access gsk train line healthcare workers malaria vaccine candidate regulatory medicine vaccine globally aim improve access healthcare approval forming groundbreake million people invest fiveyear partnership save middle income country like brazil million base profit child launch africa ncd mexico indonesia india work total million open lab put patient government healthcare reinvestment programme begin centre sale marketing effort provider provide reimbursement healthcare worker payment assistance patient train partner amref health afford medicine relvar africa care international save ellipta benlysta revolade child collaboration country ministry health improve access overall total contribution develop market pioneer healthcare million people represent decline largely few novel reimbursement approach widen patient enrol gsk patient access new medicine addition commit assistance program primarily price current treatment train additional health worker result new coverage option available kenya ghana nigeria example usa list price patient affordable care act currently support unbacked diabetes medicine tanzeum new coverage option million community health worker low medicine class usa gsk continue help support campaign run earth institute diabete affect nearly million adult patient access medicine columbia university grant age nearly provide service help interested patient type diabete potentially eligible enrollee understand multiple treatment therapy provide additional support alternative coverage option separate cost aim vulnerable community product partnership save child mindful healthcare cost work financial donation partnership save child increase access affordability contribution total million form aim help save reflect value innovative quality million include life million child world medicine bring patient support nearly people poor country combine patient assistance program usa scientific expertise global reach million tablet albendazole charitys ontheground knowledge prevent lymphatic filariasis soil transmit helminth establish signature commitment combat neglect tropical programme democratic republic giving disease million product congo drc kenya aim tackle value cost support humanitarian challenge supply demand aid country distribute effective healthcare contribute nonprofit partner reduction maternal newborn death explore antiseptic corsodyl mouthwash reformulate prevent infect umbilical cord newborn cash product inkind time management total gsk annual report strategic report governance remuneration financial statement investor information invest africa gsk investing africa increase invest million create increase local capability access medicine build capacity world africa noncommunicable capacity manufacture medicine deliver sustainable growth disease open lab gsk invest million vision gsk product available scientist external researcher expand exist facility kenya population subsaharan work improve understand nigeria build new factory africa develop country noncommunicable disease variation ensure sustainable philanthropy see african patient hope production medicine africa new way business enable researcher academia african people facility industry develop new medicine locally relevant product include year invest address specific need african antibiotic respiratory hiv million africa work patient invest medicine create job boost partner aim provide portfolio academic chair form support longterm economic prospect relevant product support african student programme research expertise increase local work partner train range healthcare relate manufacturing capacity capability healthcare worker kenya discipline initiative ghana nigeria addition promote expansion pharmaceutical train ldc science public health engineering reinvestment programme logistic african university innovation disease impact know sharing insight apply open develop world collaborate partner innovation model target area commit innovation potential progress fast open need traditional commercial disease disproportionately affect innovation strategy offer external scientist model appropriate world poor access compound library announce plan create world potential commercial malaria resource promote africa ncd open lab return investment research disease develop continue collaborate partner world external researcher accelerate development new drug pipeline include world work alongside gsk scientist alzheimer disease new antibiotic malaria vaccine candidate file open lab spain build combat grow resistance regulatory approval portfolio research project vaccine candidate tuberculosis accelerate development ebola vaccine unprecedented rate receive regulatory approval respiratory oncology hiv aid diabetes help address change health burden develop country innovation promise deliver treatment need world vulnerable people gsk annual report strategic report governance remuneration financial statement investor information behaviour put need patient consumer change way work embe value expect employee act medicine potential risk transparently respectfully integrity benefit robust policy value interest patient governance framework help detect consumer time act effect patient focus associate medicine aim core value patient safety clinical trial integrity heart decision way place respect people conduct research approach trial protocol review transparency sale marketing way interact independent ethic committee patient doctor policymaker power reject stop trial maintain global risk register help code conduct research team world monitor firstly january complete code conduct accompany quality safety control appropriately rollout change way training seeks ensure conduct audits sale team compensate sale gsk understand value trial site party carry trial professional world long practice mandatory training behalf ensure high ethical quality individual sale target instead code help employee gain safety standard assess reward primarily base confidence right decision technical skill scientific report concern maintain strict quality safety knowledge quality service deliver speak programme standard manufacturing site hcp broad business quality culture put patient speak programme offer people performance usa gsk centre effort deliver right outside gsk range rank major pharmaceutical time essential ingredient channel voice concern report company hcp value material product misconduct fear reprisal bring customer satisfaction safe high quality include telephone internet survey case study channel run independent external expect supplier uphold secondly change support operator enable anonymous report high standard set education doctor commitment standardised monitor monitor performance medical education remain unchanged contact global compliance compliance process quality away direct sponsorship management system report potential risk assessment individual hcp arm length funding allegation ask question counterfeit medicine vaccine example thirdparty independent significantly increase monitor healthcare product pose significant medical organisation activity globally lead threat patient consumer safety increase contact thirdly long pay reputation counterfeit contact hcp speak prescriber crime work closely medicine instead update code conduct appropriate law enforcement custom channel include digital realtime reinforce critical role agency combat largescale application provide information value play protect reputation highly organise counterfeiter medicine vaccine way commercial success extend introduce fingerprint hcp want want cover complementary workforce endtoend supply chain serialisation require complete training expert medical doctor programme apply unique serial gsk role talk fingerprint product answer question medicine supplier expect follow unique identifier record peer responsible standard increase focus database product measure provide right responsible procurement new scan verify information support safe effective initiative simplify standardise database point supply chain use medicine approach manage thirdparty risk end packaging line globally focus supply chain risk site serialisation capability clinical research transparency key area need share information clinical research modernise sale marketing address ongoing helps build trust support modernise way sell commitment guiding principle research benefit medical science market medicine transform business human right patient care business model industry rigorous patient consumer safety year change share information patient safety number priority reward sale representative trial result regardless development testing manufacturing engage healthcare professional outcome consider use product hcp meet customer need positive negative online ensure patient interest come clinical study register good progress commitment key area announce december gsk annual report strategic report governance remuneration financial statement investor information increase instance address misconduct expose activity interaction bribery corruption risk give complexity sector commitment case retrain extend challenge work global healthcare transparency report annually employee colleague prevent continue face risk operate address misconduct make similar mistake emerge market especially challenging business standardise breach external code give issue country capture number contact gsk find breach face fund maturity global compliance external industry government respective healthcare system management system employee promotional code time continue believe robust use report potential allegation compare time compliance system work closely ask question lead breach consumer local government presence increase contact healthcare product primarily market help improve access contact breach country specific regulation medicine broad healthcare employee code local advertising antibribery corruption abac discipline policy violation guideline remain breach programme design prevent majority prescription product include noncompliance control practical attendance payroll violation breach promotional material guidance mandatory training total discipline advertising breach local country year gsk employee complementary dismiss agree leave specific regulationscode worker complete basic level training company voluntarily policy violation investigate breach high riskrole complete related sale marketing code external code step prevent advanced abac training account dismissal reoccurrence include total discipline governance structure strong retrain corrective action employee receive document focus responsible behaviour design disciplinary action warning prevent ethical breach thing wrong happen primary reason increase type policy violation act promptly decisively number disciplinary case particularly document warning september gsk china investment relate code conduct violation ltd gskci find guilty increase number report accord chinese law bribe china nongovernment personnel verdict increase china relate follow investigation initiate china investigation chinese ministry public security june authority strengthen include fine million monitoring system introduction deeply disappointing quarterly knowledge test sale matter illegal activity representative failure pass test gskci clear breach gsk result employee receive attendancepayroll arkete governance compliance procedure document warn employee sale force receive document code conduct promotional activity wholly contrary value train completion standard expect employee warn disqualify sale ood manufacturing publish statement apology incentive programme month practicesgood alsification distribution practice document chinese government people employee remain ocal work regulation travel expense website company follow policy violation violation fraud focus learn issue receive retrain increase monitoring support take step comprehensively rectify issue identify gskci include change engagement activity healthcare professional expand gsk company expand include datum review monitor invoicing publish formal report basis company researcher payment use robust compliance submission regulatory agency submit proposal independent system work closely government know clinical study report csrs review panel ensure datum continue innovate improve access register includes appropriately commit medicine establish gskci model summary csrs publish result work reform china healthcare industry follow improvement design antibribery corruption sought apply appropriate utility register see expose bribery lesson operation increase number page view corruption risk global give complex global environment visit duration visit business operation market operate continue government structure rule face risk company provide law developed researcher detail datum sit bear bribery clinical trial result researcher corruption risk exposure addition request access detailed anonymised global nature business patientlevel datum healthcare sector highly trial online system competitive subject regulation gsk annual report strategic report governance remuneration financial statement investor information people respect people gsk core value ensure right people right skill focus talent leadership performance engagement talent leadership engage employee mission work hard attract develop value strategy give retain skilled talented people gsk clear sense help need level organisation drive business forward ceo woman management position member corporate executive employee early stage team cet employee inform career offer opportunity strategy progress include apprenticeship internship year encourage employee graduate scheme track feedback improve experience achieve global target recruit reduction injury illness rate conduct interim survey student year early covering employee year talent programme indicate manager lead acknowledge global commitment people effectively increase apprentice population decide include engagement formal consultation groundbreake global partnership early talent community alongside employee representative prevention programme aim future leader graduate esprit union work council particularly create healthy workforce postgraduate programme participant important period restructure differentiate gsk employer continue work closely offer preventive healthcare leadership development programme group propose threepart service immunisation cancer provide employee level transaction novartis lead screening preventive examination skill need effective considerable change employee family leader management essential novartis employee join business multinational company offer new management employee transfer place benefit scale advanced lead business country key priority make good progress target experienced leader coach limit number redundancy implement globally programme help participant offer support redundancy strengthen leadership capability inclusion diversity unavoidable assist case case study inclusive employer value employee need find new employment information approach different perspective experience leadership health safety resilience working style global workforce progressive approach addition flagship pulse volunteer aim improve gender balance protect health wellbeing partnership enable employee work level organisation people focus sustain time nonprofit organisation focus create opportunity strong health safety culture charity month woman management proportion year experience add new dimension woman management continue halve reportable injury development people provide increase woman illness rate reduce insight expertise organisation continue represent cet figure incident working address major healthcare board gsk rank joint hour work mean challenge send fifth government report achieve target year early employee country work women representation board nonprofit provide health safety culture seek ftse company million worth skilled service ensure employee aware health employeele women leadership partner employee safety risk continue initiative bring virtually volunteer organisation invest leadership training help regional hub people leader country manage performance engagement gsk senior leader inaugural risk effectively improve way manage global conference encourage employee performance new global recognise challenge balance action women career development performance system set clear objective personal professional responsibility coach sponsorship programme align deliver strategy run energy resilience programme support female manager complete underpin gsk expectation globally help employee lead individual group coach session promote individual responsibility healthy life home work encourage senior leader define require global workforce sponsor female manager support gsk put emphasis country participate career development result way result achieve initiative plan increase strengthen connection participation individual performance rewardgsk annual report strategic report governance remuneration financial statement investor information create pipeline strong leader level business support leader develop lead delivery programme help small number leader bestpractice management capability middle manager lead demonstrate business acuman valuesbase decision make manager translate business leadership capability range leadership strategy action drive performance appoint cet programme clarify build capability enhance trust direct report participate expect leader deliver team member colleague enterprise leadership programme strategy help patient highly customise twoyear global experienced highpotential leader customer feel well learn experience lead business programme equip live long manage support diverse introduce new strengthen common language crosscultural highperforming programme enable female leader create gsk leadership team translate strategy enhance network clarify expectation leadership programme effective action business unit career ambition build ensure exceptional month period participant confidence strong senior diverse leader level business undertake immersive experience leader believe programme mumbai london focus help organisation well management essential balance numerous leadership decision reduce risk line leader programme provide new responsibility increase innovation manager thorough ground essential management responsibility woman management position work hard ensure people employ emerge understand need people market asia pacific japan represent disability develop employment workforce svpvp opportunity establish global consumer healthcare business india director disability council support aim pharmaceutical business latin manager disability confident organisation america particularly good progress total attract develop local talent found member business disability international social enterprise increase proportion people employee gender number involve global business gsk emerge market participate male female total helping develop global standard development programme join board measure businesss disability performance company graduate managementa ensure leadership team represent mba programme total diverse market serve build talent pipeline include management senior manager define people range cultural ethnic company act strategic report background currently nationality director report regulation include person responsible planning represent corporate directing control activity executive team board company strategically significant company board include director undertaking include consolidated account gsk annual report strategic report governance remuneration financial statement investor information planet reduce environmental impact set ambitious goal reduce carbon water waste value chain carbon help supplier reduce aim achieve carbon neutral carbon emission critical achieve external benchmarking value chain reduce value chain carbon goal well operational carbon emission understand impact gsk pharmaceutical company engage supplier patient collect carbon water achieve carbon trust consumer cut emission associate waste datum standard cut carbon emission source raw material use large material supplier water use product patient consumer use product reduce scope meter dose inhaler account emission operation carbon emission million tonne value chain inhaler recycling reduction compare scheme complete cycle run reduce water scope emission country allow reduce waste year year associate raw material send landfill prevent remain gsk pharmaceutical logistic business travel use inhaler propellant release company include cdps ftse meter dose inhaler use hfa greenhouse gas climate disclosure leadership index propellant increase water increase compare cut operational water use tackle scope emission represent continue challenge sale reduction baseline propellantbase inhaler continue mean meet target cut grow operational water use year early reduce energy use carbon measure reduce wide water emission associate generating impact value chain supply chain particularly energy purchase key cutting use challenge source raw material use operational carbon impact address complete extensive estimate million water invest renewable energy assessment prioritise future effort partner teri ngo infrastructure waste fuel regard india develop diagnostic water energy example cork site impact tool use million ireland instal metre wind identify opportunity large water year operation turbine cut site electrical supplier reduce water impact systematically audit site identify carbon footprint work supplier opportunity cut usage save energy teri extend process cut water use average cost supplier higheruse site work carbon trust pilot new way reduce water impact site pilot approach site tonne coea scope emission scope emission scope emission intensity ratio scope emission sale revenue tonne coem scope fte tonne coefte carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise editiongsk annual report strategic report governance remuneration financial statement investor information waste goal halve operational waste actively eliminate reuse recycling waste generate energy waste generate tonne waste operation continue explore way cut waste bring track achieve target total waste go landfill site achieve zero waste landfill status bring total mean manufacture major research development site send zero waste landfill track hit wastetolandfill target work achieve zero landfill site recognise need continue reduce waste complex regulatory environment mean take year required improvement manufacturing process reduce environmental impact improve send waste landfill focus reuse waste possible access medicine recycling incinerate generate energy proportion waste antibiotic big amoxicillin production site recycle dispose positive carbon footprint product base quality road singapore benefit increase volume sell introduce new process journey change way eliminate chlorinate solvent cut look way save energy waste produce reduce cut water impact waste improve carbon emission yield reduce cost unrecoverable solvent waste fuel achieve reduction generate electricity steam antibiotic carbon footprint pack jurong factory singapore year increase site worthe formulate production volume package antibiotic augmentin irvine scotland fermentation amoxicillin clavulanic acid take place penicillin put tablet foil blister clavulanic acid introduce strip instead reduce wind turbine combine heat foil use pack size power plant reduce carbon enable pack emission energy use pallet instal anaerobic digester treat fermentation waste generate biogas fuel combine heat power plant save site million year change mean irvine produce product energy water reduction carbon emission gsk annual report strategic report governance remuneration financial statement investor information group financial review group financial review discuss financial architecture operate financial performance group financial resource return shareholder hockpeng senior maintenance technician tuas vaccine manufacturing site singapore hundred thousand dose synflorix year use worldgsk annual report strategic report governance remuneration financial statement investor informationstrategic report governance remuneration financial statement investor information group financial review cfos statement financial architecture design support execution strategy enhance return shareholder clearly challenge year positive see strong highlight number factor combine create progress part business significant headwind particularly invest especially great expect contracting viiv healthcare emerge competitive pressure respiratory market oncology portfolio business launch lovaza generic boost new product launch supply disruption see grow strongly sale consumer healthcare business cer exclude divestment year operate leverage cer include divestment ability deliver operate leverage despite pressure see strong improve profitability heavily impact performance number overall trend sale particularly area business progress affect change mix regional delivery multiple new product product contribution launch continue delivery significant factor sale core earning share operate financial efficiency decline drive primarily high margin cer exclude divestment restructure cost base product advair lovaza result core operating profit time protect low cer term investment need turnover decline despite business new launch million incremental cost future growth driver saving deliver year total earning share financial architecture restructuring initiative ongoing cer financial architecture design cost reduction effort support consistent execution saving reinveste strategy enhance return new launch improvement deliver shareholder simplification manufacturing capability capacity focus deliver sustainable line strategic priority highlight sale growth company improve balance sufficient offset operating leverage profitability impact mix change low sale enhance financial efficiency result core operating margin order drive growth ep ahead percentage point low sale performance convert exclude currency effect earning cash margin decrease percentage cumulative annual saving use invest business return point primarily reflect increase restructuring achieve shareholder sga percentage sale despite attractive return decline actual spend clear set priority ensure remain focused manage market consistency allocate capital cost base effectively operational different business excellence programme initiate support core business gsk investment decision rigorously complete deliver service represent gsk sale benchmarke cash flow return billion annual saving investment cfroi framework major change programme announce deliver sale performance billion annual saving date sale decline cer october announce exclude divestment decline programme refocus pharmaceutical proportion gsk sale reflect significant headwind business deliver additional billion run new global erp platform respiratory lovaza generics annual saving supply disruption consumer gsk annual report strategic report governance remuneration financial statement investor information gsk financial architecture drive improve return shareholder sale growth operate leverage eps return shareholder financial efficiency free cash flow cashflow growth reduce complexity business continue align tax strategy return shareholder remain central strategy evolve business profile gsk commitment use free cash allow enhance efficiency implement number measure flow support increase dividend reduce operating cost improve centralise pharmaceutical intellectual long term undertake share repurchase consistency execution reduce property product inventory ownership return attractive complexity allow create help reduce reinvest business include bolton flexibility cost base core tax rate acquisition decision release saving easily low tax rate allocate cash flow rigorously reallocate resource key reflect resolution number benchmarke returnsbased investment opportunity matter benefit year framework base cfroi comparison multiple new launch earning share return billion cash find detail simplification increase flexibility shareholder include million initiative report restructure programme financial dividend million share implementation endtoend efficiency deliver allow repurchase total ordinary dividend supply chain organisational redesign offset substantial proportion declare share addition initiative line pressure year deliver increase dividend share establish core business service core eps protect year expect cbs bring support investment business maintain level function order streamline total eps primarily follow completion novartis standardise functional support reflect noncash adjustment transaction gsk intend return business cbs regional business contingent consideration relation shareholder billion net centre support market viiv healthcare result improve proceed company expect represent gsk sale sale outlook tivicay triumeq ordinary share repurchase enterprise resource planning erp unfavourable comparison platform implement product asset disposal gain replace large number separate future shape business outdate system company cash conversion propose threepart transaction give common database business remain highly cashgenerative novartis accelerate strategy standard business process continue focus improve clearly meet objective financial help simplify operation drive conversion earning cash architecture particular provide efficiency detailed analytic great focus cash generation work well balanced broad range improve daytoday operation capital control capital allocation growth driver significant synergy decision make operating leverage efficiency continue net cash inflow operation financial efficiency balance financial efficiency billion year sustainable cashflow financial efficiency deliver sterling term reflect negative significant value contribute positive impact strength sterling closure transaction remain leverage report core ep low profit include impact track completion week divestment currency effect abate commencing march continue advantage fourth quarter see era low interest rate secure full review financial result improve work capital position attractive longterm funding lose set page flexibility overall reduce net funding cost percentage point continue target credit rating believe target balance equity return interest stakeholder include bond holder optimise access simon dingemans capital market chief financial officer gsk annual report strategic report governance remuneration financial statement investor information group financial review core cer growth rate calculate compare group performance core result exclude divestment state group financial review discuss operate financial reconciliation core result total result present performance group financial outlook financial resource compare result year primarily core result report align business performance report result precede year underlie trading performance group order illustrate underlying performance practice primary growth driver remove volatility inherent discuss result term constant exchange rate cer noncore item growth represent growth calculate exchange core result report utilise basis internal rate determine result overseas company performance report core result present sterling remain unchanged previous discuss group financial review believe year cer represent growth constant exchange rate approach provide investor clear view underlie represent growth actual exchange rate trading performance group believe growth rate include report constant approach group result comparable exchange rate cer state cer growth majority peer use similar form discuss underlying performance report discuss result precise calculation differ group financial use number adjust measure report performance review present discuss total result group business measure management planning reporting purpose discussion free cash flow presentation investment analyst rate agency free cash flow net cash inflow operating activity define measure define ifrs capital expenditure interest dividend pay noncontrolling comparable similarly describe measure interest plus proceed sale property plant company equipment dividend receive joint venture associate undertaking free cash flow growth calculate core result report sterling basis reconciliation present report core result performance measure core result exclude divestment work capital conversion cycle complete work capital conversion cycle calculate number day sale outstanding plus day inventory outstanding core result exclude follow item total result day purchase outstanding amortisation impairment intangible asset exclude computer software goodwill major restructuring cost order illustrate underlying performance practice include cost follow material acquisition legal discuss result term constant exchange rate cer charge net insurance recovery expense growth represent growth calculate exchange settlement litigation government investigation rate determine result overseas company operate income royalty income disposal sterling remain unchanged previous associate product business acquisition year cer represent growth constant exchange rate accounting adjustment material acquisition represent growth actual exchange rate tax effect item addition charge additional year brand prescription drug fee accordance final regulation issue irs year record noncore item normal ongoing charge remain core result major restructuring cost charge arrive operating profit include cost arise operational excellence restructure programme initiate expand substantially complete end major change restructure programme initiate restructuring cost follow acquisition human genome sciences inc august stiefel laboratories inc july pharmaceuticals restructuring programme announce october rescale commercial operation global support function relevant rdmanufacturing operation pharmaceutical follow propose divestment oncology product change dynamic respiratory market gsk annual report strategic report governance remuneration financial statement investor information financial review pharmaceutical vaccines usa group turnover business turnover restate growth growth cer pharmaceutical vaccine group turnover pharmaceutical vaccine consumer healthcare divestment cer growth total cer represent growth constant exchange rate represent growth actual exchange rate total group turnover decline million operating profit pharmaceutical vaccine turnover fall pharmaceutical turnover decline growth emerge market japan viiv healthcare offset low sale establish product europe pharmaceutical flat year worldwide vaccine operating profit turnover decline positive performance emerge market offset lower report sale europe japan vaccines sale flat consumer healthcare turnover million year compare cer growth group turnover geographic region restate growth growth cer breakdown turnover europe growth cer emerge market respiratory japan oncology cardiovascular metabolic urology immunoinflammation group sale outside usa europe account pharmaceutical total turnover report growth adversely impact vaccine sale decline japan weak market condition supply constraint emerge market performance pharmaceutical vaccine turnover decline group turnover segment million pharmaceutical vaccine flat pharmaceutical sale impact continue price restate growth growth contracting pressure primarily affect respiratory sale cer volume decline negative impact pharmaceutical vaccine price mix sale advair decline volume decline price mix europe oncology product contribute strongly year emerge market sale million benefit strong japan performance votrient promacta recent viiv healthcare launch tafinlar mekinist benlysta sale grow establish product million generic competition continue impact trading sale dermatology product decline million unallocated pharmaceutical mepron decline million sale infanrix pharmaceutical pediarix grow million benefit favourable cdc stockpile movement compare absence vaccine competitor particularly half year sale consumer healthcare hepatitis vaccine million impact supply constraint boostrix million reflect return market competitor total group turnover include divestment complete year supply constraint rotarix fall million pharmaceutical vaccine result cdc stockpile withdrawal consumer healthcare gsk annual report strategic report governance remuneration financial statement investor information group financial review continue pharmaceutical vaccines europe pharmaceutical vaccine emerge market turnover turnover group turnover group turnover flat cer growth cer growth operate profit operating profit operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer respiratory respiratory oncology oncology cardiovascular metabolic urology cardiovascular metabolic urology immunoinflammation immunoinflammation pharmaceutical pharmaceutical vaccine vaccine performance performance europe pharmaceutical vaccine turnover flat emerge market pharmaceutical vaccine turnover million pharmaceutical sale flat million increase million pharmaceutical strong growth oncology avodart franchise vaccine market outside asia show strong growth million offset decline respiratory sale notable performance brazil million newly launch relvar ellipta record sale million rest latin america million sale year offset low sale china fall reflect effect government investigation seretide million volume decline year continue growth respiratory negative impact price reflect increase competitive product oncology avodart franchise pressure transition respiratory portfolio vaccine growth strong tender sale boostrix new product particularly year oncology rotarix synflorix largely offset low sale cervarix sale million lead votrient promacta result lose tender supply constraint newly launch tafinlar vaccine sale fall low sale infanrix cervarix flu vaccine reflect increase competitive pressure partly offset sale growth number product include boostrix competitor supply issue half year gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine japan viiv healthcare turnover turnover group turnover group turnover cer growth cer growth operate profit operating profit operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer respiratory combivir oncology epzicomkivexa cardiovascular metabolic urology lexivaagenerase pharmaceutical selzentry vaccine tivicay triumeq performance trizivir japan pharmaceutical vaccine turnover grow million pharmaceutical sale increase product vaccine sale decline pharmaceutical sale benefit performance strong growth avodart oncology product viiv healthcare turnover grow million growth growth partially offset low sale generate tivicay epzicom newly launch respiratory portfolio affect triumeq offset impact generic competition old weak allergy season beginning year increase viiv healthcare product include combivir trizivir competitive pressure decline vaccine sale reflect impact cervarix continue suspension recommendation use hpv vaccine partly offset high sale rotarix gsk annual report strategic report governance remuneration financial statement investor information group financial review continue establish product consumer healthcare turnover turnover group turnover group turnover cer growth cer growth operate profit operating profit operating profit operating profit cer growth cer growth breakdown turnover breakdown turnover growth growth cer cer imigranimitrex wellness lamictal oral health lovaza nutrition seroxatpaxil skin health valtrex performance zeffix consumer healthcare turnover million product compare reflect impact number supply interruption year growth rest world performance market affect weak market condition establish product turnover fall million sale sale europe million europe directly result supply issue million emerge market million japan million generic competition lovaza million seroxatpaxil million valtrex million contribute decline category gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical turnover europe oncology grow million lead sale votrient increase million year restate growth growth promacta grow million sale tafinlar cer million respiratory emerge market japan oncology sale year oncology grow million million respectively cardiovascular metabolic cardiovascular metabolic urology urology sale category fall million avodart immunoinflammation franchise grow million growth sale pharmaceutical duodartjalyn decline sale avodart levitra viiv healthcare hiv fall million year sale prolia fall establish product million agreement amgen terminate joint commercialisation number european markets mexico russia respiratory regional basis decline million respiratory sale decline million partly offset emerge market million seretideadvair sale million japan million europe flat million flixotideflovent sale decrease million ventolin sale grow million xyzal sale immunoinflammation exclusively japan grow million immunoinflammation sale grow million benlysta turnover year million benlysta respiratory sale decline volume decline sale million negative impact price mix primarily reflect continued price contracting pressure market sale pharmaceutical advair million decline volume therapy area million principally decline price mix flovent sale reflect generic competition dermatology product ventolin sale primarily reflect primarily affect sale soriatane decline impact net favourable adjustment previous accrual sale mepron rare disease category decline return discount breo ellipta record sale million partly offset growth relenza sale primarily anoro ellipta sell million year inclusion theravance milestone income million million european respiratory sale primarily reflect increase competition seretide sale decline viiv healthcare hiv million decline volume negative impact viiv healthcare sale increase price reflect increase competitive pressure europe japan emerge market transition respiratory portfolio new product tivicay record sale million epzicomkivexa sale year relvar ellipta record sale million increase million selzentry sale flat year million launch triumeq underway record sale million year growth partly respiratory sale emerge market grow seretide grew offset decline mature portfolio mainly drive generic million help improve performance china competition combivir million sale growth ventolin million veramyst trizivir million million offset decline flixonase largely drive low sale china establish product establish product turnover fall million sale japan respiratory sale fall million sale million europe newly launch relvar ellipta million offset impact million emerge market million increase competitor action adoair fall japan million million growth xyzal million offset low sale generic competition lovaza million respiratory portfolio seroxatpaxil million valtrex million contribute decline category oncology oncology sale grow million votrient sale grow million promacta sale grow million arzerra sale fall million tykerb tyverb sale fall million generic competition hycamtin argatroban offset new launch tafinlar mekinist record sale million million respectively oncology grow million votrient sale grow million sale promacta grow million tafinlar mekinist sale million million respectively gsk annual report strategic report governance remuneration financial statement investor information group financial review continue vaccine turnover new product launch year inclusive sale new product million growth growth grow year represent pharmaceutical cer vaccine turnover sale new product infanrix pediarix million grow represent pharmaceutical boostrix vaccine turnover cervarix breo ellipta launch copd fluarix flulaval relvar ellipta launch europe copd asthma hepatitis addition anoro ellipta launch rotarix april treatment copd synflorix tivicay launch subsequently launch europe triumeq launch vaccine sale europe vaccines sale fall million decline europe consumer healthcare turnover japan partly offset growth emerge market flat emerge market performance primarily reflect strength synflorix boostrix restate growth growth cer rotarix wellness infanrixpediarix grow million growth oral health benefit favourable comparison nutrition impact withdrawal cdc stockpile offset skin health decline europe emerge market boostrix sale increase million reflect growth region sale fall reflect return competitor year supply constraint restate growth growth cer cervarix sale decline million largely usa reflect decline emerge market japan increase europe competitive pressure particularly tender market row fluarix flulaval sale decline million low production level impact increase competitive pressure consumer healthcare turnover reflect impact supply issue comparison strong cold flu sale hepatitis vaccine fall million season early slow market rest world reflect supply constraint impact estimate global market growth approximately emerge market wellness rotarix sale million growth drive wellness sale million primarily tender shipment europe emerge market partly offset supply issue product recall significantly impact sale decline impact cdc stockpile product smokers health alli withdrawal oral health synflorix sale grow million primarily reflect oral health sale grow million continue growth strong tender performance emerge market sensodyne partly offset decline sale sale new pharmaceutical vaccine launch aquafresh impact supply issue europe increase competition growth growth cer nutrition pharmaceutical nutrition sale grow million horlick respiratory relvarbreo ellipta reflect continued growth india boost anoroellipta skin health oncology tafinlar sale product skin health million mekinist primarily low sale bactroban china cvmu duodartjalyn regional performance eperzantanzeum sale europe respectively immuno reflect supply issue product recall primarily inflammation benlysta affect product smoker health alli growth rest world market restrict slow economic pharmaceutical environment reflect growth market viiv healthcare tivicay partly offset reduction sale china triumeq decline sale smoker health product primarily vaccine nimenrix supply issue synflorix gsk annual report strategic report governance remuneration financial statement investor information core result research development use core reporting basis manage performance group definition core result set restate growth review group total result set page reconciliation total result core result present turnover turnover cer research development cost sale core expenditure decline million turnover compare million turnover restate growth exclude currency effect percentage decline turnover turnover cer percentage point reflect phase ongoing project cost sale spend completion number programme continue cost management benefit core cost sale percentage turnover compare net adverse currency translation remain focused deliver improve return effect cost sale percentage increase percentage investment sale contribution reduce attrition cost point reflect adverse price mix movement reduction important driver improve internal rate particularly decline pharmaceutical sale return expenditure determine percentage cost supply remediation activity continue investment sale instead capital allocate strict returnsbased new launch capacity future manufacturing technology criterion depend pipeline opportunity available partly offset benefit ongoing cost reduction operation pharmaceutical broadly split programme discovery activity completion phase iia trial sell general administration development work phase iib onwards support specific common infrastructure share service restate growth appropriate phase cost administrative expense report sga include turnover turnover cer table sell general table analyse core expenditure administration category core sga cost percentage sale percentage point higher exclude currency effect restate sga percentage increase percentage point sga decline turnover decline reduction sga discovery reflect continue investment multiple new product development launch partly offset benefit restructure facility central support function programme ongoing cost management effort pharmaceutical vaccine advertising promotion decrease primarily reflect consumer healthcare reduce activity establish product category ongoing cost management effort partly offset new product research development launch sell distribution decrease investment proportion pharmaceutical investment product launch offset saving ongoing latestage portfolio decrease pharmaceutical cost reduction programme general administration expense cost reflect completion increase primarily high phase expenditure partly number latestage programme offset benefit restructure programme royalty income royalty income million million reflect conclusion number royalty agreement include prior year catchup adjustment gsk annual report strategic report governance remuneration financial statement investor information group financial review continue core operating profit business net finance cost restate growth finance income margin margin interest income cer fair value movement pharmaceutical vaccine pharmaceuticals finance expense vaccine interest expense consumer unwind discount liabilitie healthcare remeasurement fair value movement finance expense corporate unallocated cost core operating profit core net finance expense million compare million reflect gsk strategy improve core operate profit segment funding profile group despite average net debt marginally higher restate growth share tax profit associate joint venture turnover turnover cer share profit associate joint venture pharmaceutical million million reflect reduce vaccine shareholde aspen group currency movement number oneoff adjustment usa europe core profit taxation emerge market japan restate growth viiv healthcare turnover turnover cer establish product core profit tax pharmaceutical taxation trading tax core profit amount million reflect unallocated effective core tax rate reduction pharmaceutical effective rate include resolution number matters pharmaceutical benefit year increase benefit intellectual vaccine property incentive consumer healthcare core earning share core eps decreased cer term compare corporate decline operating profit result financial unallocated cost efficiency core operating profit dividend core operate profit million low board declare interim dividend result dividend cer term turnover decline core operating year penny pence increase dividend margin percentage point lower note financial statement dividend exclude currency effect margin decrease percentage profit forecast point primarily reflect increase sga class circular date november issue percentage sale low royalty income sga cost shareholder connection propose threepart decline drive target cost management benefit transaction novartis include follow profit forecast ongoing restructure programme sga include respect gsk expect deliver year core credit report million release eps cer exdivestment basis broadly similar year reserve follow simplification group entity structure base adjust divestment complete trading arrangement structural saving approximately million realise actual result core eps decline cer broadly line year exclude divestment complete gsk annual report strategic report governance remuneration financial statement investor information core result reconciliation december acquisition core intangible intangible major legal accounting total result amortisation impairment restructuring charge result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million core result reconciliation december restate core result acquisition core intangible intangible major legal accounting total divestment divestment result amortisation impairment restructuring charge result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report governance remuneration financial statement investor information group financial review continue total result operate income net operating expense million million growth income include follow improved sale performance turnover turnover cer tivicay triumeq increase liability contingent turnover consideration acquisition shionogiviiv cost sale healthcare joint venture increase billion sell general result charge year million million liability represent present value expect administration future payment shionogi pay number research year vary line sale product contain development dolutegravir net income include profit royalty income disposal lucozade ribena business certain operating anticoagulant product aggregate million income operating profit follow announcement propose novartis transaction gsk enter number forward exchange contract net finance cost protect sterling value net dollar proceed profit disposal group completion transaction december interest associate contract loss position result share tax recognition unrealise loss million profit associate include net operate expense joint venture contract remain loss position maturity loss partly profit taxation offset gain expect sterling value proceed taxation receive group result favourable exchange total profit movement inception forward contract taxation year maturity contract gain position gain partly total profit attributable offset loss sterling value proceed receive group result unfavourable exchange shareholder movement inception forward contract earning share earning ad operate profit total operating profit million compare million noncore item result net charge cost sale million million exclude trading profit cost sale percentage turnover compare product divest net charge include net adverse currency translation effect profit disposal lucozade ribena business cost sale percentage decrease percentage point anticoagulant product aggregate million reflect adverse price mix movement particularly intangible asset amortisation increase million decline pharmaceutical sale cost supply million reflect accelerate amortisation remediation activity continue investment new launch lovaza intangible asset impairment million capacity future manufacturing technology offset million include writeoff commercial low intangible writeoff benefit ongoing cost asset reduction programme low intangible impairment major restructuring charge million million sell general administration include million operational excellence programme sga cost percentage sale million major change programme million percentage point higher exclude currency effect new pharmaceutical restructuring programme sga percentage increase percentage point sga increase turnover decline increase sga operational excellence programme initiate reflect continue investment multiple new product expand substantially complete launch high legal cost restructuring cost charge end total cost billion deliver annual million additional catchup year brand pretax saving approximately billion major change prescription drug fee accordance final regulation programme announce focus opportunity issue irs partly offset benefit simplify supply chain process build group capability restructure programme ongoing cost management effort manufacture restructure european pharmaceutical business programme expect advertising promotion decrease reflect reduce cost billion noncash charge expect activity establish product category ongoing cost million deliver approximately billion annual management effort partly offset new product saving remain track deliver annual pretax saving launch sell distribution decrease investment billion product launch offset saving establish product general administration expense increase new pharmaceutical restructuring programme announce high phase expenditure legal restructuring cost october rescale commercial operation global support partly offset restructure benefit function relevant rdmanufacturing operation pharmaceutical programme expect cost billion research development predominantly cash charge approximately billion new expenditure decline million annual cost saving expect year turnover compare million turnover deliver exclude currency effect percentage decline percentage point reflect low intangible writeoff legal charge million million include phase ongoing project spend completion million fine pay chinese government settlement number programme continue cost management exist antitrust matter high litigation cost benefit low intangible impairment gsk annual report strategic report governance remuneration financial statement investor information acquisition accounting adjustment result net critical accounting policy charge million income million include increase liability contingent consideration consolidated financial statement prepare accordance acquisition shionogiviiv healthcare joint ifrs adopt use european union venture million million net credit ifrs issue iasb follow accounting policy include profit disposal lucozade ribena approve board describe note financial business anticoagulant product aggregate statement accounting principle policy million item include charge relate major acquisition equity investment asset disposal oneoff require require estimate assumption affect regulatory charge certain adjust item amount asset liability revenue expense report financial statement actual amount result differ net finance cost estimate finance income critical accounting policy information interest finance income judgement estimate give note financial fair value movement statement key accounting judgement estimate relevant detailed note financial statement indicate relate follow area finance expense turnover interest expense taxation note unwind discount liability legal dispute note remeasurement fair value movement impairment goodwill intangible asset finance expense note business combination note pension postemployment benefit note profit disposal interest associate information judgement estimate area pretax profit disposal associate nil give note financial statement key accounting million profit reflect disposal million judgement estimate ordinary share aspen pharmacare million turnover share tax profit associate joint venture respect turnover accounting policy large business share tax profit associate million pharmaceutical vaccine market million principally arise group holding complex arrangement rebate discount aspen pharmacare allowance follow briefly describe nature arrangement existence pharmaceuticals profit taxation vaccine business take account net finance cost profit disposal interest associate share profit associate profit arrangement certain indirect customer taxation million compare million customer able buy product wholesaler cer decrease decrease sterling reduce price chargeback represent difference term invoice price wholesaler indirect customer contractual discount price accrual estimate taxation chargeback calculate base term agreement historical experience product growth rate customer rebate offer key manage care group current taxation purchasing organisation gpo direct indirect overseas current taxation customer arrangement require customer achieve total current taxation certain performance target relate value product total defer taxation purchase formulary status predetermine market share taxation total profit relative competitor accrual customer rebate estimate base specific term agreement charge taxation total profit amount million historical experience product growth rate represent total effective tax rate reflect differ tax effect noncore item medicaid programme stateadministere include number nonrecurre tax item programme provide assistance certain poor vulnerable patient medicaid drug rebate program tax relate acquisition accounting adjustment establish reduce state federal expenditure include defer tax increase liability expect prescription drug patient protection future payment shionogi recognition defer tax asset affordable care act law participate provide respect tax loss expect completion rebate state accrual medicaid rebate calculate novartis transaction tax credit arise resolution base specific term relevant regulation number tax matter tax authority include matter relate patient protection affordable care act prior year acquisition disposal cash discount offer customer encourage prompt current tax credit include benefit resolution payment accrue time invoicing number tax matter prior year adjustment adjust subsequently reflect actual experience earning share record accrual estimate sale return apply total eps compare historical experience customer return amount invoice include arise gain equity investment asset market relate information stock level disposal remain difference currency wholesaler anticipate price increase competitor activity gsk annual report strategic report governance remuneration financial statement investor information group financial review continue reconciliation gross turnover net turnover legal dispute pharmaceutical vaccine business follow respect accounting policy legal dispute follow briefly describe process determine restate restate level provision necessary margin margin margin accordance requirement ias provision contingent liability contingent asset provide gross turnover anticipate settlement cost outflow resource consider probable reliable estimate market drive likely outcome dispute legal expense arise segment claim group involved government significant legal proceeding respect possible mandated state reliable estimate expect financial effect program result ultimate resolution proceeding case appropriate disclosure case cash discount include annual report provision customer return position change time prior year assurance loss result outcome legal proceeding exceed material adjustment provision report group financial statement item total deduction like pharmaceutical company face net turnover complex product liability antitrust patent litigation investigation operation conduct governmental market drive segment consist primarily manage care regulatory agency year general counsel medicare plan gsk negotiate contract pricing group head group legal function honour rebate chargeback mandate segment senior vice president head global litigation group consist primarily medicaid federal government program responsible litigation government investigation receive government mandate pricing rebate routinely brief chief executive officer chief financial chargeback officer board director significant litigation pende group governmental investigation balance sheet accrual rebate discount allowance group return pharmaceutical vaccine business element establish product manage meeting appropriate detail status significant combine basis december total accrual litigation government investigation review matter amount million million number claim notify information potential claim notify assessment validity claim monthly process operate monitor inventory level progress settle claim recent settlement level wholesaler abnormal movement process use gross potential reimbursement insurer sale volume prescription volume base party datum source information receive key wholesaler aim meeting include assessment maintain inventory consistent level year sufficient information available able year base pattern consumption reliable estimate potential outcome dispute external counsel assist litigation matter basis pharmaceutical vaccine inventory level investigation assist briefing board wholesaler distribution channel december senior management follow discussion estimate approximately week matter possible reliable estimate turnover calculation use party information accuracy provision require level totally verify believe sufficiently provision legal dispute review adjust reliable purpose appropriate gsk annual report strategic report governance remuneration financial statement investor information property plant equipment financial position resource business sciencebase technologyintensive highly regulate governmental authority allocate significant financial resource renewal maintenance property asset plant equipment minimise risk interruption production noncurrent asset achieve compliance regulatory standard number property plant equipment process use chemical hazardous material goodwill total cost property plant equipment intangible asset december million net book value investment associate joint venture million land building represent million plant equipment million asset investment construction million invest million defer tax asset new renewal property plant equipment mainly derivative financial instrument relate large number project renewal improvement noncurrent asset expansion facility worldwide site property total noncurrent asset mainly hold freehold new investment finance liquid resource december contractual current asset commitment future capital expenditure million inventory operate lease commitment million believe current tax recoverable facility adequate current need trade receivables observe stringent procedure use specialist skill derivative financial instrument manage environmental risk activity environmental liquid investment issue date operation modify cash cash equivalent discontinue report planet asset hold sale note financial statement legal proceeding total current asset goodwill total asset goodwill decrease year million december million decrease reflect liability goodwill allocate oncology business transfer current liability asset hold sale follow decision sell business shortterm borrowing novartis trade payable intangible asset derivative financial instrument intangible asset include cost intangible acquire current tax payable party computer software net book value shortterm provision intangible asset december total current liability million million decrease reflect transfer million asset hold sale reflect noncurrent liability propose novartis transaction capitalise development cost longterm borrowing million amortisation impairment exist defer tax liability intangible million million respectively pension postemployment benefit investment provision hold investment include associate joint venture derivative financial instrument carry value december million noncurrent liabilitie million market value december total noncurrent liability million million large total liability investment associate aspen pharmacare holding limited book value december net asset million million investment theravance equity inc theravance biopharma inc book value share capital december million million investment include equity stake company share premium account research collaboration provide access retain earning biotechnology development potential interest interest reserve company arise business divestment shareholder equity noncontrolle interest total equity gsk annual report strategic report governance remuneration financial statement investor information group financial review continue derivative financial instrument asset net debt noncurrent current derivative financial instrument hold fair value million million majority relate interest rate swap cash cash equivalent liquid investment foreign exchange contract designate nondesignate borrowing repayable year intercompany loan deposit accounting hedge borrowing repayable year inventory net debt inventory million increase million year net debt increase million reflect aggregate increase primarily reflect impact stock build new consideration million pay increase shareholding product launch remediation consumer healthcare group indian pharmaceutical subsidiary supply chain partly offset favourable exchange impact acquisition remain group trade receivable indonesian consumer healthcare business hold party trade receivables million decrease reduction cash generate operation reflect receipt defer receivable aspen group cash generation liquidity enable payment respect inventory manufacturing site form ordinary dividend million share repurchase disposal anticoagulant product business million improve recovery receivables market favourable exchange impact movement net debt derivative financial instrument liability hold noncurrent current derivative financial instrument fair value million million net debt begin year primarily relate foreign exchange contract decreaseincrease cash bank overdraft designate nondesignated intercompany loan decrease liquid investment deposit acquisition disposal external debt legal net increase longterm loan provision accounting hedge net repayment shortterm loan trade payable debt subsidiary undertaking acquire trade payable amount million decrease exchange movement million reflect effect increase movement shareholde group indian pharmaceutical subsidiary net debt end year accrue partly offset effect increase return rebate accrual favourable exchange total equity impact december total equity decrease provision million december million decrease arise carry defer tax provision shortterm principally increase pension deficit million noncurrent provision million december impact dividend pay year million respect estimate future liability summary movement equity set million million relate legal dispute provision legal dispute indemnify disposal liability employee total equity beginning year relate liability cost restructure programme total comprehensive income year extent balance sheet date legal constructive obligation exist reliably estimate dividend shareholder share issue pension postemployment benefit change noncontrolle interest account pension postemployment forward contract relate noncontrolle arrangement accordance ia deficit interest net surplus allow deferred taxation million million pension arrangement share purchase cancel hold million million unfunded treasury share postemployment liability increase deficit share acquire esop trust predominantly drive low discount rate sharebase incentive plan discount value liability tax sharebase incentive plan december scheme purchase insurance distribution noncontrolle interest contract guarantee payment specify pensioner total equity end year liability contract value million december noncurrent liability noncurrent liability million december million include million million contingent consideration payable primarily respect acquisition shionogiviiv healthcare joint venture gsk annual report strategic report governance remuneration financial statement investor information share purchase commitment respect loan future interest payable employee share ownership plan esop loan disclose take account effect trust acquire million share glaxosmithkline plc derivative million share hold trust satisfy future enter number research collaboration exercise option award group share option develop new compound pharmaceutical company award scheme proportion share hold trust term arrangement include upfront fee equity respect award rule scheme require investment loan commitment fund specify level satisfy exercise market purchase issue research addition agree payment new share share hold trust match option future milestone achieve award grant company transfer million treasury share trust agreement relate compound early stage development potential obligation milestone december esop trust hold million payment continue number year compound million gsk share future exercise successfully development process generally share option share award carry value close product marketing approval great million million deduct probability success amount show reserve market value share intangible asset represent maximum pay million million milestone achieve include billion million share repurchase cost relate externalised project discovery portfolio million note share capital share premium number new commitment account december hold million share license agreement include arrangement treasury share million share cost adaptimmune ltd million million reach agreement trustee deduct retain earning pension scheme additional contribution follow completion novartis transaction expect year period include eliminate pension week commencing march intend return deficit identify december actuarial funding shareholder billion net proceed company valuation deficit persist contribution expect ordinary share repurchase payable follow year depend level deficit ordinary share purchase period january table include commitment exclude normal february ongoing annual funding requirement approximately million information pension obligation commitment contingent liability note financial statement pension post financial commitment summarise note financial employment benefit statement commitment contingent liability obligation respect short longterm debt set contingent liability note financial statement contingent liability follow table set contingent liability comprise note financial statement net debt discount bill performance guarantee letter credit item arise normal course business amount provide pension postretirement benefit expect expire set note financial statement pension postemployment benefit amount provide restructure total yrs yrs yrs programme legal environmental dispute set note financial statement provision guarantee contractual obligation commitment contingent liability follow table set contractual obligation total commitment december fall payment normal course business provide indemnification guarantee respect business disposal total yrs yrs yrs legal dispute subsequently arise loan provision outflow resource consider interest loan probable reliable estimate likely outcome dispute include note financial finance lease obligation statement provision finance lease charge operate lease provide outcome tax legal dispute commitment outflow resource consider probable reliable estimate outflow december intangible asset dispute provision property plant equipment possible reliable estimate potential investment outflow fund require settle dispute purchase commitment possibility outflow remote pension ultimate liability matter vary significantly commitment amount provide dependent outcome total litigation proceeding negotiation relevant tax authority discuss risk factor page note financial statement taxation legal proceeding gsk annual report strategic report governance remuneration financial statement investor information group financial review continue cash generation conversion investment appraisal summary consolidated cash flow set formal process assess potential investment proposal order ensure decision align overall strategy process include assessment cash flow net cash inflow operating activity return investment cfroi net present value net cash outflowinflow investing activity npv internal rate return irr timeline project long term consider impact earning net cash outflow financing activity credit profile relevant decreaseincrease cash bank overdraft discount rate perform financial analysis decide cash bank overdraft begin year internally allow determination extent investment decreaseincrease cash bank overdraft cover cost capital specific investment discount rate exchange adjustment adjust account country risk weighting cash bank overdraft end year capital expenditure financial investment cash bank overdraft end year cash payment tangible intangible fix asset amount comprise million million disposal realise million million cash payment acquire cash cash equivalent equity investment million million overdraft year sale equity investment realise million million net cash inflow operating activity year future cash flow million million decrease primarily expect future operating cash flow sufficient fund reflect impact strength sterling profit operate debt service cost satisfy normal level low profit include impact divestment capital expenditure meet obligation exist licensing agreement meet expenditure arise major free cash flow restructuring programme precise time free cash flow cash generate business uncertain outlined note financial statement meet obligation interest tax dividend pay major restructuring cost meet routine outflow noncontrolle interest capital expenditure property include tax dividend subject risk factor discuss plant equipment intangible asset page time time additional demand finance acquisition share repurchase access source liquidity free cash flow short longterm capital market bank free cash flow growth financial institution addition cash flow operation need free cash flow million year decrease primarily reflect impact strength sterling low work capital profit include impact divestment pay dividend shareholder million spend million work capital percentage turnover repurchase share work capital conversion cycle day reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow show work capital programme continue progress improvement collection receivable effective management payable balance reconciliation free cash flow year number initiative implement supply chain support pharmaceutical vaccine consumer healthcare business provide strong endtoend net cash inflow operating activity accountability case programme early purchase property plant equipment stage reduce volatility improve purchase intangible asset responsiveness allow well inventory management disposal property plant equipment report work capital conversion cycle day distort interest pay divestment intangible asset impairment interest receive include denominator conversion cycle dividend receive joint venture computation yearend conversion cycle associate undertaking adjust factor day distribution noncontrolle interest day respectively increase day predominantly stock building new launch remediation free cash flow consumer healthcare supply chain compound reduction denominator arise translation effect strong sterle overseas revenue cost contribute increase seven day gsk annual report strategic report governance remuneration financial statement investor information maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bond usd bond commercial paper bank borrowing lease treasury policy longterm credit rating moodys investor service report sterling pay dividend sterling profit moodys stable outlook standard poor rate role corporate treasury monitor manage stable outlook shortterm credit rating external internal funding requirement financial risk standard poor moodys respectively support strategic objective operate global liquidity basis primarily subsidiary company manage december cash liquid investment capital ensure subsidiary able operate hold follow go concern optimise return shareholder appropriate balance debt equity treasury activity govern policy approve board director bank balance deposit recently july treasury management group tmg meeting chair chief financial officer take place treasury treasury repo monthly basis review treasury activity member receive money market fund management information relate treasury activity corporate debt instrument government security capital management financial strategy support group strategic priority regularly review board manage capital cash liquid investment billion include amount hold structure group appropriate mix debt viiv healthcare hold centrally december equity free cash flow conversion improve earning exclude net debt billion december aftertax legal charge legal settlement table summarise cash gross debt free cash flow low billion effect hedge compare billion reflect impact strength sterle low profit include impact divestment consequence billion cash liquid investment pay increase shareholde indian pharmaceutical gross debt fix subsidiary acquisition remain float indonesian consumer healthcare business hold noninterest bear party net debt increase billion net debt december billion december policy borrow centrally order meet anticipate funding requirement cash flow forecast funding requirement monitor tmg monthly basis strategy diversify liquidity source range facility maintain broad access funding market day sweep cash number global subsidiary central treasury account liquidity management purpose gsk annual report strategic report governance remuneration financial statement investor information group financial review continue treasury operation counterparty risk management objective treasury activity manage posttax net set global counterparty limit banking cost income financial operation benefit earning investment counterpartie base longterm credit rating use variety financial instrument finance operation moodys standard poor corporate treasury usage derivative financial instrument manage market risk limit monitor daily corporate compliance officer operation derivative principally comprise forward cco operate independently corporate treasury foreign currency contract foreign currency option interest breach limit report cfo immediately rate swap swap borrowing liquid asset cco monitor credit rating counterpartie currency require group purpose manage exposure change rating occur notifie corporate treasury financial risk change foreign exchange rate change investment level authority interest rate limit appropriate addition relationship bank credit rating review regularly report present annually hold issue derivative speculative purpose tmg approval treasury policy specifically prohibit activity transaction financial instrument undertake manage risk arise underlie business activity strategic report speculation strategic report approve duly authorise interest rate risk management committee board director february objective minimise effective net interest cost sign behalf balance mix debt fix float interest rate time policy interest rate risk management limit float interest payment prescribe percentage operating profit simon dingemans interest rate swap redenominate fix chief financial officer rate bond mature float interest rate february duration swap match duration principal instrument interest rate derivative instrument account fair value hedge relevant liability foreign exchange risk management foreign currency transaction exposure arise internal external trade flow generally hedge objective minimise exposure overseas operating subsidiary transaction risk match local currency income local currency cost possible internal trading transaction match centrally manage intercompany payment term reduce foreign currency risk foreign currency cash flow hedge selectively management corporate treasury tmg include hedge foreign exchange risk arise acquisition disposal asset possible manage cash surplus borrowing requirement subsidiary company centrally forward contract hedge future repayment originate currency order reduce foreign currency translation exposure seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterle certain borrowing swap currency require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major currency reduce exposure investment overseas group asset tmg review ratio borrowing asset major currency monthly gsk annual report strategic report governance remuneration financial statement investor information governance remuneration section board corporate executive team chairman letter corporate governance framework board report shareholder oversight stewardship future action leadership effectiveness committee report audit risk nomination corporate responsibility remuneration report chairman annual statement annual report remuneration remuneration policy report ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statement investor information board diversity experience international experience composition tenure nonexecutive scientific global executive year finance usa nonexecutive year industry europe male year emap female year sir christopher gent skill experience chairman sir christopher year experience lead global business track record deliver outstanding performance nationality highly competitive industry appoint manage director british vodafone plc chief executive officer appointment date retirement sir christopher june chairman nonexecutive director ferrari spa member british january airways international business advisory board committee membership external appointment corporate responsibility sir christopher senior adviser bain committee chairman nomination remuneration finance sir philip hampton skill experience chairman designate prior join gsk sir philip chair major ftse company include sainsbury plc serve group finance nationality director lloyds tsb group group plc group plc british british gas british steel plc sir philip previously appoint appointment date executive director lazards nonexecutive director rmc january deputy group plc belgacom chairman chairman april financial investment limit manage government nonexecutive chairman shareholding bank external appointment committee membership sir philip currently chairman royal bank scotland group nominations committee plc senior independent director anglo american plc chairman finance chairman remuneration committee member audit committee sir andrew witty skill experience chief executive officer sir andrew joined gsk work south africa usa singapore senior role nationality appoint president europe join gsk corporate british executive team sir andrew serve lead nonexecutive board appointment date member department business innovation skill january december president european federation chief executive officer pharmaceutical industry association july external appointment committee membership sir andrew member prime minister business advisory finance group appoint business ambassador group school economic management advisory board sem tsinghua university beijing china sir andrew chancellor university nottingham simon dingemans skills experience chief financial officer prior join gsk simon year experience investment banking warburg goldman sachs nationality time advise broad range large corporate number british industry sector include pharmaceutical consumer healthcare appointment date simon advise gsk decade appointment january chief closely involve number gsk key strategic project financial officer april external appointment committee membership simon chairman group member corporate finance development council national theatre gsk annual report strategic report governance remuneration financial statement investor information moncef slaoui skill experience chairman global vaccines moncef join gsk vaccine engineer development robust vaccine pipeline lead worldwide nationality business development pharmaceutical product moroccan belgian american appointment lead give overall responsibility appointment date gsk oncology business gsk vaccine global franchise moncef advise president council advisor science technology member committee membership board agency science technology research astar finance january phd molecular biology immunology universit libre bruxelle publish scientific paper presentation prior join gsk moncef professor immunology university mon belgium external appointment moncef member phrma biotechnology industry organization board usa member advisory committee director national institutes health adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serve nonexecutive director international aids vaccine initiative iavi sir deryck maughan skill experience senior independent sir deryck wealth international corporate investment nonexecutive director banking experience previously serve chairman chief executive officer citigroup international salomon nationality brothers inc serve vice chairman new york stock british exchange sir deryck senior adviser appointment date partner kohlberg kravis roberts previously serve june senior nonexecutive director thomson reuters independent nonexecutive external appointment director sir deryck nonexecutive director blackrock inc trustee committee membership british museum new york university langone medical center audit risk nomination remuneration finance professor sir roy anderson skill experience independent nonexecutive professor sir roy worldrenowne medical scientist advanced director scientific expert knowledge infectious disease epidemiology currently professor infectious disease faculty medicine imperial nationality college london fellow royal society academy british medical sciences royal statistical society honorary appointment date fellow institute actuary foreign associate member october institute medicine national academy sciences french academy sciences professor sir roy bring scientific committee membership expertise board deliberation nomination finance external appointment professor sir roy member international advisory board holdingham group trustee natural history museum london member vaccine international advisory board vacciab pharma hold sdn bhd malaysia stephanie burn skill experience independent nonexecutive stephanie recognise global business leader serve director chairman president ceo dow corning corporation retirement end strong scientific background nationality phd organic chemistry organosilicon specialty american advocate science education stephanie previously sit appointment date president export council officer society chemical february industry american section past honorary president ukbased parent society stephanie officer chairman committee membership american chemistry council corporate responsibility remuneration finance external appointment stephanie appoint nonexecutive director corning inc january nonexecutive director kellogg company february gsk annual report strategic report governance remuneration financial statement investor information board continue stacey cartwright skill experience independent nonexecutive stacey charter accountant significant experience director global consumer business corporate finance serve executive vice president chief financial officer burberry group plc nationality july prior join burberry group plc stacey hold british role chief financial officer egg plc appointment date work financerelated position april granada group plc committee membership board determine stacey recent relevant financial audit risk finance experience agree appropriate qualification background audit committee financial expert external appointment stacey chief executive officer harvey nichols group company lynn elsenhans skill experience independent nonexecutive lynn wealth experience run global business director significant knowledge global market gsk operate serve chair president chief executive officer sunoco nationality inc prior join sunoco president american chief executive officer lynn work royal dutch shell appointment date join hold number senior role include july executive vice president global manufacturing committee membership external appointment audit risk corporate lynn nonexecutive director baker hughes inc responsibility nomination flowserve corporation director texas medical center finance nonexecutive director tee great houston trustee united way great houston trustee rice university judy lewent skill experience independent nonexecutive judy extensive knowledge global pharmaceutical industry director corporate finance join merck serve chief financial officer retire nationality judy previously nonexecutive director purdue pharma inc american napp pharmaceutical holding limit certain mundipharma appointment date international limited company december judy april previously serve nonexecutive director dell inc quaker oats company committee membership audit risk committee board determine judy recent relevant financial chairman nomination experience agree appropriate qualification remuneration finance background audit committee financial expert external appointment judy nonexecutive director thermo fisher scientific inc motorola solutions inc trustee rockefeller family trust chairperson audit committee rockefeller financial service life member massachusetts institute technology corporation member american academy arts sciences daniel podolsky skill experience independent nonexecutive daniel worldrenowne researcher advanced knowledge director scientific expert underlie mechanism disease new therapy gastrointestinal disorder mallinckrodt professor nationality medicine chief gastroenterology massachusetts general american hospital harvard medical school previously serve appointment date chief academic officer partner healthcare system daniel july current responsibility lead large academic medical centre relevant insight healthcare delivery daniel bring scientific committee membership expertise board audit risk committee deliberation audit risk corporate responsibility finance external appointment daniel president university texas southwestern medical center hold philip obryan montgomery distinguish presidential chair academic administration doris bryan wildenthal distinguish chair medical science member institute medicine national academy sciences member board southwestern medical foundation director antibe therapeutics inc member national academies sciences board army science technology gsk annual report strategic report governance remuneration financial statement investor information urs rohner skill experience independent nonexecutive urs broad range business legal experience serve director chairman number board recently credit suisse world lead financial service company prior join credit nationality suisse urs serve chairman executive board swiss ceo prosieben prosiebensat media follow appointment date number year private practice major law firm switzerland january usa admit bar canton zurich state new york committee membership remuneration finance external appointment urs currently appoint chairman board credit suisse group chairmans governance committee appoint chairman member board trustees credit suisse research institute credit suisse foundation tom swaan skill experience independent nonexecutive tom long distinguished career european banking director industry member managing board chief financial officer abn amro tom hold executive nationality position dutch central bank nonexecutive director dutch financial service authority financial conduct authority appointment date previously nonexecutive director january kpmgs public interest committee vice chairman supervisory board chairman audit committee royal ahold committee membership remuneration committee board determine tom recent relevant financial chairman audit risk experience agree appropriate qualification nomination finance background audit committee financial expert external appointment tom chairman supervisory board van lanschot bankiers chairman board director zurich insurance group member supervisory board royal dsm senior adviser ondra partner je ulrich skill experience independent nonexecutive jing managing director vice chairman asia pacific jpmorgan director chase advise firm senior global client asset class build relationship executive asias lead nationality enterprise je prominent adviser large global american asset management company sovereign wealth fund multinational appointment date corporation work line business jpmorgan chase july foster great crossborder collaboration strengthen senior client relationship asia pacific rest world committee membership audit risk finance jing managing director chair global market china jpmorgan jing work deutsche bank manage director head great china equity previously hold financial position specialise asia pacific region clsa asia pacific markets emerge market investor corporation educate harvard stanford university external appointment jing currently independent director ermenegildo zegna spa member bocconi universitys international advisory council han wijer skill experience independent nonexecutive han broad range business economic political director experience serve chief executive officer chairman akzo nobel hans long nationality distinguish career academia public service strategy dutch consulting serve senior partner boston consulting appointment date group april external appointment committee membership han chairman supervisory board heineken corporate responsibility deputy chairman nonexecutive director royal dutch shell remuneration finance chairman supervisory board afc ajax member supervisory board hal holding gsk annual report strategic report governance remuneration financial statement investor information corporate executive team sir andrew witty deirdre connelly roger connor simon dingemans chief executive officer president north america president global manufacturing chief financial officer pharmaceutical supply board board deirdre join gsk cet roger join cet president north america appoint president global pharmaceuticals february manufacturing supply gms work eli lilly company work year year hold variety president designate gms position include president roger join gsk operation senior vice president astrazeneca work global commercialisation finance manufacturing strategy woman health senior vice role include gsk site president human resource cork ireland ware deirdre hold bachelor degree prior position gms roger marketing economics vice president office lycome college pennsylvania ceo corporate strategy graduate harvard february universitys advanced management hold degree mechanical program manufacturing engineering serve director queen university belfast phrma board board masters manufacturing leadership macys inc harvard cambridge university university public health policy charter accountant council deirdre native san juan puerto rico deirdre announce retirement gsk step cet february nick hiron abbas hussain bill louv david redfern senior vice president global president global pharmaceuticals senior vice president core chief strategy officer ethic compliance business service abbas join cet david join cet chief strategy nick appoint cet appoint president global bill join cet officer september senior vice pharmaceutical october appoint april create responsible corporate president global ethic join company lead core business service cbs development strategic planning compliance responsible president emerge market integrate share service addition current role compliance risk management asia pacific june join global support function chairman board corporate security investigation viiv healthcare ltd board viiv healthcare ltd april october aspen board join company nick join gsk december vice president medical datum previously senior vice international auditor sciences hold increasingly president northern europe later head audit assurance previously spend year senior role responsibility manage gsk combine separate eli lilly hold position pharmaceutical business audit function independent include president europe prior join gsk bill region prior senior team operate common vice president europe marion merrell dow early vice president central riskbase methodology june hold position eli lilly associate professor eastern europe david join gsk nick take role china australia usa india turkey university alabama medical center finance director establish new germany role include bill bachelor science european business governance model china business development sale degree biology college business create consistent marketing management william mary master david bachelor science approach compliance degree medicinal science doctor philosophy degree bristol university nick fellow charter chemistry pharmacology degree statistic charter accountant cti otu sanagement rng inb mor inn div sity uor eid gie inin apn inf tii irs ctor aspen pharmacare holdings ltd south africa base global generic company gsk hold minority equity stake gsk annual report strategic report governance remuneration financial statement investor information moncef slaoui claire thomas phil thomson chairman global vaccine senior vice president senior vice president human resource communication board government affair claire appoint cet senior vice president human phil join cet resource appoint senior vice president claire join company communication government affair senior manager human responsibility medium resource sale marketing relation investor relation corporate group pharmaceutical responsibility internal communication director human product communication resource pharmaceutical government affair appoint senior joined glaxo wellcome trainee vice president human resource move pharmaceutical brand pharmaceutical europe marketing product communication senior vice president human director medium resource international relation glaxo wellcome plc prior join company director investor relation work ford motor company return hold position human corporate medium relation vice resources president phil work numerous corporate product reputational claire bachelor science matter gsk degree economic management industrial relation phil earn degree english university wale history durham university dan troy patrick vallance emma walmsley senior vice president president pharmaceuticals president consumer healthcare general counsel patrick join cet emma join gsk dan joined gsk cet appoint president pharmaceutical appoint cet president senior vice president general january prior consumer healthcare counsel september senior vice president medicines business october discovery development emmas leadership business previously partner new strategy washington law firm sidley austin patrick join company lead fast move consumer llp represent mainly head drug discovery healthcare company pharmaceutical company trade focus organisation science association matter relate good chance lead april gsk announce food drug administration new medicine create small interconditional deal novartis fda government regulation multidisciplinary team call include proposal create dan chief counsel discovery performance unit joint venture company fda serve transform gsk approach consumer healthcare business primary liaison white house late stage clinical trial design provisional deal complete department health execution emma ceo joint human service join gsk patrick venture member board dan graduate cornell clinical academic university prior join gsk emma work universitys school industrial college london director loreal year labor relation earn genome research limited degree classic modern law degree columbia languages oxford university university school law dan name legend law burton awards gsk annual report strategic report governance remuneration financial statement investor information corporate governance letter shareholder addition judy lewent chair audit risk committee provide overview work committee sir deryck maughan senior independent director provide insight board culture dynamic listening view shareholder receive feedback session hold run corporate reporting season help shape key area governance remuneration disclosure corporate governance code review responsibility report requirement new standard include financial reporting council update corporate governance code publish september effective financial year principal change relate go concern viability statement internal control risk management area bring code uptodate new remuneration reporting practice review indicate strong position comply fully dear shareholder new standard board report formally chairman board commit gsk seek year annual report implementation operate high standard corporate governance believe governance structure underpin ability appointment chairman designate deliver strategy grow diversified business deliver welcome appointment sir philip hampton designate product value simplify operating model successor joined board january create additional longterm value shareholder deputy chairman april sir philip succeed end agm important board need firmly undergo thorough wideranging induction process embe valuesbased conduct behaviour employee tailor role background governance structure want ensure detail provide firm basis board employee guide commitment valuable early contribution board deliberation value compliance local law fully conversant business environment regulation operate foundation operate chairman meantime commitment lay code conduct work closely sir philip support sir strengthen reissue january available deryck maughan senior independent director governance area website draw number handover period ensure smooth seamless transition key company policy principle provide work guide way apply value global operation china investigation abac chinese authority reach conclusion investigation highlight key corporate governance prioritie chinese business september board address deeply disappointing matter gsk cooperate fully board evaluation authority take step comprehensively rectify issue independent external evaluation undertaken board identify operation china audit risk committee committee please report result board member attend fully appraise tracy long review positive confirming board development continue closely monitor group abac operate effective deal activity detail set judy lewent challenge face time significant transition audit tender company board key priority board regularly review development level close propose threepart transaction novartis reform audit market particularly relation regulation track complete week commencing march govern audit contract tender audit firm rotation integrate novartis vaccine consumer healthcare take consideration view shareholder business exist governance arrangement overall assessment auditor performance audit risk committee review implication tender manage orderly refreshment board result external audit contract detail conclusion set number plan retirement board committee intend initiate tender year address identify additional exercise significant level change skill experience gap company experience expect initiate sir philip hampton chairman designate succeed preparation tender process second half nomination committee chairman immediately order new auditor audit focus tailor refreshment board requirement follow page outline approach governance future reshape group lead practice underpin delivery strategy structure chapter development evolve external landscape corporate governance report maintain continue serve committee provide continuity statutory risk disclosure previously appear support sir philip details long key finding report continue refer shareholder information action point board agree address section page risk management section set page respectively annual investor meeting commend report shareholder session hold november please discuss corporate governance practice large shareholder tom swaan remuneration committee sir christopher gent chairman cover executive remuneration arrangement chairman february gsk annual report strategic report governance remuneration financial statement investor information corporate governance framework board coherent corporate governance framework clearly define responsibility accountability design safeguard enhance longterm shareholder value provide robust platform realise group strategy grow deliver simplify internal control risk management arrangement describe page integral gsk governance framework board committee order board operate effectively consideration key matter board committee establish board summary role board committee set table term reference committee available website report membership work undertake audit risk remuneration nomination corporate responsibility committee give page board chief executive officer chairman executive independent director nonexecutive director corporate executive team corporate corporate administration audit risk remuneration nomination responsibility finance transaction committee committee committee committee committee committee review review review review review review responsible recommend recommend external issue approve approve financial internal board board potential annual report matter report process overall executive structure size impact form connection integrity remuneration policy composition gsk business convene administration financial statement appropriate fee board reputation agm group system internal chairman appointment management quarterly result business control director committee announcement certain corporate annual governance identification determine member cet oversight gsk certain major transaction management term service member responsible business licensing capital risk external remuneration succession commitment transaction internal audit executive director board cet change process member group investment initiate audit cet instrument tender counterparty limit selection review appointment approve external auditor remuneration remuneration report oversight work gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue board report shareholder oversight stewardship future action board board please report compliance requirement corporate governance code respect position audit tender board responsible longterm success company corporate governance strategy risk management financial performance accountable shareholder ensure group appropriately manage governed deliver gsk strategy grow deliver simplify board programme board meet time board member attend schedule board meeting board agenda shape create time strategic discussion debate closely manage time allocate routine item ensure focused consideration strategic priority agenda board meeting include follow business month strategy board risk oversight governance january approval plan review financial result review internal outlook board evaluation report reappointment auditor secretary report include regulatory governance update march review gms performance secretary report include strategy update regulatory governance update deep dive pipeline launch deep dive india review financial result preparation agm patent protection year date secretary report include regulatory governance update july credit profile distribution policy annual emap vaccine secretary report include review funding strategy business review regulatory governance update treasury policy annual update review pension strategy north american review insurance strategy pharmaceutical annual update october review output annual threepart novartis transaction board cet strategy meeting shareholder approval process review talent leadership secretary report include regulatory development strategy governance update december review plan europe annual update review external board evaluation secretary report include regulatory governance update year board member invite attend audit risk committee meeting risk matter routinely discuss board performance board identify certain action assist add value deliberation performance board action set action progressachievement strategy propose transformational threepart novartis transaction board look long term view year explore ipo minority interest viiv healthcare enhance future key strategic issue face company strategic flexibility reshape group demonstrate board long term strategic positioning gsk board meeting consideration regular annual business unit update time spend routine matter manage board adjust focus principally strategic issue enable strategicbusiness discussion priority assurance risk management aspect update ensure critical area oversight maintain consider audit risk committee meeting attend board iii annual boardcet meeting format session refine simplify presentation structure format session review shorten cet member responsible ensure appropriately gear realise maximum propose shape direction strategic issue value term strategic insight direction set consideration increase time challenge develop strategy great depth enhance personal accountability propose direction set china review board remain committed review implement appropriate action reviewed board appropriate recommend action rope gray implement necessary conclusion external independent review action undertake china investigation rope gray independent review set action set gsk annual report discuss internally facilitate evaluation board activity senior independent director gsk annual report strategic report governance remuneration financial statement investor information board report shareholder oversight stewardship future action continue agms key highlight glance agm hold qeii conference centre agm hold qeii conference centre london london director attendance sir christopher gent tom swaan jing ulrich stand billion vote cast resolution issue board year service share capital respectively sir robert wilson stand year service sir philip hampton urs rohner stand election board director retire reelect board receive director stand reelection board vote cast favour board believe director effective demonstrate igh vote favour reelect number director commitment role ow vote favour reduce require notice director formally evaluate chairman general meeting standing reelection chairman designate induction programme sir philip hampton sir philips induction programme design arrange chairman consultation company secretary ceo base principle company new nonexecutive director induction programme customise account sir philips designate leadership role gsk seeks build clear comprehensive view industry gsk strategy position induction programme roll phase set area understand induction content pharmaceutical industry briefing industry external consultant investor perspective business teachin session head global pharmaceutical consumer healthcare vaccine operating model teachin session head gms corporate operation onetoone meeting cfo head remuneration corporate strategy communication government affair legal global ethic compliance core business service senior executive responsible tax treasury pension medium government affair audit assurance security shareholder external programme meeting arrange stakeholder adviser induction underpin thorough ground corporate governance arrangement include meeting board director review current past board evaluation attend meeting committee member assess understand corporate governance framework boardroom culture dynamic addition induction activity supplement extensive programme visit principal gms vaccine site meet external adviser board performance action point main finding agree action point arise board evaluation review externally facilitate tracy long boardroom review limited progress disclose gsk annual report set key finding agree action point composition board change chairman designate nomination committee seek enhance year governance process relate board composition tenure size require carefully plan thoughtfully execute refreshment programme review seek develop objective specification plan board role alignment strategy external landscape company evolve circumstance director identify gap board close knowledge experience gap consider process current composition relate pricing recruitment new nonexecutive director combine refreshment designate healthcare emerge market consumer specialist role board medical scientific expertise senior independent healthcare knowledge director sid give speed complexity external critical skill set potential candidate international market cultural experience landscape change potential surprise crisis stakeholder management consider composition choice peer group highly experienced nonexecutive director board benchmarke crucial component board composition replacement current sid chairman designate lead search involve internal external candidate role retire agm priority issue sid specification develop balance replacement exist knowledge ability work chairman designate conduct robust board evaluation interact shareholder able commit necessary time role consideration give reduce aspiration consider refresh board competenceskill matrix size board judge board refreshment programme link company strategy strong composition dynamic consideration give enhance chairman designate lead process consider good practice technique nonexecutive director evaluation process combination annual individual peer evaluation gsk annual report corporate governance continue senior independent director leadership effectiveness sir deryck maughan senior independent director sid sir deryck role act sound board board chairman trust intermediary board meet time member attend director available additional point contact follow shareholder responsibility include evaluation number number performance chairman request chairman meeting hold whilst meeting board member attend evaluate board committee collaboration sir christopher gent committee chairman year evaluation conduct internally sid work process selection sir andrew witty new chairman appropriate chair nomination simon dingemans committee agree recommendation board moncef slaoui chairmans successor detail sid role professor sir roy anderson process undertake select sir philip replace sir christopher stephanie burns chairman available stacey cartwright sir deryck maintains understand issue concern lynn elsenhans major shareholder meeting report judy lewent investor relation team briefing company sir deryck maughan secretary corporate governance issue daniel podolsky tom swaan ceo sir andrew responsible management business je ulrich develop group strategic direction consideration han wijer approval board implement agree strategy sir robert wilson assist members corporate executive team cet addition schedule meeting board meet meet time year require quorate basis occasion consider corporate transaction short biography member cet give include threepart novartis transaction chinarelate corporate executive team page development approve appointment sir philip hampton urs rohner board company secretary company secretary victoria whyte solicitor sir philip hampton urs rohner appoint fellow institute charter secretary administrator nonexecutive director effect january victoria deputy secretary secretary sir robert wilson retired board remuneration committee act secretary board board committee appointment chairman company secretary january role chairman lead manage business board provide direction focus ensure victoria support chairman design induction new clear structure effective operation board director delivery corporate governance agenda committee set agenda board discussion particular planning agenda annual cycle board promote effective constructive debate support committee meeting ensure information sound decisionmake process ensure board receive available board member timely basis victoria advise accurate timely clear information particular director board procedure corporate governance matter companys performance arrange nonexecutive director meet investor discuss aspect corporate governance arrangement chairman work closely chief executive officer request arrange attend internal management sir andrew witty ensure strategy action meeting visit business operation enhance agree board effectively implement provide knowledge understand business support advice sir andrew respect executive responsibility manage group division responsibility company secretary respond chairman ceo agree board consultation evolve global governance corporate set governance section website report agenda behalf group engage shareholder ensure fully understand gsk governance chairman responsible shareholder performance remuneration arrangement group lead discussion development independence relation board consider nonexecutive director sir philip hampton join board january independent character judgement free deputy chairman april succeed business relationship materially interfere sir christopher gent chairman effect end exercise judgement sir christopher gent sir agm philip hampton satisfied independence test respective nonexecutive director appointments board nonexecutive director provide strong independent independence nonexecutive director serve element board place constructively board year subject rigorous review challenge support management shape proposal strategy succession planning bring particular board consider sir deryck maughan independent judgement breadth skill experience serve board year continue demonstrate gain senior level international business characteristic independence challenge management operation academia take rigorous debate whilst possess outstanding knowledge company business affair gsk annual report strategic report governance remuneration financial statement investor informationstrategic report governance remuneration financial statement investor information board composition diversity time allocation seek build effective complementary board nonexecutive director letter appointment capability appropriate scale complexity strategic set term condition directorship position business process board appointment chairman nonexecutive director expect lead nomination committee describe page devote time necessary proper performance duty precise timing give vary mindful need balance composition board year year depend company activity director committee refresh progressively time expect attend board meeting additional draw experience long serve director meeting require tap new external perspective insight expect attend meeting committee recent appointee bring board deliberation member audit risk committee meeting nonexecutive director draw wide range industry open director furtherance risk background include pharmaceutical healthcare medical compliance responsibility strategy session research academia retail insurance financial service visit operational site appropriate experience complex organisation global external evaluation board reach considerable experience pharmaceutical board carry evaluation performance industry recent appointee bring new approach committee year evaluation facilitate group board discussion externally year evaluation carry board diversity policy set detail independent external facilitator tracy long boardroom gender diversity gsk global workforce review limited connection company responsible business indepth process involve long board induction business awareness training conduct individual interview current company secretary assist chairman design director exception sir philip hampton urs facilitate tailor induction programme new director rohner join board january company ongoing training chairman designate induction secretary key senior executive regularly attend programme devise sir philip hampton board committee meeting commence joined board present review past paper minute induction programme nonexecutive director typically include meeting member cet senior attend board committee meeting september executive explain company business commercial october include annual board cet regulatory environment operate investor strategy session perspective guidance duty obligation compile output external evaluation report director list company visit business operation contain finding recommendation feature induction programme hold ensure nonexecutive director develop maintain great insight understand business individual feedback session director invite attend internal management meeting include session lead sid nonexecutive director meeting cet research development executive ceo chairman present product executive scientific review board portfolio investment board commercial accountability board session chairman risk oversight compliance council meet finally collective feedback session entire board employee informally visit group operation area principal focus recommend reception hold board meeting action point discuss detail formally chairman meet director annually consider agree board december meeting onetoone basis discuss ongoing training long report focus principally culture development requirement environment boardroom composition board keep uptodate legal regulatory governance tenure board succession planning arrangement matter regular paper company secretary overall view board performance positive presentation internal external adviser confirm board effective dealing year board brief regulatory challenge face quality decision make corporate governance development principally include contribution board member influence anticipated impact new rule audit market open culture strong support board senior role reform financial reporting council consultation subsequent publication update corporate governance thoughtful discipline approach use code associate guidance cover remuneration go management time concern internal control risk management improve risk control remuneration oversight board member undertake specific refresher training long report note good engagement provision corporate integrity agreement issue management interact board cia new board member require committee respond positively constructive challenge induction programme receive comprehensive training enquiry aspect board dynamic cia sir philip hampton urs rohner take consider outstanding compare board training session january induction programme gsk annual report corporate governance continue long report stress time briefing process place nonexecutive director significant transition company board context manage chairman focus sector specific issue board operate change board general shareholder preference modus operandi need evolve future challenge year aspect corporate governance include board ability arrangement raise investor discuss anticipate change external landscape relevant board director include manage transition sir christopher sir philip board composition refreshment include process search sir christophers replacement chairman refresh composition board include senior role board china company abac procedure practice agree action point long report focus mainly external audit contract tender arrangement addressing challenge disclose report annual bonus performance description chairman nonexecutive director evaluation operation malusclawback mechanism nonexecutive director lead sir deryck meet separately sir christopher present discuss performance accountability consider leadership performance overall contribution high standard continue internal control framework support board recognise responsibility present fair chairman meet nonexecutive director discuss balanced understandable assessment group individual contribution performance training position prospect development need board accountability review approve addition chairman meet nonexecutive director effectiveness internal control operate group independently executive director include financial operational compliance control risk management relation shareholder gsk internal control framework framework mean gsk assure compliance law work engage effectively shareholder regular regulation reliability financial reporting communication agm investor relation activity effectiveness risk management framework assist identification evaluation management principal risk announce financial result quarterly basis annual require corporate governance code code result include annual report shareholder receive design manage eliminate risk annual summary advise annual report achieve business objective fitforpurpose internal control notice annual general meeting available website framework conjunction embed gsk value year sir andrew witty simon dingemans give speak reporting line ensure principal risk presentation institutional investor analyst medium actively effectively control information year result available webcast risk management page teleconference second quarter result framework design ensure risk associate hold webcast teleconference audience conduct business activity effectively control line result available website gsk risk appetite believe framework provide investor relation department office london reasonable absolute assurance material philadelphia act focal point communication misstatement loss investors ceo cfo chairman maintain continuous ensure effective governance ethical culture gsk dialogue institutional shareholder performance plan establish risk oversight compliance council rocc objective programme regular meeting team senior leader authorise board assist year hold individual meeting investor audit risk committee committee oversee risk host approximately group meeting investor management internal control activity provide potential investor business framework risk management upward report company secretary act focal point communication significant risk gsk value policy report upwards corporate governance matter small central rocc risk board structure business unit corporate responsibility team coordinate strategy global support function risk management policy development report specifically respect compliance board rmcb responsible local tone matter team communicate socially responsible risk management internal control investor stakeholder rocc rmcbs assist global ethic chairman meet regularly institutional shareholder compliance gec responsible support hear view discuss issue mutual importance risk management development implementation communicate view member board practice facilitate employee compliance law sid nonexecutive director available policy gec provide assistance help employee meet meet shareholder high ethical standard operating accordance value comply applicable law regulation chairman remuneration audit risk committee corporate responsibility chairman sid company secretary head human resource hold annual meeting major shareholder november discuss executive remuneration corporate governance matter gsk annual report strategic report governance remuneration financial statement investor informationstrategic report governance remuneration financial statement investor information erprise oversight ies rad nit tos mpr tid div control fra inmdeepweonrd kent assurance fohei nts reeh tic sta soe ron iae srmki dtm mty tta tto hem oee vla frti ang rre net wsa nftr ooo nms spa aao nln owc lnd nyth tisf ufie tnn acf afie lao sct hnl hoo peb sit orh rdr rei tieim tir dvt nae dohre opi ehh eea ehe hpr haen esa aas ar rve oee eod mog ledi nep gond eap mede otn itge ebn rot iled nat dtn nfs gonde iru cre vieais nmnn mem dek cdn otn oae ebp msn inat gsm nss iiu cse vics nso inka cnaio reo dwo iln sav dti stse man utm raa ini csc inae onth ndwo lsar rrt dti sten training approval board board review focus company subsidiary extend material associate undertaking joint venture investment consider risk company participation activity establish procedure control gsk valguse value place identify entity result consolidated group result key key individual acc nintdaibviidliutayl accountability believe process follow board review line management accountability compliance line management accountability compliance system internal control accord guidance internal business management accountability compliance business man eamudeitn aascscuoraunncetability compliance control issue turnbull committee accordance audit assurance provision code provide board responsible determine nature extent significant risk willing achieve strategic objective board provide oversight help ensure group maintain sound risk management internal control system framework operation year continue operate date approval annual report review group risk management approach discuss risk management section strategic report page management principal risk explain risk factor section financial report page committee report report audit risk nomination corporate responsibility committee describe activity committee year set page remuneration report remuneration report comprise remuneration committee chairman annual statement annual report remuneration set page addition reproduce convenience remuneration policy report set page gsk annual report corporate governance continue enhance abac arrangement audit risk committee report remain high priority committee continue review lesson learn recent investigation particularly chinese operation ask improve effectiveness antibribery corruption abac approach significant step committee take strengthen abac capability control group include detailed review operation ongoing presence high risk territory enhance ongoing monitoring compliance abacrelate control target emerge market territory help identify implement enhanced control appropriate emerge market european general manager completing review key control document dear shareholder adherence gsk value policy procedure year committee report stress importance applicable local law regulation specific improvement vigilance continuous improvement internal control plan identify process financial reporting risk management process system implement number country committee focus number creation specialist abac centre excellence provide activity associate core remit order train diligence expert guidance capability review risk environment exposure group senior management group comprehensively oversee implementation number plan change enhancement expand footprint capability global ethic governance principally compliance risk compliance gec organisation designate high risk management policy procedure close monitoring emerge market ongoing transformation finance process control ensure resource capability abac environment include extensive upgrade update investigation team strengthen system consider implication change market environment particularly price increase oversight party supplier dynamic implementation ongoing cyber initiation new risk assessment monitor protection programme infoprotect framework roll group refocusing rocc inclusion enterprise risk review progress external rope gray committee strengthen key area risk internal china investigation management structure follow review risk oversight ongoing year half continue compliance council rocc purpose practice standing agenda item committee meeting membership representation business unit adjust committed implement rope gray ensure membership appropriately align conclusion action implement change shape business particular cet new management team include enhanced procedure representation increase provide strong strategic monitoring use party supplier local financial direction roccs deliberation increase ability transaction committee continue monitor progress consider cross enterprise risk exposure alongside exist relate investigation closely conclude review gsk principal risk leadership global compliance audit assurance reinforce approach committee agree rocc risk management board support global implement designation enterprise risk specifically compliance operation reorganise consider particular risk potential exposure global ethic compliance leadership nick gsk individual business unit hiron previously head audit assurance function rocc committee especially audit assurance function reorganise focused assess managing compound new leadership function report cfo consequential factor directly accountable committee provide incountry risk oversight board effective assurance recent external benchmarking operational level committee approve confirm team provide assurance establishment country executive risk board cerb identify number area enhancement include local provide mean different business unit operate coverage frequent short audit review alongside particular country manage principal risk regular detailed review enhance flexibility improve impact business unit effectively visibility believe change improve committee country perspective work complement work ability identify emerge risk proactively exist risk management compliance board rmcbs wellembedde major business unit cerb rmcbs report rocc regular review cycle gsk annual report strategic report governance remuneration financial statement investor informationstrategic report governance remuneration financial statement investor information finance transformation role committee continue focus ongoing enhancement finally role chair committee continue widen programme finance process include creation deepen knowledge understanding group strong share service capability core business external environment gsk operate good service cbs operation programme target improve practice development addition hold regular meeting control environment standardise finance policy key senior executive attend range management process update change shape meeting include cet rocc finance leadership team business programme include substantial upgrading meeting attend briefing meeting external platform particular enterprise resource planning auditor discuss aspect committee work erp system create common platform shareholder network audit committee chairman business unit improvement deliver peer exchange view regulatory market development consistent process control allow business principally risk management compliance arena manage financial risk effectively judy lewent implementation programme create significant change audit risk committee chairman business committee review progress detail february input external auditor ensure effective control remain place transition year end review membership attendance identify material concern membership committee appointment pricing date attendance meeting set light significant change see year attendance market place committee review implication meeting change principal risk particular carry member committee member significant provision return rebate offer customer judy lewent chairman times significant change need especially january april carefully monitor ensure align current lynn elsenhans january experience investment new platform recent year stacey cartwright april allow remain responsive year despite rapid sir deryck maughan january change external environment committee believe daniel podolsky january provision area remain appropriate adequate tom swaan january infoprotect jing ulrich company underway multiyear programme addition schedule meeting committee meet enhance strengthen cyber security defence committee quorate basis occasion review approve matter review progress programme detail recently associate annual report form preliminary appoint chief information security officer quarterly result announcement significant progress despite increase level threat additional investment agree support effort detail member financial accounting scientific experience give biography board page propose threepart novartis transaction preparation transformative transaction committee entire board invite attend committee meeting review roccs assessment risk profile attendee include novartis business group review regular attend utilise principal enterprise risk framework attendee attendee require detailed mitigation plan place risk issue identify chairman ensure incoming novartis business successfully ceo incorporate gsk risk monitoring framework cfo risk identify expect rise material exposure general counsel position monitor closely transaction financial controller integration planning team rocc place plan head audit assurance review progress manage risk regular basis company secretary secretary committee committee review shortly close ensure chairman global vaccine standard value culture properly embed head global ethic compliance reshape enlarge organisation chief medical officer external auditor chief product quality officer like assure shareholder seriously external auditor committee take role responsibility appoint assess monitor performance company auditor accordance code board determined committee usual review pwcs performance stacey cartwright judy lewent tom swaan recent year audit process undertook believe relevant financial experience board agree continue provide high quality service company appropriate qualification background audit shareholder committee recommend committee financial expert define sarbanesoxley act reappointment year give current level change determine independent business committee conclude appropriate meaning securities exchange act amend audit tender review addition judy lewent sir deryck maughan tom swaan relative merit conduct tender recent change member remuneration committee allow regulation area committee conclude provide input committee review group tender new auditor target performance oversight risk factor relevant new firm take audit financial year deliver remuneration matter objective expect start prepare tender second half gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue work undertaken committee committee work largely recur structured programme activity agree conjunction committee chair management external auditor start financial year programme comprise standing item committee require consider meeting matter time coincide key event annual financial reporting cycle business event committee consider discuss decision relation number matter year significant set global internal control governance month financial reporting compliance external auditor risk matter january integrity draft financial annual internal control assessment external china investigation compliance statement compliance report auditor effectiveness abac update corporate governance appropriateness itigation report external audit process emerge risk review code accounting policy orporate integrity eappointment late annual report draft annual agreement cia update auditor propose regulation report approval agm orporate governance annual summary leaflet xternal auditor update irector expense yearend audit finding private meeting external auditor february oing concern arbanesoxley uditnonaudit assumption confirmation expenditure reliminary result xternal auditor announcement sarbanesoxley control approval annual finding report form external auditor annual annual summary report form leaflet finding march approach sarbane erformance china investigation private meeting oxley compliance expectation abac update external auditor external auditor emerge risk review gms business unit rocc meeting update report audit assurance work plan itigation report april quarter result xternal auditor announcement quarter result review finding compliance external audit plan hina investigation private meeting itigation report fee proposal abac update external auditor roduct quality enterprise risk vaccine emerge market business unit risk merge risk review rocc meeting update july oe concern control gsk list xternal auditor china investigation orporate governance assumption subsidiary quarter result abac update update quarter result itigation report review finding patient safety enterprise private meeting announcement pharmaceutical risk external auditor north american emerge risk review pharmaceutical rocc meeting update business unit report september japan consumer china investigation private meeting healthcare business unit abac update external auditor report ehss enterprise risk xternal independent merge risk review review rocc meeting update evolution emerge market compliance model cia update report october quarter result itigation report xternal auditor announcement quarter result review finding gsk annual report strategic report governance remuneration financial statement investor information global internal control governance month financial reporting compliance external auditor risk matter december key accounting issue europe business unit external auditor phase china investigation corporate governance appropriateness report finding abac update update accounting policy global support preapproval budget abac commercial tax strategy review function business unit auditor provide practice scientific external committee report nonaudit services engagement enterprise evaluation litigation report update risk private meeting budget infoprotect review external auditor operational excellence collective meeting programme review head emerge risk review gec individual meeting head gec respect financial reporting activity committee review recommend finance committee approval financial result announcement consider quarterly financial result announcement annual financial result contain annual report committee review significant issue judgement management determine result committee review paper prepare management set key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue relate financial statement significant issue consider relation financial statement year end december set follow table summary financial outcome appropriate addition committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis committee consider outcome management halfyearly review current forecast net debt preparation financial position financing facility option available group following review risk statement potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include committee review management approach time recognition revenue accrual return rebate rar customer return rebate pharmaceutical vaccine accrual return rebate accrual billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter committee receive detailed report actual potential litigation internal external legal include recent government counsel number detail update concern government investigation relation china investigation relation management outlined level provision correspond disclosure consider necessary respect china extent potential adverse litigation outcome area possible determine provision determine necessary december provision legal matter billion set note financial statement provision provision tax issue committee consider current tax dispute area potential risk concur management judgement level tax contingency require december group balance sheet include tax payable liability billion impairment intangible committee review management process review testing goodwill intangible asset asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail provision pension committee review significant assumption adopt management valuation obligation postemployment obligation group large pension postretirement healthcare scheme resultant net obligation amount calculate external actuary group net deficit december amount billion set note financial statement pension post employment benefit brand prescription committee review concur management assessment additional charge necessary drug fee account year fee accordance final regulation issue irs year valuation contingent committee consider management judgement follow improve sale performance tivicay consideration triumeq necessary increase liability pay contingent consideration acquisition shionogiviiv healthcare joint venture december group balance sheet include net contingent consideration liability billion note financial statement acquisition disposal detail gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue effectiveness external audit process robustness audit process evaluate effectiveness audit process prior make quality delivery recommendation reappointment external auditor quality people committee review effectiveness performance quality service criterion agree conjunction management review feedback provide begin year audit mechanism outline note area improvement undertaking review committee consider overall implement respect team follow year quality audit independence auditor audit provide committee exhibit appropriate level challenge satisfied effectiveness auditor external scepticism work audit process annual committee evaluation seek feedback committee satisfied auditor independence appropriate level member independently relationship auditor qualification expertise resource quality insight provide committee work committee sufficient access auditor consider good interest shareholder executive management company initiate defer tender finally committee consider feedback prior year consider recommend board external audit survey seek view financial reappointment auditor forthcome agm management team corporate business unit level cover detailed criterion committee use judge key area effectiveness external auditor override responsibility deliver smooth run thorough efficiently execute audit set performance expectation gsk external auditor specific auditor responsibility wide auditor responsibility discuss approach area focus advance early rovide uptodate knowledge technical issue provide engagement understanding implication gsk new accurate timely advice operating model erve industry resource communicate good practice ensure sarbanesoxley scope additional procedure industry trend report discuss endorse management communicate dhere independence policy include gsk policy timely basis gsk pricewaterhousecooper llp pwc financial reporting council isa applicable avoid surprise timely reporting issue level securities exchange commission standard group eliver focus consistent audit approach globally ensure clarity role responsibility reflect local risk materiality auditor local management iaise gsk audit assurance team avoid duplication work global ethic compliance team ensure common respond issue raise management timely basis understand audit outcome meet agree deadline rovide consistency advice level organisation provide continuity succession planning key employee auditor provide sufficient time management consider draft auditor report respond request query employ consistent communication local central audit team audit tender give integration challenge threepart novartis pwc remain place auditor group transaction ongoing finance transformation service inception december performance enhancement pwc receive competitive review annually audit partner rotation requirement audit fee proposal pwc committee agreed observe time audit contract currently preference distract management tender period committee undertake tender stage committee conclude plan undertake tender observe financial reporting council current transitional process second half view appoint arrangement audit tender tie end cycle new firm effect january current rotate audit partner current audit partner hold position year implication transitional nonaudit service arrangement competition market authoritys sarbanesoxley act prohibits engagement audit contract tender regulation audit firm rotation external auditor provision certain service legal requirement assess committee consider actuarial internal audit outsource financial information system put audit contract tender design external auditor permit provide nonaudit service auditrelate tax service addition committee review evolve market committee ensure auditor objectivity independence practice change expectation shareholder safeguard policy require preapproval note committee service contractual similar obligation restrict group choice external auditor gsk annual report strategic report governance remuneration financial statement investor information nonaudit service competitive auditnonaudit service year comparison graph tender financial service provider external auditor line group procurement process skill experience external auditor suitable supplier nonaudit service consideration case request proposal submit relevant cet member cfo approval follow policy guideline engage external auditor provide nonaudit service observe ascertain skill experience external auditor suitable supplier nonaudit service ensure adequate safeguard place objectivity independence group audit threaten compromise ensure total fee level exceed annual audit fee special circumstance clear advantage company auditor undertake additional work audit assurance service service include tax regulatory compliance year fee nonaudit service work carry treasuryrelate service pwc annual audit fee exceptional level service relate threepart novartis transaction reflect considerable service pwc provide relate report accountant role connection class circular threepart novartis transaction exclude novartis work code conduct report line pwcs nonaudit service fee represent number establish policy include annual audit fee committee consider hire pwc code conduct available governance section undertake class circular work good interest website confidential speak reporting line shareholder report investigation unlawful conduct update version code conduct publish january pwc possess type expertise experience size international scope require handle major class fair balanced understandable assessment transaction scale complexity key compliance requirement group financial company benefit specifically pwcs indepth statement annual report fair balanced knowledge understand vaccine consumer understandable coordination review groupwide healthcare oncology business process contribution annual report follow establish compliance environment document process perform parallel formal process undertake external auditor management time devote educate firm company business committee receive summary approach take operation instead spend deliver transaction management preparation gsk annual report substantially strengthen group core ensure meet requirement code enable business create significant new option increase value committee board confirm gsk shareholder annual report take fair balanced understandable committee leverage pwcs capability negotiate advantageous costeffective price committee evaluation committee annual evaluation externally facilitate addition note million novartis tracy long boardroom review limited supplement related fee pwc arise work novartis questionnaire circulate committee member auditor pwc committee chairman conclude committee maintain external auditor independence objectivity continue operate effectively term enhancement class circular workstream self review threat committee deliberation agree follow identify independent partner involve audit area consider underpin committee appoint lead management review effectiveness consider pwcs finding pwc decision regular update new emerge issue behalf management additionally pwc input anticipate streamlined reporting process respect production financial information subsequently potential risk audit issue audit team increase focus set monitoring adjust risk appetite fee pay company auditor associate set detail give note financial widening deepen committee exposure certain statement operate profit area business external landscape increase understand potential threat opportunitie possible accounting firm engage undertake nonaudit service enhance training requirement committee member consider division focus risk area board committee gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue follow key attribute identify nomination committee report experience run list global organisation highly regulate industry clear collegiate style leadership possess comprehensive knowledge understand corporate governance arrangement sir philip hampton nominations committee deep appreciation shareholder medium chairman perspective treat role primary commitment view membership serve role medium long term membership nomination committee committee criterion deem key success new appointment date attendance meeting appointee mwm specialise recruitment high set calibre board director engage ensure widest possible pool candidate available select mwm attendance meeting provide recruitment consultancy service committee member committee member work validate timetotime ensure sir philip hampton gap search process committee chairman receive good possible market advice key appointment search initiate chairman senior independent january january director sid support head human resource professor sir roy anderson october company secretary search progress draw lynn elsenhans january conclusion lead sid regular oversight sir christopher gent process exercise committee shareholder chairman january brief search criterion progress january december committee identify suitable candidate judy lewent pool suitable candidate reduce shortlist sir deryck maughan july briefing report shortlist candidate review tom swaan october candidate meet key board member clear sir robert wilson march board committee sir philip hampton sir robert wilson retired board suitable candidate succeed sir christopher chairman addition schedule meeting committee meet september accordance committee quorate basis occasion consider recommend term reference sir deryck maughan sid chair board appointment sir philip hampton urs rohner meeting nominations committee recommend chairman designate nonexecutive director sir philips appointment nonexecutive director successor sir christopher attendee committee meeting include feedback investor seek committee regular attend recommendation board positively attendee attendee require support sir philips appointment chief executive officer head human resource subsequent appointment recommendation receive unanimous board approval september company secretary secretary committee announce sir philip join board nonexecutive appropriate external adviser director effect january chairman succession deputy chairman effect april succeed unanimously agree extend sir christopher sir christopher nonexecutive chairman effect gents appointment chairman year end agm effect january subject annual reelection sir philip meet independence requirement set shareholder time board enter corporate governance code appointment able programme progressive refreshment ensure continuity dedicate requisite time role board leadership period nonexecutive director approach end tenure new nonexecutive director appointment reflect committee desire plan shape addition search successor composition balance board long term sir christopher chairman committee search nonexecutive director phase committee commence search sir refreshment board christopher successor intention step chairman end search process broad selection criterion focused achieve balance continental start search process committee draw european emerge market experience job specification role chairman job specification individual expertise capability develop draft emphasise importance board sector specialities committee place chairman oversee company strategy time industry continue evolve pace gsk annual report strategic report governance remuneration financial statement investor information mwm egon zehnder korn ferry engage conduct committee responsible develop measurable search dossier potential nonexecutive appointee objective support implementation board diversity consider committee egon zehnder korn ferry policy include gender monitor progress provide recruitment consultancy service committee achievement objective term gender diversity candidate shortlist interview merit assess exceed target set relevant qualification time commitment pleased maintain female board level representation seek interview select candidate committee maintain level go forward pleased recommend board urs rohner nonexecutive director appoint board good representation woman management effect january board consider position illustrate gender broad business background extensive seniorlevel experience diversity gsk global workforce continue support multinational company achieve aim appoint effort increase pipeline woman senior candidate experience run highly regulate position gsk support engagement organisation understand investor perspective executive search firm mwm egon zehnder korn bring fresh insight board deliberation ferry sign voluntary code conduct gender diversity good practice board committee change refreshment board result orderly change cet change composition board committee set term executive succession planning committee recommend appointment nick hiron cet sir robert wilson stand reelection agm september senior vice president global ethic year service sir christopher gent tom swaan compliance nick join company internal jing ulrich stand reelection agm auditor take role increase seniority year service respectively give appoint head audit assurance june current stage board refreshment programme take role china responsible board member step board establish new governance model china business sir deryck maughan agree stand reelection shareholder year stepping ensure focus management company board agm provide continuity balance consumer healthcare vaccine pharmaceutical business composition board give significant knowledge advance completion threepart transaction experience gsk business affair sir deryck novartis nomination committee recommend bring style role sid discharge april emma walmsley currently president responsibilitie role great diligence play consumer healthcare appoint ceo consumer important smooth transition sir christopher healthcare joint venture business member board sir philip transaction successfully complete board confirm sir deryck continue demonstrate appointment october moncef slaoui characteristic independence carry role abbas hussain chairman global vaccines head board search replacement sid succeed currently global pharmaceutical respectively abbas subsequently conduct committee assume responsibility pharmaceutical sir philip succeed sir christopher chairman role february moncef previously chairman global nominations committee january sir christopher vaccine continue provide scientific counsel continue serve member committee pharmaceutical activity ceo board remainder tenure board successor tom abbas previously president europe japan emap swaan chairman remuneration committee follow announcement deirdre connelly president retire board agm appoint north america pharmaceuticals february membership remuneration committee intention retire gsk give recent change appointment recommend committee include global pharmaceutical role replace lynn elsenhans join audit risk committee effect cet january nominations committee effect committee evaluation january judy lewent appoint committee annual evaluation externally facilitate nomination committee effect day tracy long boardroom review limited conclude sir robert wilson step committee committee continue operate effectively key finding board diversity long evaluation concern tenure committee commit diversity boardroom member committee accountability safeguard similarly commit equal opportunity employee majority committee member serve alongside new level organisation diversity inclusiveness board appointee medium long term committee workforce promote gsk agree continue refresh membership suitable balance long serve director key requirement effective board comprise recent appointee support new committee chairman range balance skill experience knowledge gender shaping board independence individual prepare challenge work team need back diversity personal attribute include character intellect sound judgement honesty courage gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue main responsibility corporate responsibility committee report main responsibility corporate responsibility committee set committee rolling agenda receive report member cet senior manager ensure progress meeting gsk corporate responsibility commitment sir christopher gent set review annual basis corporate responsibility commitment group area committee chairman health innovating address currently unmet health need improve access product irrespective membership people live ability pay control eliminate membership corporate responsibility committee disease affect world vulnerable people committee appointment date attendance behaviour put interest patient consumer meeting set drive value back robust policy strong compliance process attendance meeting people enable people thrive develop member committee member individual deliver mission sir christopher gent chairman planet grow business reduce january december environmental impact value chain stephanie burns december committee review approve responsible lynn elsenhans october business supplement available reference daniel podolsky july wwwgskcomresponsibility hans wijers october work committee sir robert wilson committee focus attention issue include sir robert wilson retired board han wijer unable attend committee meeting focus area committee area focus prior business commitment health lexible open approach disease attendee committee meeting include develop world area great medical need antibiotic regular attend dementia attendee attendee require trategic partnership address access chief executive officer child mortality save child chairman global vaccine neglect tropical disease trategic approach drive access general counsel medicine africa include pricing capacity head governance ethic assurance building health system strengthen head global communication accine strategy support global public government affair health priority include pricing model head global corporate responsibility malaria vaccine ebola response company secretary secretary committee iiv healthcare ltds strategy drive innovation access hiv medicine executive independent external corporate behaviour lobal incentive compensation programme responsibility adviser sell competency model hange gsk engage independent external corporate responsibility adviser healthcare professional augment gsk engagement stakeholder opinion urther embed valuesbased decision sophia tickell appoint independent external making organisation include training adviser committee position hold previously compliance march july tickell extensive experience rogress address human right pharmaceutical industry improve health system onduct public disclosure clinical productivity sustainability energy supply distribution research transparency detail datum climate change policy shorttermism financial market trial result patient safety eplacement refinement reduction use cofounder director meteo animal research development direct pharma future series aim align well societal shareholder value hold number people rganisational change employee relation board advisory role nclusion diversity eadership development approach tickell attend meeting committee provide performance management independent advice guidance corporate responsibility mployee health safety wellbeing matter chairman ceo olunteering planet nvironmental performance carbon water waste impact gsk annual report strategic report governance remuneration financial statement investor information committee evaluation committee annual evaluation externally facilitate tracy long boardroom review limited conclude committee continue operate effectively review note nomination committee identify recommend new committee chairman succeed sir christopher gent retire board end agm director report purpose company act director report glaxosmithkline plc year end december comprise page corporate governance report director responsibility statement page page investor information entitle company act board choose set strategic report matter require disclose director report consider strategic importance company follow risk management objective policy page likely future development company strategic report research development activity page inclusion diversity page provision information consultation employee page carbon emission page addition disclosure relate appointment replacement director director power year end require corporate governance code disclose information follow table incorporate director report location detail annual report interest capitalise financial statement note publication unaudited financial information group financial review detail longterm incentive scheme remuneration report waiver emolument director applicable waiver future emolument director applicable non preemptive issue equity cash applicable non preemptive issue equity cash unlisted major subsidiary applicable undertaking parent company participation place list subsidiary applicable contract significance shareholder information provision service control shareholder applicable shareholder waiver dividend financial statement note shareholder waiver future dividend financial statement note agreement control shareholder applicable director report draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law director report approve duly authorise committee board director february sign behalf sir christopher gent chairman february gsk annual report strategic report governance remuneration financial statement investor information remuneration report chairman annual statement vest psp dabp defer annual bonus plan matching award impact tsr adjust free cash flow performance threshold set positive note key investment longterm success group sacrifice overall vest level achieve threshold performance new product business diversification performance measure please report executive continue align personal interest shareholder sir andrew elect year defer maximum permit dabp share ownership requirement sor hold time base salary gsk share currently hold time base salary gsk share time level require detail remuneration executive relate dear shareholder performance annual bonus longterm incentive psp award dabp matching award give page chairman remuneration committee committee please present remuneration report executive remuneration follow year change new remuneration key change structure remuneration reporting regulation year stability disclose year report award time year committee operate bind remuneration policy horizon psp award executive director revise receive overwhelming shareholder support extension vest period year award agm ease reference shareholder include continue subject threeyear performance period copy approve remuneration policy report end implement malus clawback provision prior document confirm structure incentive plan year change require regard comply remain unchanged exception extension recent update corporate governance code time horizon psp award grant executive director agenda include year performance period year vest period structural change propose year committee decide salary level executive director agm shareholder ask increase management award support annual report remuneration average increase employee usa remuneration outcome respect level cet financial perspective total turnover threepart transaction novartis expect billion challenging trading condition face complete week commencing march group particularly primary care market core operate wideranging implication executive remuneration gsk profit core group pbit cer cost saving anticipate adjust free cash flow new product financial efficiency offset substantial proportion target psp dabp award impact line pressure year help business diversification target award need deliver core ep protect investment revise reflect nature business business dividend year increase transaction committee aware potential challenge make adjustment appropriately engage challenging year gsk shareholder point course notable example company deliver positive outcome include great progress key product launch committee executive remuneration improve formulary positioning continue progress arrangement review ensure continue meet respiratory pipeline newly launch product include need business committee proud track tivicay triumeq viiv healthcare tafinlar mekinist record listening view shareholder tanzeum contribute billion turnover cer continue engage shareholder executive remuneration represent pharmaceutical vaccine sale matter ensure remuneration policy operate furthermore respond ebola crisis gsk longterm interest hold annual meeting clear leader develop vaccine happen gsk large investor listen view feedback alongside effort complete transformational threepart corporate governance matter transaction novartis approach later background key decision respect finally retire nonexecutive director gsk performance committee highlight agm consequently present final report chairman committee successor appoint bonus outcome executive director determine committee work forward like group operating profit group pbit achieve opportunity thank fellow committee member performance threshold target deliver shareholder support tenure chairman significantly reduce bonus payment ceo cfo committee compare vaccine performance value driver deliver ontarget performance look forward receive support annual report result reduced bonus payment slaoui remuneration agm welcome compare strong performance detail shareholder feedback report bonus award give page tom swaan remuneration committee chairman february gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration total remuneration audit value earn annual longterm total salary benefit pension bonus incentive remuneration award fix pay pay performance pension total remuneration executive director set table moncef slaoui sir andrew witty simon dingemans chairman ceo cfo global vaccine total total total total total total fix pay salary benefit total fix pay pay performance annual bonus include defer value earn lti awards matching award defer annual bonus plan performance share plan total value earn lti awards total pay performance pension total remuneration note certain expense incur normal course business consider taxable benefit revenue custom table include figure detail provide analysis value ltis earn sir andrew witty simon dingemans moncef slaoui set page ull detail pension contribution pension accrue date executive director give committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee reduction outstanding award vest level malus apply respect executive director follow section provide detail element total remuneration include implement remuneration policy approve shareholder apply gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue comparator group pay performance salary committee use primary pay comparator group average salary increase budget employee consider executive pay level cet approximately usa crossindustry global pharmaceutical comparator group comparator group committee decide increase executive director salary anglo american france sanofi astrazeneca switzerland novartis table set base salary executive group roche holding director year bhp billiton astrazeneca base salary usa abbvie change british american tobacco amgen sir andrew witty diageo bristolmyers squibb simon dingemans reckitt benckiser eli lilly moncef slaoui rio tinto johnson johnson royal dutch shell merck benefit audit sab miller pfizer follow table show breakdown gross cash tesco value benefit receive executive director unilever vodafone sir andrew simon moncef amgen abbvie include remuneration benchmarke witty dingemans slaoui include tsr comparator group benefit global pharmaceutical comparator group basis tsr comparator group feature longterm employee benefit incentive award travel benefit primary pay comparator group executive total benefit director show table benefit primary pay comparator group employee benefit global director crossindustry pharmaceutical travel sir andrew witty benefits simon dingemans international assignment moncef slaoui total benefit review ceo remuneration committee employee benefit include healthcare car allowance personal financial reference pay group lead european company advice life assurancedeath service selection base size complexity travel expense include car travel family spouse partner cost associate accompany director gsk business summary total package competitive positioning ceo deem taxable benefit individual benefit comprise expense incur ordinary course total remuneration benchmarking business deem taxable benefit individual include table slaoui include accommodation moncef slaoui second november order enable close vaccine business assume operational responsibility group secondment end december line senior gsk expatriate receive appropriate assignment expense include accommodation location allowance relocation specific financial advice tax equalisation significant change provision benefit propose detail refer policy report crossindustry global pharmaceutical european crossindustry group group group low quartile median median upper quartile current position benchmarking include salary expect value incentive base committee agree benchmarke methodology gsk annual report strategic report governance remuneration financial statement investor information pay performance audit annual bonus majority annual bonus opportunity base formal ipm set committee take account review performance stretch financial target performance individual objective multipli outcome adjusted reflect individual performance set generally year apply individual performance multipli ipm executive director perform strongly objective expect receive financial measure bonus threshold target ipm range maximum payable achievement target bonus threshold reflect stretch nature bonus target performance target annual bonus base follow financial performance measure weighting core group operate core group pbit vaccine performance value driver profit sir andrew witty simon dingemans moncef slaoui actual financial target link company financial strategic plan committee believe target remain commercially sensitive specific target disclose follow illustrate performance achieve year target measure individual performance multiplier set substantially low performance performance performance performance target performance measure threshold target range performance threshold target range maximum maximum core group operating profit core group pbit vaccine performance value driver financial performance core group operating profit core group profit interest tax face major headwind impact group performance term core group operating profit core group profit interest tax resilient strong sale performance deliver important part business include emerge market japan viiv healthcare oncology europe help benefit refocus commercial organisation deliver relatively stable performance despite ongoing government competitive pressure addition tight rein cost add delivery incremental saving restructure structural initiative approximately million helped offset substantial portion impact line pressure importantly protect key investment require longterm success group vaccine performance value driver target year pipeline growth value achieve reflect important approval incruse ellipta arnuity ellipta respiratory triumeq hiv tanzeum type diabete important regulatory filing breo ellipta use asthma mepolizumab firstinclass antiil treatment severe asthma file europe start major phase iii programme triple combination therapy copd mepolizumab copd losmapimod acute coronary syndrome global sale vaccine strong performance boostrix rotarix synflorix infanrixpediarix offset impact ongoing suspension hpv vaccine japan return market compete vaccine supply constraint business deliver exciting phase iii datum group vaccine prevent shingle achieve major milestone programme malaria ebola gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue table set matter committee consider respect individual objective set executive director personal performance sir andrew witty sir andrews bonus reflect financial performance development offer opportunity positively reshape group business management response issue challenge face course year include group financial performance response challenge trading condition year include great expect contracting competitive pressure respiratory business launch lovaza generics supply disruption consumer healthcare sale billion core eps cer help delivery cost financial efficiency initiation innovative propose threepart transaction novartis accelerate group strategy reshape business provide well balance broad range growth driver synergy operate leverage opportunity financial efficiency increase balance sustainability cash flow commencement new restructure programme simplify gsk global pharmaceutical business approximately billion annual cost saving expect deliver year million net incremental cost saving deliver exist restructure programme structural saving establishment new executive management structure simplify organisation ensure focus core global business global pharmaceutical consumer healthcare vaccine group continue restructure way work global rollout measure modernise gsk commercial model interaction healthcare professional sustain delivery approval filing key product major market include continue build new product core pharmaceutical area respiratory hiv sustain progress asset advanced pipeline advanced asset view high potential close triple combination respiratory iosmapimod acute coronary syndrome mepolizumab severe asthma copd sirukumab vaccine prevent shingle cabotegravir hiv anaemia strengthen gsk business contribution public health middleincomedeveloping country year company file candidate vaccine prevent malaria develop candidate ebola vaccine help respond crisis west africa launch new longterm africa strategy investment launch new pricing approach vaccines gsk place access medicine index fourth consecutive year group response china investigation reform subsidiary business implementation step strengthen abac monitoring control procedure market impact investigation consider evaluation sir andrew remuneration overall evaluation sir andrew performance leadership group lead committee award bonus represent reduction compare bonus award simon dingemans gsk deliver core eps line revise financial guidance provide july protect ongoing investment new launch additional manufacturing capability capacity longterm success group simon continue drive operate financial efficiency help lead plan new restructure programme expect deliver billion annual saving gsk able return billion cash shareholder roll gsk erp system establishment core business service bring support function order streamline standardise functional support business continue significant pace moncef slaoui moncef slaoui deliver year good performance number candidate selection commit medicine development file approve line ahead rds fill flow target time human submission slightly target new product sale encourage slaoui transition leadership vallance follow plan period development slaouis leadership vaccine business deliver strong performance line plan gsk annual report strategic report governance remuneration financial statement investor information follow table show actual bonus earn compare opportunity bonus opportunity total bonus bonus pay base salary target maximum salary salary salary salary sir andrew witty simon dingemans moncef slaoui operation annual bonus plan line policy performance measure base relevant business unit performance give change moncef slaouis responsibilities slaouis financial performance measure weighting follow core group operate core group pbit vaccine performance value driver profit moncef slaoui change propose operation annual bonus plan inevitably target link directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus target year detail performance achieve disclose annual report longterm incentive plan audit defer annual bonus plan matching award performance share plan level participation respect table show performance share plan psp award executive director show table level executive director maximum matching award grant respect deferral bonus total bonus defer award level award level matching share ad award award base salary base salary sir andrew witty share sir andrew witty shares simon dingemans share simon dingemans share moncef slaoui ad moncef slaoui ad vest matching award performance period end sir andrew wittys psp award subject december show page twoyear vest period year total psp award executive director subject year performance condition matching award performance period year vest period defer annual bonus plan dabp performance share plan describe psp dabp matching awards subject performance continue employment gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue award performance period end december audit committee review performance psp dabp matching award grant executive director target set performance achieve year december actual vest level set table committee previously provide estimate vest award gsk annual report estimate base performance achieve time follow reflect performance achieve course performance period discretion exercise determine vest level commercial sensitivity target new product business diversification disclose time grant committee commit disclose time vest target show table performance vest measure relative weighting performance target performance achieve maximum award business business diversification measure base aggregate threeyear revenue diversification target vaccine consumer healthcare dermatology emerge market asia performance pacific japan vest schedule show aggregate sale period billion target vest maximum billion billion billion threshold billion new product new product performance measure base aggregate threeyear performance revenue target new product sale new product define product launch performance period precede year product launch year include vest schedule show aggregate sale period billion target vest maximum billion billion billion threshold billion adjust free adjust free cash flow afcf year billion line cash flow committee agree principle include adjustment number material performance distort item include legal settlement exchange rate movement special pension contribution afcf vest schedule disclose time grant threshold award vest achieve afcf billion achieve billion achieve billion maximum achieve billion straightline vest point relative tsr gsk tsr rank position comparator group pharmaceutical performance company gsk company vest schedule comparator group set awards total vest respect straightline vest apply point use malus clawback company policy malus clawback set remuneration policy report committee jurisdiction malus clawback respect executive recoupment committee exercise authority wide employee base comprise senior executive relevant oversight appropriate experience include senior vice president global ethic compliance senior vice president general counsel january respect financial year committee disclose recoupment committee exercise clawback malus disclosure matter subject public report misconduct fully resolve legally permissible disclose unduly prejudice company shareholder committee determine release share lti plan delay case leaver reinforce implementation malus clawback policy case defer bonus award dabp grant executive retire redundant vest award normally delay vest original timescale vest early end year termination date fall gsk annual report strategic report governance remuneration financial statement investor information update performance ongoing awards committee review performance psp dabp matching award grant executive director follow table provide estimate vest take account performance date actual vest level determine base performance threeyear performance period indication regard prediction final vest level note relation measure adjustment require follow close threepart transaction novartis expect complete week commence march reflect impact transaction business award performance period end december performance measure relative weighting performance update business business diversification performance award measure aggregate threeyear sale vaccine consumer diversification healthcare emerge market asia pacific japan threshold performance result vest maximum performance performance threshold result vest good sale year business area base aggregate sale period base performance measure definition vest currently estimate maximum element new product new product sale performance measure aggregate threeyear sale new product launch threeyear performance performance period precede year threshold performance result vest maximum performance threshold result vest strong sale new product year base aggregate sale new product year base performance measure definition vest currently estimate adjusted free afcf vest schedule award disclose time grant cash flow threshold award vest achieve afcf billion achieve billion achieve performance billion maximum achieve billion straightline vest point base afcf year performance measure definition vest currently estimate threshold relative tsr period january december gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set awards rank position remain level vest threshold current estimate potential total vest award vest award performance period end december performance measure relative weighting performance update new product new product sale performance measure aggregate threeyear sale new product launch threeyear performance performance period precede year threshold performance result vest maximum performance threshold result vest strong sale new product year base aggregate sale new product year base performance measure definition performance currently estimate maximum vest level element adjust free adjust free cash flow afcf vest schedule award disclose time grant cash flow threshold award vest achieve afcf billion achieve billion achieve performance billion maximum achieve billion straightline vest point base afcf year performance measure definition vest currently estimate threshold relative tsr period january january gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set award rank position remain level vest threshold current estimate potential total vest award vest gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue performance target award inevitably measure link directly strategy commercially sensitive particular committee consider appropriate disclose target new product performance grant result competitive harm target disclose gsk annual report end performance period detail extent meet committee provide update estimate vest target performance period performance target vest schedule set table award performance period end december performance measure relative weighting link strategy vest schedule new product recognise importance future business performance performance growth threshold vest revenue target base new product sale maximum incentivise well performance new product threshold define product launch performance period precede year performance period product launch year include measurement aggregate threeyear revenue target award new product sale reflect growth historic performance new product sale adjust free recognise importance effective work capital performance target measure determine cash flow cash management communicate follow close implementation performance threepart transaction novartis expect complete week commencing march anticipate communicate end july relative tsr focus delivery value shareholder tsr ranking performance relative tsr comparator group comparator comprising gsk global group vest pharmaceutical company maximum relative tsr measure year twelvemonth averaging period tsr measure local currency threshold median comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company threshold vest achieve median performance gsk annual report strategic report governance remuneration financial statement investor information historical vest gsk ltis follow table show historical vest level companys longterm incentive plan defer annual bonus plan matching award performance share plan share option plan respect award executive share defer annual bonus plan performance share plan option plan vest vest vest vest vest total adjust free new business total year vest tsr cash flow product diversification vest eps grant performance period dabp award subject wholly tsr performance award subject performance measure psp award allemployee share plan payment past director audit executive director participate allemployee share payment past director plan include sharesave sharereward payments loss office audit sharesave plan revenue customs approve plan payment loss office director open employee participant save share ownership requirement month net salary fix term year align interest executive shareholder end saving period option buy gsk executive require build maintain significant share discount market price set holding share gsk time launch saving contract sir andrew witty simon dingemans contribute month sharesave executive require continue satisfy shareholde plan requirement minimum month follow retirement company sharereward plan revenue customs approve plan open employee term participant current share ownership requirement sor set contribute month gross salary table purchase gsk share company match number gsk share buy month arrangement share ownership requirement sir andrew witty simon dingemans contribute ceo base salary month buy share sharereward plan executive director base salary cet member base salary dilution limit award plan incorporate dilution executive director shareholding purpose sor limit consistent guideline provide investment february achievement sor base average association provide association british share price working day precede date set insurer limit roll year period follow table audit plan roll year period executive share plan estimate dilution exist award holding sor year december follow purpose increase achievement february december shareholding sor gsk employee share plan executive share plan sir andrew witty simon dingemans moncef slaoui outstanding share award subject performance criterion continue employment include shareholding purpose sor actual limit gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pension audit arrangement current executive director set table pension arrangement sir andrew witty sir andrew witty member glaxo wellcome define benefit pension plan accrual rate final pensionable salary plan close new entrant section plan sir andrew member provide normal retirement age maximum pension value rd pensionable salary april pensionable earning increase limit annum member include sir andrew simon dingemans simon dingemans member gsk pension plan pension contribution instead receive cash payment lieu pension base salary line gsk define contribution pension plan rate simon dingemans receive death service illhealth insurance provide pension plan include employee benefit moncef slaoui slaoui member cash balance pension plan supplemental cash balance pension plan provide executive pension credit gsk make annual contribution slaouis pension plan base salary plan provide cash sum retirement fund increase interest rate set annually advance base year treasury bond rate plan entitlement spouse pension pension increase slaoui active member belgium insurance exfortis plan defer member plan define benefit plan lump sum payable normal retirement age company contribution plan slaoui member gsk saving scheme open employee executive supplemental saving plan essp saving scheme open executive accrue benefit government limit impose gsk plan contribution plan invest range fund combine contribution rate plan core contribution plus match total base salary bonus bonus defer defer annual bonus plan follow table show breakdown pension value set sir andrew witty simon dingemans moncef slaoui pension remuneration value define benefit define benefit belgian define benefit employer cash contribution member contribution define benefit plan total pension remuneration value pension remuneration figure calculate accordance methodology set remuneration regulation calculate define benefit pension value difference accrue pension december accrue pension december increase inflation define benefit define benefit belgium define benefit multiply result negative value deem zero calculate total value amount translate euro dollar exchange rate sir andrew detail pension value set table accrue pension accrue pension pension remuneration sir andrew witty december december value fund unfunded total sir andrew join gsk predecessor company progress role increase seniority gsk appoint ceo time build pensionable service different tier glaxo wellcome pension plan current pension entitlement product service progression gsk note figure small adjustment follow change inflationary measure value fund pension total pension number unchanged moncef slaoui detail pension value set table accrue pension accrue pension pension remuneration moncef slaoui december december value fund unfunded belgium fund essp total slaoui join gsk predecessor company progress number senior role gsk appoint chairman research development june chairman global vaccine october time build pensionable service belgium insurance exfortis plan cash balance plan supplemental pension plan annual employer cash contribution plan executive supplemental saving plan essp current pension entitlement product service progression gsk gsk annual report strategic report governance remuneration financial statement investor information performance graph table percentage change remuneration ceo follow graph set performance company sir andrew witty employee relative ftse index pharmaceutical performance comparator group sixyear period change change december graph prepare accordance salary remuneration regulation indication benefit likely vest award grant company annual bonus incentive plan index select comparison purpose reflect index gsk reflect salary earn benefit receive annual constituent industry operate bonus earn respect compare wide employee population salary increase include annual salary review additional change year promotion increase benefit employee reflect change benefit policy level year reflect change level benefit individual receive result change role promotion population consider relevant comparison closely reflect economic environment encounter ceo relative importance pay follow table set percentage change group dividend pay shareholder share buyback total employee pay change total employee pay gsk total return dividend gsk pharma peer total return index share buyback ftse total return index index comprise astrazeneca bristolmyers squibb eli lilly figure table set page johnson johnson merck novartis pfizer roche holding sanofi dividend declare respect million million increase determine remuneration table specific share repurchase level company consider development free cash flow year give impact sustain strength sterle free cash flow company ceo suspend share repurchase programme sir andrew witty follow completion threepart novartis transaction ceo single figure gsk intend return shareholder billion net remuneration proceed company expect ordinary annual bonus award share repurchase maximum total employee pay group employee globally vest lti awards maximum external appointment executive director bonus amount include amount pay operational efficiency bonus place year overall board encourage executive director hold external maximum bonus receivable subject limit base directorship establish role salary broaden experience development help increase respect psp award sir andrew pool nonexecutive director candidate outside outstanding award share option grant appointment consider nomination committee lapse include total ensure cause conflict interest vest percentage distort effect aggregate approve chairman behalf board conditional share share option company policy remuneration earn respect psp award sir andrew appointment keep individual executive director outstanding award share option grant lapse include total moncef slaoui receive relation vest percentage distort effect aggregate membership qatar biomedical research institute scientific conditional share share option advisory committee earn honorarium respect threeyear element psp award attend board meeting advisory committee director national institute health external respect fouryear element psp award appointment receive remuneration threeyear element psp award dabp sir andrew witty simon dingemans hold matching award external appointment remunerate respect fouryear element psp award threeyear element psp award dabp matching award respect psp dabp matching awards gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue adviser committee remuneration committee committee access external advice require role committee committee carry formal review independent adviser role committee set company remuneration committee result review committee policy gsk able recruit retain motivate reappointe deloitte llp provide independent advice executive remuneration policy regularly review executive remuneration committee chairman agree ensure consistent company scale scope protocols deloitte provide advice committee operation support business strategy growth plan satisfied advice receive deloitte help drive creation shareholder value objective independent term reference deloitte member remuneration consultant group committee term reference available voluntarily operate code conduct relation company website term reference review executive remuneration consulting code conduct annually revise december reflect find wwwremunerationconsultantsgroupcom good practice corporate governance development deloitte provide independent commentary matter governance consideration committee update market practice board consider members committee legislative requirement deloitte fee advice provide independent nonexecutive director accordance committee fee charge corporate governance code exception sir time material basis deloitte llp provide consult christopher gent chairman company consider tax assurance service gsk year independent appointment committee satisfied compromise independence advice receive deloitte committee meet time schedule meeting member attending follow tower watson provide additional market datum committee commitment shareholder attendance committee committee engage regular dialogue shareholder member meeting hold annual meeting gsk large investor discuss member feedback remuneration policy particular tom swaan committee discuss significant change policy stephanie burn measure assess performance sir christopher gent january shareholder vote remuneration matter judy lewent january sir deryck maughan july vote total vote total vote total vote withhold han wijers october agm cast billion million remuneration report sir deryck maughan unable attend committee meeting remuneration policy prior business commitment urs rohner appoint committee january attend meeting addition schedule meeting committee meet quorate basis occasion approve formal grant longterm incentive awards employee corporate executive team defer investment award share value plan award material use annual investor meeting committee meeting usually include close session member committee present individual invite attend committee meeting year executive committee attendee involve decision present discussion remuneration attendee committee meeting include regular attend attendee attendee require ceo cfo head human resource head reward company secretary secretary committee committee adviser deloitte llp gsk annual report strategic report governance remuneration financial statement investor information principal activity matter address committee principal activity matter address set remuneration item specific governance month overall annual bonus ltis matter january pprove executive eview approve eview draft remuneration include executive bonus remuneration report salarie cet member ceo bonus new remuneration policy executive lti objective statement shareholder award level feedback emuneration environment rivate session update committee member february eview lti performance pprove outcome approve remuneration report vest outstanding lti awards lti awards pprove lti measure target award grant award executive director march emuneration environment verview bonus eview shareholder update include employee cet feedback consideration new committees agenda reporting regulation rivate session committee member july pdate new remuneration eview lti design eview agm feedback reporting regulation performance measure external environment include early draft comparator group time pprove committee remuneration report horizon evaluation process remuneration review rant interim lti eview implication eview executive director awards executive threepart novartis pay competitiveness transaction eview chairman rivate session deputy chairman fee committee member september rant interim share value plan award executive october pdate remuneration pdate lti vest pdate remuneration report disclosure award report disclosure gree key message annual investor meeting november raft message disclosure performance pay annual meeting investor december nnual benchmarke dministrative change eview feedback competitiveness review dabp investor meeting pprove executive director eview finding salary committee evaluation onsider cet remuneration eview draft change remuneration report paper provide pdate implication committee examine threepart novartis equivalent remuneration transaction element operate orporate governance employee cet update rivate session committee member gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue letter appointment nonexecutive director term engagement nonexecutive director chairman nonexecutive director set letter appointment available inspection company aim provide chairman non company register office agm executive director fee competitive pay nonexecutive director initial appointment company equivalent size complexity subject subsequent reappointment subject election limit contain gsk article association periodic reelection shareholder chairmans fee nonexecutive director letter appointment sir christopher gent take role chairman january contain provision notice period compensation chairmans fee increase january appointment terminate approximately sir follow table show date initial letter christopher total fee deliver share appointment nonexecutive director defer step board later nonexecutive director date letter appointment chairman designate sir philip hampton appoint non executive director effect january take sir christopher gent role deputy chairman april receive sir philip hampton september standard annual cash retainer nonexecutive director professor sir roy anderson september deputy chairman april stephanie burns february receive fee annum appointment stacey cartwright march chairman september late receive lynn elsenhans fee annum elect judy lewent march fee gsk share sir deryck maughan daniel podolsky july nonexecutive director fee urs rohner october nonexecutive director fee increase january increase supplemental fee minimum tom swaan december fee continue deliver share defer jing ulrich nonexecutive director step board han wijer january nonexecutive director fee apply january table audit set value fee benefit set receive nonexecutive director form cash share ad detail nonexecutive director annum share allocation plan set standard annual cash retainer fee supplemental fee chairman audit risk committee senior independent director scientificmedical expert chairman remuneration corporate responsibility committee nonexecutive director undertake intercontinental travel meeting meet sir christopher gent chairman corporate responsibility committee receive additional fee list nonexecutive director fee fee emolument audit cash sharesad benefit total cash sharesad benefit total professor sir roy anderson stephanie burn stacey cartwright lynn elsenhans sir christopher gentc judy lewent sir deryck maughan daniel podolsky tom swaan jing ulrich hans wijersd sir robert wilsond sir crispin davisd benefit primarily consist travel subsistence cost incur normal course business relation meeting board committee matter gskhoste event consider taxable overseasbase nonexecutive director include travel meeting nonexecutive director fee pay gbp convert exchange rate set annually base average rate quarter year prior payment rate review move significantly year amount benefit total emolument respect sir christopher gent restate result increase amount record remuneration report sir crispin davis retired board han wijer join board april sir robert wilson retired board gsk annual report strategic report governance remuneration financial statement investor information director interest share audit follow interest director company office december connect person show total share plan interest december total director interest sharesad option aunveste unvested aunveste unvested february december january subject subject subject subject vest exercise performance performance performance performance exercise year executive director share sir andrew wittyb simon dingemansb moncef slaouig ads moncef slaouic nonexecutive director sharesj professor sir roy anderson stephanie burn stacey cartwright sir christopher gent tom swaan hans wijers adsj stephanie burns lynn elsenhans judy lewent sir deryck maughan daniel podolsky jing ulrich unvested share ad unvested option hold executive director subject performance reflect bonus deferral dabp sharesave share value plan svp awards total director interest include share purchase glaxosmithkline sharereward plan sir andrew witty simon dingemans award share plan balance share plan follow sharereward plan share february december january sir andrew witty simon dingemans moncef slaoui eligible participate sharereward plan total director interest include share ad result deferral bonus subsequent reinvestment dividend dabp total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion amount represent gross share ad balance prior sale share ad satisfy tax liability defer annual bonus plan bonus deferral february december january sir andrew witty shares simon dingemans share moncef slaoui ad total director interest february include share ad vest performance element psp award sell satisfy tax liability vest amount page detail moncef slaoui total director interest include ad purchase plan executive supplemental saving plan essp ad award slaouis connect person svp relevant balance follow moncef slaoui ad february december january retirement saving plan share value plan executive director moncef slaoui eligible receive award svp svp award show reflect holding slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arise vest include moncef slaouis total remuneration figure year connect person grant ad september grant price face value slaouis total share plan interest include psp award hold connected person award subject performance criterion relevant employee cet december connect person hold ad psp comprise award ad ad ad amount include dividend reinvestment gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue sharesave plan sir andrew witty simon dingemans unvested option subject performance include holding respectively sharesave plan participate term employee sharesave award grant sir andrew witty simon dingemans grant option plan october remainder unvested option subject performance relate bonus deferral structure nilcost option dabp share option plan executive director follow table provide detail vest unexercised option december share option plan sop gsk grant option plan executive director annual basis number share option date grant lapse date exercise price sir andrew witty moncef slaoui ad vest unexercised option totalling moncef slaoui represent ad option hold moncef slaouis connect person follow table set detail option include nilcost option dabp exercise executive director simon dingemans exercise option year nilcost option dabp exercisable number share market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty sop sop dabp deferral dabp match moncef slaoui sop respect option sop sharesave plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share ad total value share ad vest date executive director choose exercise option vest date subsequent increase decrease realise movement share ad price vest date date exercise increase decrease value result investment decision executive director record remuneration option vest executive director respect nilcost option dabp bonus defer director record remuneration annual bonus year relate gain record exercise nilcost option comprise remuneration total amount receive reinveste dividend prior vest gain loss result movement share price date grant exercise initial bonus defer date dividend reinvestment exercise reinveste dividend matching element dabp remuneration director record year performance criterion end represent number vest share multiply price vest gain record exercise nilcost option comprise total remuneration gain loss result movement share price vest exercise sir andrew witty total gain follow exercise option grant sop comprise remuneration nil respect share option grant december subject performance criterion year period end vested february vest price investment gain gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment loss relate movement share price vest exercise date moncef slaoui total gain follow exercise option grant sop comprise remuneration respect option vest investment gain nonexecutive director total interest include share ad receive fee nonexecutive director share allocation plan detail balance note dividend receive share ad plan convert share ad december gsk annual report strategic report governance remuneration financial statement investor information defer annual bonus plan matching award defer annual bonus plan dabp matching award annually executive director base individual mandatory deferral voluntary bonus deferral election company match share ad oneforone depend company performance threeyear performance period performance condition vest level describe page report award ukbase executive director form nilcost option award vest ukbased executive director choose exercise award time year date grant awards usbased executive director conditional award ad remuneration receivable respect matching share ad calculate share ad price date relevant award vest award vest date remuneration report calculation perform average share ad price quarter financial year executive director choose exercise nilcost option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision record remuneration dividend reinveste nilcost option conditional award share ad executive director date vest follow table provide detail executive director respect dabp matching awards market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration remuneration vest march estimate vest price calculate remuneration actual vest price report remuneration report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue defer annual bonus plan matching award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste unvested december grant face value grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration vest march estimate vest price calculate remuneration actual vest price report remuneration report performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested february vest ad number ad market price vest gain remuneration remuneration vest march estimate vest price calculate remuneration actual vest price report remuneration report gsk annual report strategic report governance remuneration financial statement investor information performance share plan award performance share plan psp award executive director annual basis term psp number share ad vest determined follow end relevant performance period dependent gsk performance period performance condition vest level describe page dividend reinveste performance share ad award executive performance period date vest vest participant receive relevant number share participant defer receipt vested award remuneration receivable respect performance share calculate share ad price date relevant psp award vest psp award sir andrew witty year performance period deed award specify award subject year vest period year total year period additional performance criterion awards lapse sir andrew dismiss cause remuneration respect award consider realise follow determination remuneration committee vest level initial award remuneration recognise end threeyear performance period awards award executive director year performance period vest year final year vest period award director lapse dismiss cause remuneration respect award recognise end year performance period remuneration report follow table provide detail executive director respect psp award market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue performance share plan award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested february vest share number share market price vest gain remuneration remuneration performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested february vest ad number ad market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information nonexecutive director share allocation plan table set accumulate number share ad hold nonexecutive director december share allocation plan relation fee receive board member movement account year number share ad december dividend allocate december share allocation plan nonexecutive director footnote pay reinveste elect share professor sir roy anderson stacey cartwright sir christopher gent tom swaan hans wijers sir robert wilson ads stephanie burn lynn elsenhans judy lewent sir deryck maughan daniel podolsky jing ulrich robert wilson retired board elect receive share nonexecutive director share allocation plan immediately retire board dividend entitlement respect dividend pay cash accordance plan rule gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director member corporate executive team company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company share plan set table award dividend reinvestment award award share ad share ad defer annual bonus plan performance share plan defer investment awardsa share value planb february group follow interest share ad company holding issue executive share plan describe note financial statement employee share scheme interest february share ad own unexercised option defer annual bonus plan performance share plan defer investment awardsa share value planb notional share ad executive director eligible receive defer investment award participate share value plan basis preparation remuneration report prepare accordance company act large mediumsize company group account report amendment regulation regulation accordance regulation follow part annual report remuneration subject audit total remuneration figure executive director include detail element remuneration salary benefit annual bonus longterm incentive award pension nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section remuneration report subject audit page refer audit section remuneration report approve board director sign behalf tom swaan remuneration committee chairman february gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report company remuneration policy report approve gsk annual general meeting receive overwhelming vote favour shareholder remain place policy present approve shareholder change policy certain confirmatory statement operate policy public describe page report committee satisfied refinement provide additional payment permit approve policy line good practice interest shareholder copy shareholder approve policy available wwwgskcom investor section total remuneration executive director comprise follow element value earn annual longterm total salary benefit pension bonus incentive remuneration awards committee specific circumstance line state principle apply clawbackmalus determine appropriate future policy table company remuneration policy respect element outline table salary benefit international assignment policy purpose link strategy purpose link strategy purpose link strategy provide core reward role level set recruit retain high calibre gsk require executive director individual execute business strategy relocate order meet business set level appropriate secure retain requirement high calibre individual need deliver operation group strategic priority executive director eligible receive operation benefit line policy line policy employee operation employee vary location secondment travel expense provide individual role experience performance include car allowance healthcare executive overseas placement independently source datum relevant life assurancedeath service facilitate relocation process comparator group consider provide individual pension provide continue standard live determine salary level arrangement personal financial advice assignment salary increase typically effect contractual postretirement benefit international assignment allowance cover quarter year executive director eligible relocation cost accommodation base participate allemployee share scheme salary normally pay currency size family appropriate security sharesave sharereward plan executive director home country location allowance relocationspecific tax subject financial advice school fee tax opportunity term employee equalisation formal maximum limit order recognise high business ordinarily salary increase broadly opportunity travel requirement role executive line average increase wide relocation benefit dependent director entitle car travel gsk workforce number factor home host accompany spousepartn country family size duration increase higher reflect business trip benefit include assignment change scope individual role expense incur ordinary course responsibility experience salary business deem taxable possible provide typical adjustment reflect wide market benefit individual value limit condition geography benefit provision tailor reflect market performance measure individual operate practice geography salary level set executive director base different annual report policy apply current future executive director base different performance measure country overall performance individual key consideration determine opportunity salary increase formal maximum limit benefit cost fluctuate depend change provider cost individual circumstance detail current benefit cost set annual report remuneration performance measure gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue pension purpose link strategy opportunity pension arrangement provide pension arrangement exist eligible benefit competitive level retirement income executive director follow senior executive operation sir andrew witty member legacy cash balance pension plan pension arrangement structure glaxo wellcome define benefit plan supplemental cash balance pension accordance plan operate accrual rate final plan include executive pension credit country individual likely pensionable salary annum april provide maximum contribution retire individual choose pensionable earning increase base salary pension plan member pension plan limit annum member cash lieu relevant pension include sir andrew witty gsk plan contribution pay instead retirement saving plan simon dingemans member executive supplemental saving plan new executive director gsk pension plan pension core contribution salary entitle join define contribution instead receive cash bonus match contribution contribution pension plan receive payment salary lieu pension salary bonus cash payment lieu pension contribution contribution global moncef slaoui member individual member gsk cash balance pension plan gsk eligible appropriate equivalent legacy define benefit plan define plan executive arrangement excess contribution plan alternative pension supplemental saving plan usuk arrangement plan arrangement subsequently defer member belgium fortis performance measure appoint board plan remain member plan policy new external recruit salary contribution define contribution plan match contribution line policy member plan salary cash payment lieu pension contribution annual bonus purpose link strategy defer bonus share eligible performance measure incentivise recognise execution dividend equivalent date vest base financial target individual business strategy annual basis performance objective committee apply judgement reward achievement stretch make appropriate adjustment individual base core group profit annual financial strategic business annual bonus amount interest tax executive director target delivery personal objective ceo cfo balance clawback andor malus provision apply base core group operating profit operation describe annual executive director balance financial operational business target report base relevant business unit set start year opportunity performance committee bonus level threshold maximum bonus determine committee base individual performance objective opportunity executive director performance target multipli base achievement follow threshold maximum individual performance target apply individual objective set start bonus bonus bonus award performance year committee performance objective assess base base financial operational target salary salary committee ceo executive director require defer cfo bonus earn share ad appropriate year chairman global defer additional bonus vaccine earn overall maximum deferral defer share vest end year performance period gsk annual report strategic report governance remuneration financial statement investor information defer annual bonus plan dabp performance share plan psp purpose link strategy opportunity performance measure incentivise recognise delivery dabp equally weight performance long term business priority financial maximum bonus deferral annual measure growth increase shareholder value bonus mandatory new product performance compare pharmaceutical additional voluntary company adjust free cash flow maximum matching opportunity level addition provide alignment share share basis subject relative tsr shareholder interest retention element performance criterion year vest threshold encourage longterm shareholde psp maximum performance discourage excessive risk take normal maximum award limit comparator group currently operation times base salary annum comprise gsk global dabp maximum initial value performance pharmaceutical company vest deferred share match subject share grant psp median rise vest upper achievement performance condition individual year quartile performance year matching award detail unvested psp rule allow committee conditional share nilcost option award page award salary eligible dividend equivalent page annual exceptional circumstance respect performance period report current award level psp executive director follow conditional award annually vest dependent achievement salary performance condition year ceo award onwards vested awards cfo hold year year total prior release chairman global vaccine ceo psp award subject additional twoyear vest period award eligible dividend equivalent date vest confirmatory statement issue april state flexibility performance target dabp exceptional circumstance psp set start relation external recruit performance period detail set clawback andor malus provision apply approach recruitment section describe clawback malus effect annual bonus payable executive director require defer minimum annual bonus dabp event trigger event significant misconduct way violation regulation law significant gsk policy code conduct company ability claw year annual defer bonus vest unvested ltis separate recoupment committee establish investigate relevant claim misconduct additionally continuity responsibility initiation adverse event emergence problem adverse event take account assess annual bonus award lti vest level year problem identify future period committee appropriate adjustment individual annual bonus grant vest level lti awards reflect thisment individual annual bonus amount gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue longterm incentive measure committee select equally weight performance measure focus executive director longterm remuneration delivery gsk key strategic priority psp dabp award executive director base new product performance adjust free cash flow relative tsr addition set robust target committee implement number safeguard ensure target meet sustainable way performance reflect genuine achievement target represent delivery value shareholder performance measure impact acquisition divestment quantify adjust event major adjustment calculation performance measure disclose shareholder vest principal safeguard detailed measure chairman audit risk committee member member remuneration committee provide input audit risk committee review group performance oversight risk factor relevant remuneration decision rationale performance measure calculate follow vest schedule annual report remuneration performance measure rationale calculation methodology new recognise importance future business target base sale new product launch product growth performance period precede year performance key indicator assess performance aggregate threeyear revenue target reflect growth pharmaceutical industry strength company product historic performance pipeline new product performance measure recognise importance future business growth vest reduce insufficient progress include measure order incentivise performance performance period gsk target drive development sale new product return investment committee believe robust appropriate measure reflect actual delivery pipeline launch committee recognise time time excellence appropriate company respond emerge pandemic support gsk ethical responsibility value impact revenue include committee consider add shareholder value provide underlying performance sufficiently positive adjust free recognise importance effective work capital aggregate threeyear adjust free cash flow target cash flow cash management adjustment materially distort item performance use cash flow performance measure intend include exchange rate movement major legal recognise importance effective work capital management taxation settlement special pension contribution generate cash asset future valuecreate investment return shareholder relative tsr focus delivery value shareholder relative tsr measure year performance committee recognise delivery value month averaging period tsr measure local shareholder key priority relative total shareholder return currency peer group global pharmaceutical company select order closely align interest executive director investors committee regularly review composition tsr comparator group gsk annual report strategic report governance remuneration financial statement investor information annual bonus measure annual bonus design drive achievement gsk annual financial strategic business target delivery personal objective majority annual bonus opportunity base formal review performance stretch financial target outcome adjust reflect individual performance apply individual performance multipli reason commercial sensitivity specific personal objective keep confidential financial performance individual performance committee believe important majority ceo ceo cfos financial target base core group operating profit individual performance objective sir andrew witty set small element base core group profit interest tax board january year board focus strategic reflect wide responsibility drive profitable investment priority develop group follow associate joint venture end financial year board review performance bonus measure employee include moncef slaoui generally set objective determine link pipeline performance robust governance structure appropriate bonus payable performance establish ensure bonus payable fairly reflect executive director productivity performance ceo set individual objective executive recognise moncef slaouis current dual responsibility global director line company strategy make vaccine element bonus currently base vaccine recommendation committee performance performance consistent executive director element objective end year bonus currently base core group profit interest recommendation consider committee tax determine level bonus payable approach recruitment remuneration committee determine remuneration package new committee mindful sensitivity relate recruitment executive director casebycase basis depend package particular buying right relate role market operate experience previous employment signon payment total remuneration level set reference relevant pay seek minimise arrangement certain comparator group appropriate allow future circumstance enable recruitment exceptional talent development role committee determine arrangement good interest company shareholder arrangement expect new executive director participate short possible likeforlike basis forfeit longterm incentive plan basis exist award arrangement vary depend plan director exceptional circumstance committee arrangement place previous employer reserve flexibility set incentive limit new executive form cash share subject director additional exist limit performance condition explanation provide committee retain flexibility recognition high payment compensation previous level variable pay gsk global pharmaceutical competitor remuneration forfeit signon payment committee use flexibility remuneration arrangement newly appoint executive consider good interest company director disclose soon practicable investor appointment confirmatory statement issue april state follow policy principle apply role chairman committee anticipate ability grant awards nonexecutive director psp time salary exceptional chairman circumstance recruitment fee set level competitive pay executive director outside gsk limit set company equivalent size complexity fee psp award maximum time salary pay partly share nonexecutive director pension arrangement external appointment executive fee level new nonexecutive director set director set remuneration policy table basis exist nonexecutive director annual report company subject local law regulation fee benefit provide line policy exist pay partly share executive director event nonexecutive director different role require meet business need relocation support responsibility appoint fee level benchmarke provide line company policy set reference comparable role company equivalent size complexity internal appointment entitlement exist remuneration element continue include pension entitlement outstanding award case internal appointment require executive director contractual term include termination provision gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue loss office payment policy follow table set contractual framework executive director term specifically relate termination set detail policy duration company policy fix term contract generally contract new appointment expire line contract applicable policy retirement age contract exist executive director expire date show annual report notice period notice period termination employ company executive director calendar month mitigation ability impose month noncompete period nonsolicitation restriction executive director consider important company ability protect group intellectual property staff light committee believe appropriate provide mitigation contract termination employment event executive director employment company terminate follow policy payment apply element remuneration loss office payment policy termination termination notice month annual salary payable termination company prorate notice payment period work termination payment respect notice period extend contract expiry date bonus element normally include termination payment term contract seek balance commercial imperative good practice company enforce noncompete clause current ceo chairman global vaccine month ontarget bonus payable redundancy termination notice statutory redundancy pay apply general severance policy apply retirement death illhealth injury disability termination payment lti award psp dabp matching awards govern plan rule approve shareholder termination notice unvested awards lapse redundancy retirement generally award vest original timescale subject original performance condition award month forfeit death illhealth injury disability generally award vest follow end financial year normally take account performance date award prorate time event change control psp dabp matching awards vest take account performance date normally take account proportion performance period elapse alternatively award exchange new award annual bonus termination notice individual individual serve notice termination date fall december bonus forfeit termination notice company redundancy retirement death illhealth injury disability termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result dabp defer termination notice defer share vest date termination bonus award redundancy retirement death illhealth injury disability generally defer share vest end financial year termination date fall benefit generally benefit continue apply termination date termination notice company retirement executive line policy applicable senior executive chairman global vaccine eligible future date receive continue medical dental insurance terminationretirement termination mutual agreement certain circumstance good interest company board manage proactively succession planning development senior talent pipeline circumstance board agree executive departure mutual agreement order apply committee need satisfied executive demonstrate performance line expectation require contribute orderly succession complete year service group termination date case executive director treat good leaver purpose gsk longterm incentive plan termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result case ceo member define benefit pension scheme pension payable later termination date age actuarial reduction gsk annual report strategic report governance remuneration financial statement investor information committee anticipate exercise discretion difference remuneration policy provide psp dabp plan rule respect termination executive director employee payment unforeseen circumstance good interest company set remuneration level executive director shareholder necessary exercise discretion committee consider prevail market condition explanation provide competitive environment comparison executive director leave company committee remuneration executive company similar size complexity carry assessment individual performance international reach position relativity pay conduct time role determine individual employment condition broad gsk workforce performance conduct contrary legitimate particular committee consider range base salary expectation company committee reserve right rise workforce part gsk ceo apply appropriate mechanism clawback cfo chairman global vaccine employ annual report reduction lapsing outstanding consider relevant comparison incentive award malus ensure termination payment population reflect closely economic environment good interest company shareholder encounter individual case termination cause payment unvested principle apply remuneration policy executive award forfeit share defer dabp director employee remuneration offer vest date termination accrue salary executive director policy strong emphasis expense performancerelate pay offer employee service contract group table set relevant date current salary benefit include pension tailor local executive director service contract available market review company register office office hour annual bonus plan apply wide employee population date effective contract date expiry date note base business individual performance sir andrew contract amend combination performancerelate restrict share witty plan apply wide employee population remove entitlement bonus allemployee share plan available employee termination include revenue customs approve sharesave sharereward plan simon dingemans company conduct regular employee survey include moncef contract replace feedback remuneration matter slaoui wide organisation align performance principally remove reward system value introduce new entitlement bonus performance system formally evaluate employee termination need senior people disincentivise unethical working practice clawback mechanism allow recover performancerelate pay gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue scenario future total remuneration ceo chart opposite provide illustration future total remuneration executive director respect remuneration opportunity grant policy range potential outcome provide executive director underlie assumption set scenario base salary benefit pension figure base actual amount receive respect ongoing policy executive director assume defer annual bonus maximum permit receive fix expect maximum correspond matching award dabp include value lti awards cfo amount show value lti awards dabp psp base bonus opportunity relevant multiple salary respectively include amount respect dividend reinveste factor change share price vest period fix pay performance annual bonus lti payable expect annual bonus assume target financial performance achieve performance executive director result individual performance multipli increase financial performance element bonus apply result assume bonus salary sir fix expect maximum andrew witty simon dingemans moncef slaoui respectively chairman global vaccines lti awards threshold level vest assume maximum assume annual bonus payable maximum level award dabp psp vest fix expect maximum longterm variable remuneration annual variable remuneration fix remuneration gsk annual report strategic report governance remuneration financial statement investor information nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum fee review annually set competitive pay reference review chairman performance independently company equivalent sourced market datum size complexity subject remuneration committee responsible evaluating make limit contain gsk article recommendation board fee payable chairman association chairman participate discussion respect fee fee pay combination cash andor gsk share ad detail gsk nonexecutive director share allocation plan basic fee formal maximum fee review annually set reference independently source market datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director minimum deliver form gsk share ad detail gsk nonexecutive director share allocation plan supplemental provide additional compensation additional fee committee chairman intercontinental travel fee nonexecutive director senior independent director current fee level set exclude chairman take annual report remuneration additional board responsibility undertake intercontinental travel meeting benefit facilitate execution travel subsistence cost nonexecutive director incur responsibility duty require normal course business relation meeting board committee role matter gskhoste event overseasbase nonexecutive director include travel meeting nonexecutive director time time accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director nonexecutive enhance link nonexecutive director total fee exclude director share director shareholder gsk chairman pay form gsk share ad allocate allocation plan require nonexecutive director share ad account receive significant nonexecutive director opportunity invest fee form gsk share balance fee share ad account ad gsk share ad notionally award nonexecutive director allocate interest account set table annual report include director interest table annual report accumulate balance gsk share ad notional dividend accrue pay nonexecutive director leave board leave nonexecutive director receive gsk share ad cash equivalent value gsk share ad date leave date payment later letter nonexecutive director nonexecutive director subject annual election reelection appointment chairman term engagement normally serve long year date election set letter appointment shareholder general meeting set table chairman subject annual appointment shareholder annual report serve long year date election shareholder general meeting gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue operation scope remuneration policy current remuneration policy policy set page annual report intend policy gsk executive nonexecutive director apply close company annual general meeting submit committee approval shareholder committee currently intends operate accordance policy prior annual general meeting exception additional twoyear hold period performance share plan award apply award onwards committee write policy principally relation remuneration arrangement ceo cfo chairman global vaccine whilst take account possible recruitment replacement additional executive director operation policy committee intend policy operate period set entirety consideration seek change policy period believe appropriate longterm success company consultation shareholder seek shareholder approval general meeting draft policy committee reserve right remuneration payment payment loss office include exercise discretion available connection payment notwithstanding line policy set term payment agree policy come effect time relevant individual director company opinion committee payment consideration individual director company purpose payment include committee satisfy awards variable remuneration relation award share term payment agree time award grant committee minor amendment policy set report regulatory exchange control tax administrative purpose account change legislation obtain shareholder approval amendment statement consideration shareholder view committee engage regular dialogue shareholder hold annual meeting gsk large investor discuss feedback remuneration policy governance matter annual meeting hold november tom swaan committee chairman shared update remuneration matter month proposal onwards particular covered change performance condition apply longterm incentive introduction additional twoyear hold period performance share award year total apply executive director award onwards policy require disclose remuneration policy report gsk annual report strategic report governance remuneration financial statement investor information financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap gsk annual report strategic report governance remuneration financial statement investor information director statement responsibilitie director responsible prepare annual report disclosure information auditor remuneration report group financial statement director office date annual report accordance applicable law regulation confirm company law require director prepare financial far aware relevant audit information statement financial year law director company auditor unaware require prepare group financial statement take step ought accordance international financial reporting standard take director aware ifrs adopt european union prepare group relevant audit information establish company financial statement director elect comply auditor aware information ifrs issue international accounting standard board iasb company law director approve confirmation give interpret accordance group financial statement satisfied provision section company act true fair view state affair group go concern basis profit loss group period page contain information performance prepare financial statement director group financial position cash flow net debt position require borrowing facility information include treasury risk management policy exposure market credit risk select suitable accounting policy apply hedging activity give note financial statement consistently financial instrument relate disclosure make judgement accounting estimate enquirie director reasonable expectation reasonable prudent group adequate resource continue operational existence foreseeable future reason state group financial statement comply ifrs continue adopt go concern basis prepare adopt european union ifrs issue financial statement iasb subject material departure disclose explain group financial statement internal control board audit risk committee review prepare financial statement go concern basis assessment risk internal control framework operate inappropriate presume group gsk consider effectiveness system continue business internal control operation group year cover director responsible keep adequate accounting annual report date approval board record sufficient explain company director transaction disclose reasonable accuracy time corporate governance code financial position group enable ensure board consider glaxosmithkline plc apply group financial statement remuneration report principle provision corporate governance code comply company act article ias maintain financial reporting council describe regulation responsible safeguard asset corporate governance section page group take reasonable step comply provision board consider prevention detection fraud irregularity annual report take fair balanced group financial statement year end december understandable provide information necessary comprise principal statement support note shareholder assess group performance business set financial statement page model strategy report responsibilitie auditor relation group require financial conduct authority list rule financial statement set independent auditor auditor consider director statement report page compliance relation point corporate group financial statement year end december governance code specify review include annual report publish annual report print form available website director annual report year end december responsible maintenance integrity annual report comprise report director remuneration report website accordance legislation govern financial statement additional information investor preparation dissemination financial statement access approve board director sign website available outside comparable behalf legislation different current director name function list corporate governance section annual report confirm good knowledge sir christopher gent chairman group financial statement prepare february accordance ifrs adopt ifrs issue iasb true fair view asset liability financial position profit group strategic report risk section annual report include fair review development performance business position group description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement investor information independent auditor report members glaxosmithkline plc report group financial statement audit approach overview opinion materiality opinion group financial statement define overall group materiality million represents true fair view state group affair profit tax add certain nonrecurre item december profit cash flow audit scope year end audit include scope audits report component properly prepare accordance international specific audit procedure perform financial reporting standard ifrss adopt reporting component european union take component audit work prepare accordance requirement perform account consolidated revenue company act article ias regulation consolidated profit tax cover component individually contribute revenue profit separate opinion relation ifrss issue iasb tax explain note group financial statement addition apply ifrss adopt european union area focus group apply ifrss issue international rebate discount allowance return accounting standard board iasb pharmaceutical vaccine business opinion group financial statement comply ifrss transformation group finance process issue iasb potential implication allege illegal act audit litigation glaxosmithkline plcs group financial statement comprise carry value goodwill intangible asset consolidate balance sheet december uncertain tax position consolidate income statement statement comprehensive income year end scope audit area focus conduct audit accordance international consolidate statement change equity year standard audit ireland isas ireland end design audit determine materiality consolidated cash flow statement year end assess risk material misstatement group financial statement particular look director note consolidated financial statement subjective judgement example respect significant include summary significant accounting policy accounting estimate involve make assumption explanatory information consider future event inherently uncertain audits address risk management override financial reporting framework apply internal control include evaluate preparation group financial statement comprise evidence bias director represent risk applicable law ifrss adopt european union material misstatement fraud risk material misstatement great effect audit include allocation resource effort identify area focus table set tailor audit address specific area order provide opinion group financial statement comment result procedure read context area focus appropriate evaluated design test operating effectiveness key internal control financial reporting include testing operation system financial information generate complete list risk identify audit gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continued area focus audit address area focus rebate discount allowance return obtain management calculation accrual applicable pharmaceutical vaccine business scheme validate assumption reference group refer note group financial statement state commercial policy term applicable contract party datum relate patient enrolment government fund benefit scheme group make sale customer fall historical level product return certain commercial government mandate contract reimbursement arrangement significant compare assumption contract price historical rebate medicaid medicare group provide right return discount allowance return level relevant current customer certain product payment trend consider historical accuracy group estimate previous year include evaluation release accrual arrangement result deduction gross sale arrive follow payment settlement state authority turnover rise obligation group provide customer rebate discount allowance right return form independent expectation large element unsettle amount recognise accrual accrual december party datum compare expectation actual accrual recognise group undertaking focused area rebate discount allowance work consider impact decrease revenue certain return arrangement complex establish respiratory product principally advair relevant change price appropriate accrual require significant judgement estimation billing arrangement commercial government director director determine accrual billion healthcare provider necessary december base procedure perform identify material difference independent expectation accrual transformation group finance process centrally manage work perform component audit team group continue rationalise simplify finance process bpos bsc consist control substantive testing include rollout enterprisewide resource planning system conduct oversight visit bsc bpo site group erp core business service addition financial transaction audit scope india malaysia direct work process continue migrate party business process perform outsourcing location bpos related accounting service evaluate design test operating effectiveness key centralised inhouse business service centre bsc automate manual control migration change represent financial reporting risk migration centralise processing environment include general control control happen control process establish respect datum migration erp system substantively embed number year update migrate test accuracy completeness datum migration new erp new erp environment increase risk breakdown control process note significant internal financial control transition increase risk exception inaccurate incomplete migration financial datum turn increase risk material misstatement group financial statement potential implication allege illegal act inspect rule changsha intermediate people court refer note group financial statement hunan province china respect allegation bribery china incorporate risk area focus audit validate amount pay final settlement liability result allegation illegal act carry group chinese consistent ruling pharmaceutical business addition group conduct specialist forensic knowledge independently assess investigation number market group continue scope finding investigative work perform group cooperate enquiry department justice doj external legal counsel respect allegation china consider fraud office sfo sfo announce output assessment determine audit approach meet commence criminal investigation group component audit team shanghai china understand evaluate commercial practice addition group announce step take group address allegation pay million fine chinese government connection allegation meet director management inhouse legal counsel group external advisor assess risk occurrence similar act focus follow risk material impact outside china status ongoing investigation potential group financial statement fine penalty include understand evaluate illegal act similar previously allege china group internal investigation process consider risk occur group allegation report channel include whistleblowe fine penalty forthcoming respect hotline evaluate enhancement change ongoing investigation group commercial practice control process business practice rise need additional provision asset supplement centralise procedure select territory impairment outside china include certain market include group audit scope countryspecific risk corruption bribery deem high territory obtain specific reporting component audit team provide evidence appropriately design perform audit procedure address audit risk group financial statement materially misstate potential financial impact illegal act discuss status investigation open doj sfo audit risk committee board director management inhouse general counsel addition engage directly group external advisor corroborate understand satisfied group provision decision december adequacy disclosure give status investigation gsk annual report strategic report governance remuneration financial statement investor information area focus audit address area focus litigation discuss status significant know actual potential litigation refer note group financial statement inhouse legal counsel obtain substantively test pharmaceutical industry heavily regulate increase evidence support decision rationale provision hold inherent litigation risk group engage number legal decision recognise provision include correspondence legal action include product liability antitrust relate private counsel counterpartie litigation monitor litigation significant disclose note consider external information source identify potential legal action focus area eventual outcome claim uncertain develop independent expectation litigation provision position take director base application base product litigation history available evidence material judgement estimation accordingly unexpected adverse challenge valuation completeness provision recognise outcome significantly impact group report profit group obtain confirmation external legal counsel balance sheet position confirm understand settle outstanding litigation assert claim evaluate significant adjustment legal reserve december group hold provision million record year determine indicative respect legal action management bias disclose note group financial statement eventual outcome legal proceeding dependent outcome future event position take group inherently judgemental find context group financial statement take judgement management reasonable disclosure respect provision contingent liability appropriate carrying value goodwill intangible asset leverage specialist valuation knowledge obtain group refer note group financial statement impairment analysis test reasonableness key assumption group billion intangible asset include significant include profit cash flow growth terminal value impact license patent acquire brand billion goodwill expiry patent potential product obsolescence selection december group recognise impairment intangible discount rate challenge management substantiate asset total million year assumption include compare relevant assumption industry economic forecast focus acquire intangible asset significant individually aggregate number indefinite interrogate integrity support calculation live group recognise goodwill number corroborate certain information party source include acquisition expectation performance certain asset component business carry value goodwill intangible asset contingent future cash flow risk cash flow obtain evaluated management sensitivity analysis ascertain meet group expectation asset impair impact reasonably possible change perform impairment review perform group contain number independent sensitivity calculation quantify downside change significant judgement estimate include revenue growth management model require result impairment focus success new product launch profit margin cash conversion particular emerge market sensitive change discount rate change assumption lead change cgus carrying value intangible asset goodwill risk great result work determine quantum impairment emerge market pharmaceutical vaccine cash recognise appropriate intangible asset include generate unit cgus valuation headroom compare goodwill management determine impairment require carrying value lower previous year find judgement support reasonable assumption require significant downside change additional material impairment necessary uncertain tax position specialist international tax transfer pricing refer note group financial statement knowledge evaluate challenge management judgements group operate complex multinational tax environment respect estimate tax exposure contingency order assess open tax transfer pricing matter overseas adequacy group tax provision include obtain tax authority addition time time group enter evaluate certain party tax opinion group obtain transaction complicate accounting tax consequence assess appropriateness assumption include respect judgement require assess level provision require step take advance propose threepart transaction respect uncertain tax position december group novartis recognise provision uncertain tax provision offset current understanding evaluate management judgement consider tax asset include current tax payable million status recent current tax authority audits enquirie million outturn previous claim judgemental position take tax return current year estimate development tax environment evidence obtain consider level provision acceptable context group financial statement take note assumption judgement require formulate provision mean range possible outturn broad gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue tailor audit scope specific audit procedure central function identify area focus tailor scope group consolidation area significant judgement include audit ensure perform sufficient work able taxation goodwill intangible asset treasury postretirement opinion group financial statement take benefit litigation elimination unrealise intercompany account geographic structure group profit inventory directly lead group audit team accounting process control industry take territory function perform group operate audit work account consolidated revenue group financial statement consolidation consolidated profit tax consider report unit consider component contribution audit evidence perform audit work identify reporting unit view require divisional group level include test monitor audit complete financial information size control disaggregate analytical review procedure risk characteristic specific audit procedure significant cover significant portion group small low risk balance transaction perform component directly include group audit report unit appropriate coverage material scope addition obtain audit evidence certain balance report unit support share outofscope component procedure undertake financial service centre centre include group share service centre encompass bpos group audit scope report unit include bsc centralise infrastructure group audit scope individually contribute process standardise consolidated revenue profit tax materiality work perform component auditor scope audit influence application determine level involvement need materiality set certain quantitative threshold materiality audit work reporting unit result overseas qualitative consideration help component visit senior member group audit determine scope audit nature timing team include group significant component extent audit procedure evaluate effect visit annually alongside belgium china misstatement individually group financial france germany italy addition share statement service centre support reporting component group audit base professional judgement determine materiality scope visit component group audit scope group financial statement follow site visit undertaken involvement include review component auditor work paper attendance certain component audit clearance meeting overall group materiality million million determined profit tax million add nonrecurre item include remeasurement charge shionogiviiv healthcare contingent consideration million major restructuring cost million legal cost include fine pay china million item income expense relate major acquisition disposal activity net million incremental cost change time recognition brand prescription drug fee million impairment intangible asset million rationale benchmark apply group principal measure earning comprise core result add statutory result number item income expenditure include detailed management use measure believe eliminate volatility inherent oneoff item take measure account determine materiality adjusted profit tax add amortisation intangible asset certain small noncore item view recur item introduce volatility group earning materiality low year primarily effect low profitability agree audit risk committee report misstatement million million identify audit misstatement view warrant reporting qualitative reason go concern require reporting listing rule require review director statement set relation go concern consistency information report perform review company act opinion note director statement director conclude opinion appropriate prepare group financial statement information give strategic report director go concern basis accounting going concern report financial year group financial basis presume group adequate resource remain statement prepare consistent group financial operation director intend statement year date group financial statement sign audit conclude director use information give corporate governance statement go concern basis appropriate set page respect internal control risk management system share capital structure future event condition consistent group financial statement predict statement guarantee group ability continue go concern gsk annual report strategic report governance remuneration financial statement investor information isas ireland report information annual report exception materially inconsistent information audit group finanical statement report arise apparently materially incorrect base materially inconsistent knowledge group acquire responsibility course perform audit misleading statement give director accordance provision corporate governance exception code code consider annual report take fair balanced understandable report arise provide information necessary member assess group performance business model strategy responsibility materially inconsistent knowledge group acquire course perform audit section annual report require provision code describe work exception audit risk committee appropriately address matter communicate audit risk committee report arise responsibility adequacy information explanation receive reasonableness significant accounting estimate company act require report director opinion receive information overall presentation group financial statement explanation require audit exception report arise responsibility primarily focus work area assess director judgement available evidence form director remuneration judgement evaluate disclosure group company act require report financial statement opinion certain disclosure director remuneration specify law exception test examine information sampling report arise responsibility auditing technique extent consider necessary provide reasonable basis draw conclusion obtain corporate governance statement audit evidence testing effectiveness control list rule require review substantive procedure combination corporate governance statement relate parent company compliance provision corporate addition read financial nonfinancial information governance code report perform annual report identify material inconsistency review audit group financial statement identify information apparently materially incorrect base materially company act require report inconsistent knowledge acquire course opinion corporate governance statement perform audit aware apparent material prepare parent company exception report misstatement inconsistency consider implication arise responsibility report responsibilitie financial statement matter audit report separately parent company financial responsibility director statement glaxosmithkline plc year end explain fully director statement december information director responsibility set director responsible remuneration report describe audit preparation group financial statement satisfy true fair view company pass resolution accordance section company act senior statutory auditor responsibility audit express opinion group state financial statement accordance applicable law isas ireland standard require comply auditing practice board ethical standard auditor pricewaterhousecooper llp report include opinion prepare charter accountant statutory auditor company member body accordance london chapter company act february purpose give opinion accept assume responsibility purpose person report show hand come save note expressly agree prior consent writing maintenance integrity glaxosmithkline plc audit financial statement involve website responsibility director work carry audit involve obtain evidence amount auditor involve consideration disclosure group financial statement sufficient matter accordingly auditor accept responsibility reasonable assurance group financial statement change occur group financial free material misstatement cause fraud error statement initially present website include assessment egislation united kingdom govern preparation accounting policy appropriate group dissemination financial statement differ circumstance consistently apply legislation jurisdiction adequately disclose gsk annual report strategic report governance remuneration financial statement investor information financial statement consolidate income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating income operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny consolidate statement comprehensive income year end december profit year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement lossesgain define benefit plan defer tax actuarial movement define benefit plan comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board february sign behalf sir christopher gent chairman gsk annual report strategic report governance remuneration financial statement investor information financial statement continue consolidated statement change equity year end december shareholder equity non share share retain control total capital premium earning reserve total interest equity january profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive incomeexpense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire disposal business investment associate joint venture proceeds disposal subsidiary interest associate decrease liquid investment interest receive dividend associate joint venture net cash outflowinflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation hold treasury share purchase noncontrolle interest increase longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft cash bank overdraft begin year exchange adjustment decreaseincrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report strategic report governance remuneration financial statement investor information note financial statement presentation financial statement implementation new accounting standard amendment ia offset financial asset financial description business liability issue december implement glaxosmithkline major global healthcare group gsk january amendment provide additional engaged creation discovery development manufacture guidance financial asset financial liability market pharmaceutical product include vaccine offset material impact current period overthecounter otc medicine healthrelate consumer product gsk principal pharmaceutical product include financial period medicine follow therapeutic area respiratory anti financial statement cover financial year january viral central nervous system cardiovascular urogenital december comparative figure financial metabolic antibacterial oncology emesis dermatology year january december rare disease immunoinflammation vaccine hiv appropriate january december compliance applicable law ifrs parent company financial statement financial statement prepare accordance financial statement parent company glaxosmithkline company act article ias regulation plc prepare accordance gaap international accounting standard ias international accounting presentation company balance sheet present financial reporting standard ifrs relate interpretation accounting policy give adopt european union financial statement compliance ifrs accounting principle policy issue international accounting standard board consolidation composition financial statement consolidated financial statement include consolidated financial statement draw sterling asset liability result cash flow functional currency glaxosmithkline plc accordance company subsidiary include esop trust ifrs accounting presentation financial statement comprise group share result net asset associate joint venture consolidate income statement group share asset liability revenue expense consolidate statement comprehensive income joint operation consolidated balance sheet financial statement entity consolidate consolidated statement change equity december year consolidated cash flow statement entity group power direct relevant activity affect return group generally note financial statement control financial operating policy account composition group subsidiary group ability exercise joint list subsidiary associate undertaking control right net asset entity entity opinion director principally affect profit account joint venture group net asset group give note principal ability exercise joint control arrangement right group company specify asset obligation specify liability arrangement arrangement account joint accounting principle policy operation group ability exercise significant financial statement prepare historical influence entity account associate cost convention modify revaluation certain item result asset liability associate joint state accounting policy go concern basis venture incorporate consolidated financial financial statement prepare accordance statement equity method accounting group accounting policy approve board group right asset liability revenue expense describe note accounting principle policy joint operation include consolidated financial information application accounting policy statement accordance right obligation include area estimation judgement give note interest acquire entity consolidate date key accounting judgement estimate group acquire control interest sell deconsolidate preparation financial statement conformity date control cease generally accept accounting principle require management estimate assumption affect report amount asset liability disclosure contingent asset liability date financial statement report amount revenue expense report period actual result differ estimate gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue revenue revenue recognise income statement good transaction balance subsidiary eliminate service supply available external customer profit tax take sale subsidiary order receive title risk loss pass product sell customer outside group customer reliable estimate relevant deduction relevant proportion profit transaction joint venture relevant obligation fulfil joint operation associate defer product earning process regard complete sell party transaction noncontrolle interest record directly equity defer tax relief unrealise turnover represent net invoice value deduction intragroup profit account extent discount allowance give accrual estimate future consider recoverable rebate return methodology assumption estimate rebate return monitor adjust regularly goodwill capitalise separate item case light contractual legal obligation historical trend subsidiary cost investment case past experience project market condition market joint venture associate goodwill denominate condition evaluate wholesaler thirdparty currency operation acquire analysis market research datum internally generate cost acquisition fair value information value add tax sale taxis exclude net asset acquire difference recognise directly revenue income statement group copromote product counterparty business combination record sale group record share revenue business combination account acquisition copromotion income turnover nature copromotion accounting method identifiable asset liabilitie contingent activity group record cost sale liability acquire measure fair value acquisition date pharmaceutical turnover include copromotion revenue consideration transfer measure fair value million million million addition include fair value contingent consideration initial eventbase milestone income exclude royalty income consideration transfer noncontrolle arise development marketing collaboration group interest exceed fair value net asset liability compound product party recognise contingent liability acquire excess record goodwill turnover milestone income million include turnover cost acquisition charge income statement million period incur royalty income recognise accrual basis accordance equity subsidiary acquire non term relevant licensing agreement control interest recognise fair value expenditure noncontrolle interest share net asset subsidiary expenditure recognise respect good service casebycase basis change group ownership receive supply accordance contractual term percentage subsidiary account equity provision obligation exist future liability foreign currency translation respect past event obligation foreign currency transaction book functional reliably estimate manufacturing startup cost currency group company exchange rate rule validation achievement normal production expense date transaction foreign currency monetary asset incur advertising promotion expenditure charge liability retranslate functional currency rate income statement incur shipment cost inter exchange rule balance sheet date exchange difference company transfer charge cost sale distribution include income statement cost sale customer include sell general administrative expenditure consolidation asset liability include related goodwill overseas subsidiary associate joint venture restructure cost recognise provide translate sterling rate exchange rule balance appropriate respect direct expenditure business sheet date result cash flow overseas subsidiary reorganisation plan sufficiently detail associate joint venture translate sterling advanced appropriate communication average rate exchange affect undertaken exchange adjustment arise open net asset profit year retain overseas subsidiary associate joint venture translate sterling exchange difference arise related foreign currency borrowing hedge group net investment operation take separate component equity translating sterling asset liability result cash flow overseas subsidiary associate joint venture report currency hyperinflationary economy adjustment material reflect current price level loss net monetary asset charge consolidated income statement gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue employee share plan incentive form share provide employee research development share option share award scheme research development expenditure charge income statement period incur development fair value option award calculate expenditure capitalise criterion recognise grant date blackschole option pricing model asset meet usually regulatory filing charge income statement relevant vesting period major market approval consider highly probable property group provide finance esop trust purchase company plant equipment research development share open market meet obligation provide share capitalise depreciated accordance group policy employee exercise option award cost environmental expenditure running esop trust charge income statement environmental expenditure relate exist condition result share hold esop trust deduct past current operation current reserve transfer reserve retain future benefit discernible charge income statement earning vest period relate share option group recognise liability sitebysite basis award reflect ultimate proceed receivable employee reliably estimate liability include group exercise portion total cost portion potentially property plant equipment responsible party cost probable property plant equipment ppe state cost able satisfy respective share cleanup obligation purchase construction provision depreciation recovery reimbursement record asset impairment financing cost capitalise cost virtually certain qualifying asset construction legal dispute depreciation calculate write cost residual value provision anticipate settlement cost legal ppe exclude freehold land straightline basis dispute group outflow resource expect useful life residual value life review consider probable reliable estimate appropriate adjust annually normal expect likely outcome addition provision legal useful life major category ppe expense arise claim receive dispute respect product liability claim relate certain product freehold building year sufficient history claim settlement leasehold land building lease term year enable management reliable estimate provision plant machinery year require cover unasserted claim certain case incur equipment vehicle year report ibnr actuarial technique determine estimate disposal ppe cost relate accumulate depreciation impairment remove financial group involved legal proceeding respect statement net proceed take possible reliable estimate income statement expect financial effect result ultimate lease resolution proceeding case appropriate disclosure case include provision leasing agreement transfer group substantially cost associate claim group benefit risk ownership asset treat party charge income statement finance lease asset purchase outright incur asset include ppe computer software capital element leasing commitment show obligation pension postemployment benefit finance lease asset hold finance lease cost provide pension define benefit scheme depreciate basis consistent similar own asset calculate project unit credit method spread lease term short interest element lease rental period benefit expect derive include income statement lease operate employee service consistent advice qualified lease rental cost charge income statement actuarie pension obligation measure present value straightline basis lease term estimate future cash flow discount rate reflect goodwill yield high quality corporate bond pension scheme asset measure fair value balance sheet date goodwill state cost impairment goodwill deem indefinite useful life test impairment cost postemployment liability calculate annually similar way define benefit pension scheme spread period benefit expect derive fair value interest acquire entitys asset employee service accordance advice liability contingent liability exceed consideration pay qualified actuary excess recognise immediately gain income statement actuarial gain loss effect change actuarial assumption recognise statement comprehensive income year arise group contribution define contribution plan charge income statement incur gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue availableforsale investment liquid investment investment classify intangible asset availableforsale investment initially record fair intangible asset state cost provision amortisation value plus transaction cost remeasure subsequent impairment report date fair value unrealised gain loss licence patent knowhow marketing right separately availableforsale investment recognise directly acquire acquire business combination comprehensive income impairment arise significant amortise estimate useful life generally exceed prolong decline fair value equity investment reduce year straightline basis time carry asset directly charge available use estimate useful life determine income statement amortisation charge account patent life disposal impairment investment gain applicable value obtain period non loss defer comprehensive income exclusivity asset life review appropriate reclassify income statement dividend equity adjust annually contingent milestone payment recognise investment recognise income statement point contingent event probable group right receive payment establish equity investment development cost incur group associate record noncurrent asset expect acquire licence patent knowhow marketing right sell year write income statement incur criterion recognition internally generate intangible asset purchase sale equity investment account meet usually regulatory filing major trade date purchase sale availableforsale market approval consider highly probable investment account settlement date inventory acquire brand value independently fair value business acquire party brand inventory include financial statement low value substantial long term brand cost include raw material direct labour direct cost contractual legal nature sell separately relate production overhead net realisable value cost rest business acquire brand amortise generally determine basis prelaunch estimate useful life year inventory hold asset high probability consider useful economic life indefinite regulatory approval product point provision carry value recoverable cost acquire develop computer software provision reverse point high probability internal use internet site external use capitalise regulatory approval determine intangible fix asset software site support trade receivable significant business system expenditure lead creation durable asset erp system software amortise trade receivables carry original invoice seven year computer software provision doubtful debt provision year evidence risk nonpayment take account age previous experience general economic condition impairment noncurrent asset trade receivable determine uncollectable write carry value noncurrent asset review firstly provision available income impairment standalone basis large statement cash generating unit indication asset impair additionally goodwill intangible asset subsequent recovery amount previously provide indefinite useful life intangible asset credit income statement longterm receivable available use test impairment annually provision discount effect material impairment charge income statement year trade payable concern trade payable initially recognise fair value hold impairment goodwill reverse impairment loss amortise cost equate nominal value longterm noncurrent asset reverse payable discount effect material change estimate determine recoverable amount cash cash equivalent extent revise recoverable amount cash cash equivalent comprise cash hand current exceed carry value exist net balance bank similar institution highly liquid depreciation amortisation impairment recognise investment maturity month investment associate joint venture joint operation readily convertible know amount cash investment associate joint venture carry insignificant risk change value consolidate balance sheet group share net borrowing asset date acquisition postacquisition borrowing initially record proceed retain profit loss goodwill arise receive net transaction cost borrowing subsequently acquisition group recognise right asset carry amortise cost difference liability revenue expense joint operation proceed net transaction cost redemption recognise charge income statement period relevant borrowing gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue key accounting judgement estimate taxation prepare financial statement management require current tax provide amount expect pay estimate assumption affect amount apply tax rate enact substantively enact asset liability revenue expense report financial balance sheet date statement actual amount result differ estimate follow consider key accounting defer tax provide temporary difference arise judgement estimate tax basis asset liability carry amount financial statement defer tax asset turnover recognise extent probable future taxable revenue recognise title risk loss pass profit available temporary difference customer reliable estimate relevant deduction utilise defer tax provide temporary difference relevant obligation fulfil arise investment subsidiary associate joint earning process regard complete venture time reversal temporary gross turnover reduce rebate discount allowance difference control probable temporary product return give expect give vary difference reverse foreseeable future defer tax product arrangement buy group arrangement provide rate tax enact substantively purchase organisation dependent enact balance sheet date submission claim time initial recognition derivative financial instrument hedge sale accrual time sale estimate derivative financial instrument manage exposure rebate discount allowance payable return market risk principal derivative instrument gsk base available market information historical experience foreign currency swap interest rate swap foreign exchange amount estimate fully reflect forward contract option group hold issue final outcome amount subject change dependent derivative financial instrument trade speculative thing type buy group purpose product sale mix derivative financial instrument classify heldfortrading level accrual review adjust regularly carry balance sheet fair value derivative light contractual legal obligation historical trend past designate hedge instrument classify inception experience project market condition market condition cash flow hedge net investment hedge fair value hedge evaluate wholesaler thirdparty analysis change fair value derivative designate cash flow market research datum internally generate information hedge recognise comprehensive income future event cause assumption extent hedge effective ineffective portion accrual base change affect future recognise profit loss immediately amount defer result group comprehensive income reclassify income taxation statement hedge item affect profit loss current tax provide amount expect pay net investment hedge account similar way defer tax provide temporary difference cash flow hedge tax basis asset liability carry amount rate enact substantively enact change fair value derivative designate fair value balance sheet date hedge record income statement change fair value hedge asset liability defer tax asset recognise extent probable future taxable profit available change fair value derivative instrument temporary difference utilise base qualify hedge accounting recognise immediately management assumption relate amount time income statement future taxable profit factor affect tax charge discount future year set note taxation change time value money material balance group effective tax rate change discount current value appropriate rate interest total tax charge year approximately million unwind discount record finance income group open tax issue number revenue finance expense authority outflow fund believe probable reliable estimate outcome dispute management provide good estimate liability estimate account specific circumstance dispute relevant external advice inherently judgemental change substantially time new fact emerge dispute progress gsk continue believe adequate provision liability likely arise open assessment open issue exist ultimate liability matter vary amount provide dependent outcome negotiation relevant tax authority necessary litigation proceeding gsk annual report strategic report governance remuneration financial statement investor information key accounting judgement estimate business combination contingent consideration include consideration continue payable business combination record fair value legal dispute date acquisition fair value generally base group provide anticipate settlement cost riskadjuste future cash flow discount appropriate outflow resource consider probable reliable interest rate fair value review regular basis estimate likely outcome dispute annually change reflect income legal expense arise claim group statement estimate account specific circumstance december liability contingent consideration dispute relevant external advice inherently amount million note acquisition judgmental change substantially time new disposal million arise acquisition fact emerge dispute progress detail status shionogiviiv healthcare joint venture uncertainty involve significant unresolved dispute set note legal proceeding assumption relate future cash flow discount rate base business forecast inherently company director take legal advice judgemental future event cause assumption established provision take account relevant projection change consequent adverse effect fact circumstance matter accordance future result group accounting requirement respect product liability claim relate certain product sufficient history claim pension postemployment benefit settlement enable management reliable cost provide pension postemployment estimate provision require cover unasserted claim benefit charge income statement accordance group involved legal proceeding respect ias employee benefit period benefit possible reliable estimate derive employee service cost assess expect financial effect result ultimate basis assumption select management resolution proceeding case appropriate assumption include future earning pension increase disclosure case include provision discount rate expect longterm rate return asset contingent liability quantify mortality rate disclose note pension december provision legal dispute postemployment benefit surplus define benefit amount billion billion scheme arise potential surplus arise commit future contribution right trustee ultimate liability legal claim vary amount prevent group obtain refund surplus future provide dependent outcome litigation consider determine necessary restrict proceeding investigation possible settlement negotiation surplus recognise position change time assurance loss result outcome expect longterm rate return bond determine legal proceeding exceed provision base portfolio mix indexlinke government report group financial statement material corporate bond equity risk premium add equity goodwill intangible asset impairment goodwill deem indefinite life discount rate derive rate corporate bond yield amortise annual impairment test cash generating country deep market corporate unit goodwill allocate performed impairment bond government bond yield sensitivity test base established market multiple riskadjuste analysis provide note pension post future cash flow discount appropriate interest rate employment benefit reduction discount assumption impairment test set rate lead increase net pension deficit note goodwill approximately million increase annual pension cost approximately million selection different case valuation indicate sufficient headroom assumption affect future result group reasonably possible change key assumption unlikely result impairment relate goodwill impairment test intangible asset undertake event occur question carry value asset brand intangible asset available use amortise subject annual impairment test valuation impairment test base established market multiple riskadjuste future cash flow estimate useful life asset limit discount appropriate interest rate set note intangible asset assumption relate future cash flow estimate useful life discount rate base business forecast inherently judgemental future event cause assumption impairment test change consequent adverse effect future result group gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue new accounting requirement exchange rate follow new amend accounting standard group use average exchange rate prevail issue iasb likely affect future annual report period translate result cash flow overseas exception amendment ias impact subsidiary joint venture associate undertaking result financial position group currently sterling period end rate translate net asset assess undertaking currency influence translation relevant exchange rate amendment ia define benefit plan employee contribution issue november implement group january amendment average rate provide additional guidance treatment contribution define benefit plan employee party euro expect material impact result financial yen position group amendment ifrs consolidated financial statement period end rate ia investment associate joint venture issue september implement group euro january amendment require recognition yen gain loss arise sale contribution business associate joint venture investor share gain loss asset constitute business sell contribute associate joint venture amendment ifrs joint arrangement issue implement group january amendment require acquisition joint operation meet definition business account accordance ifrs business combination ifrs revenue contract customer issue implement group january standard provide single principlesbased approach recognition revenue contract customer focus identification performance obligation contract require revenue recognise performance obligation satisfy ifrs financial instrument issue final form july implement group january standard replace majority ia cover classification measurement derecognition financial asset financial liability impairment financial asset provide new hedge accounting model gsk annual report strategic report governance remuneration financial statement investor information segment information group operate segment report base financial information provide chief executive officer responsibilitie corporate executive team cet individual member cet responsible geographic segment pharmaceutical vaccine business viiv healthcare establish product consumer healthcare business respectively establish product segment create certain product reclassification principally otc dermatology brand acquire stiefel business pharmaceutical vaccine segment consumer healthcare segment effect january comparative information restate accordingly addition segment turnover profit restate exclude divestment complete investment essential sustainability pharmaceutical business segment report europe emerge market japan establish product pharmaceutical vaccine segment profit exclude allocation globally fund central cost principally corporate function unallocate manufacturing cost viiv healthcare consumer healthcare operating profit include cost group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis trading unallocated pharmaceutical vaccine include canada puerto rico australasia central vaccine tender sale contract manufacturing sale cost vaccine central dermatology cost central manufacturing cost attribute segment pharmaceutical report separate segment corporate unallocated cost represent cost corporate function work capital relation establish product manage pharmaceutical vaccine segment restate restate turnover segment pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product trade unallocated pharmaceutical pharmaceutical vaccine turnover consumer healthcare turnover segment turnover exclude divestment divestment complete turnover include divestment restate restate pharmaceutical vaccine turnover therapeutic area respiratory oncology emesis cardiovascular metabolic urology immunoinflammation pharmaceutical establish product vaccine viiv healthcare hiv gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue segment information continue restate restate consumer healthcare turnover category wellness oral care nutrition skin health pharmaceutical vaccine element viiv healthcare establish product sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product pharmaceutical trading unallocated cost pharmaceutical vaccine segment profit consumer healthcare segment profit segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring charge legal charge expense settlement litigation government investigation certain item relate major acquisition disposal activity depreciation amortisation segment restate restate pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product pharmaceutical trading unallocated cost pharmaceutical vaccine depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statement investor information segment information continue ppe intangible asset goodwill impairment segment restate restate pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product pharmaceutical trading unallocated cost pharmaceutical vaccine impairment consumer healthcare impairment segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment restate restate pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product pharmaceutical trading unallocated cost pharmaceutical vaccine impairment reversal consumer healthcare impairment reversal segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue segment information continue restate net asset segment pharmaceutical vaccines usa europe emerge market japan viiv healthcare establish product pharmaceutical trading unallocated asset pharmaceutical vaccine net operating asset consumer healthcare net operating asset segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset pharmaceutical vaccine segment net liability position december principally result accrual million additional year brand prescription drug fee trading unallocated pharmaceutical consumer healthcare segment include asset centrally manage pharmaceutical vaccine consumer healthcare manufacturing operation depreciation total million million million recover standard cost product charge business geographical information regard group country domicile turnover location customer usa rest world external turnover turnover location subsidiary usa rest world turnover include intersegment turnover usa rest world intersegment turnover usa rest world external turnover gsk annual report strategic report governance remuneration financial statement investor information segment information continue operate profit location usa rest world total operating profit net operating asset location usa rest world net operating asset noncurrent asset location usa rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables operating income impairment equity investment disposal equity investment disposal business asset gain settlement preexisting collaboration acquisition hgs gain acquisition shionogiviiv healthcare joint venture fair value remeasurement contingent consideration recognise business combination fair value adjustment derivative financial instrument incomeexpense disposal business asset include gain disposal treximet include gain disposal lucozade ribena business suntory million gain sale worldwide intellectual property right exclude certain emerge market anticoagulant product business aspen group million fair value remeasurement contingent consideration recognise business combination include million relate contingent consideration payable acquisition shionogiviiv healthcare joint venture fair value adjustment derivative financial instrument relate foreign exchange forward contract option take hedge foreign currency movement sale purchase denominate foreign currency note financial instrument relate disclosure include unrealised loss million arise loss position number forward exchange contract enter follow announcement propose novartis transaction protect sterling value net dollar proceed group completion transaction contract remain loss position maturity loss partly offset gain expect sterling value proceed receive group result favourable exchange movement inception forward contract maturity contract gain position gain partly offset loss sterling value proceed receive group result unfavourable exchange movement inception forward contract gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset goodwill net reversal net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidated financial statement audit company subsidiary auditrelate assurance service include attestation sarbanesoxley act audit auditrelated service taxation compliance taxation advice assurance service service addition fee pay respect gsk pension scheme audit service gsk annual report strategic report governance remuneration financial statement investor information employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance charge pension postemployment cost include credit million follow restructure postretirement medical obligation charge include credit million follow change policy relate discretionary pension increase certain pension scheme introduction limit future pensionable pay increase scheme set note pension postemployment benefit cost sharebase incentive plan analyse follow share value plan performance share plan share option plan plan average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue major restructuring cost major restructuring cost charge arrive operating profit include restructure cost arise operational excellence programme initiate expand major change programme initiate pharmaceutical restructuring programme announce october follow propose novartis transaction announce total restructuring cost million incur million incur operational excellence programme million major change programme million pharmaceutical restructure programme million preintegration planning propose novartis transaction follow area restructuring pharmaceutical business north america emerge markets europe lead staff reduction sale force administration project rationalise core business service simplify eliminate process lead staff reduction support function transformation manufacture vaccine business deliver step change quality cost productivity rationalisation consumer healthcare business remain cost million incur restructuring programme relate integration stiefel hgs human genome sciences inc business analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost asset impairment nil million million noncash charge total million million million noncash item principally accelerate depreciation asset life shorten result major restructuring programme charge settle cash include termination lease site closure cost consultancy project management fee finance income interest income arise cash cash equivalent availableforsale investment loan receivables realise gain liquid investment fair value adjustment derivative fair value profit loss derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ias gsk annual report strategic report governance remuneration financial statement investor information finance expense interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss unwind discount provision movement amount owe noncontrolle interest finance expense derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense associate joint venture december group hold significant associate aspen pharmacare holding limit aspen summarise income statement information respect aspen set turnover profit taxation comprehensive income total comprehensive income result aspen include summarise income statement information represent estimate earning aspen group year adjust transaction gsk aspen amount relate joint venture principally arise interest joint venture japan vaccine ltd daiichi sankyo ltd aggregate financial information respect associate undertaking joint venture set associate share turnover share tax lossesprofit share comprehensive income share total comprehensive income joint venture share turnover share tax loss share comprehensive income share total comprehensive income sale joint ventures associate gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation taxation charge base profit year current taxation overseas current taxation total current taxation total defer taxation recognition defer tax asset tax loss expect completion novartis transaction include net defer tax credit defer tax credit arose predominantly result non cash item relate continue restructure supply chain intellectual property ownership follow table reconcile tax charge calculate statutory rate group profit tax actual tax charge year information reanalyse present comparable basis reconciliation taxation group profit profit tax statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit intercompany inventory profit impact sharebase payment benefit previously unrecognised loss permanent difference disposal acquisition permanent difference reassessment prior year estimate disposal associate tax unremitte earning defer tax adjustment restructure tax charge tax rate group operate country tax rate differ tax rate taxable profit earn tax rate country vary year year million defer tax charge relate unwind deferred profit inventory arise reorganisation intellectual property ownership supply chain restructuring present difference overseas tax rate impact present restructure well reflect nature item group qualify intellectual property incentive patent box regime number country permanent difference associate disposal acquisition present separately include benefit low tax rate apply disposal lucozade ribena business recognition defer tax asset tax loss expect completion novartis transaction show benefit previously unrecognised loss permanent difference include non tax deductible legal settlement reassessment prior year estimate include benefit million resolution number tax matter country future tax charge affect factor acquisition disposal restructuring location research development activity tax regime reform agreement tax authority tax item charge equity statement comprehensive income current taxation sharebase payment defer taxation sharebase payment define benefit plan exchange movement fair value movement cash flow hedge fair value movement availableforsale investment total creditcharge equity statement comprehensive income item charge statement comprehensive income tax share base payment gsk annual report strategic report governance remuneration financial statement investor information taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue ongoing requirement gsk group continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate aggregate unremitte profit balance sheet date approximately billion billion legislation relate company distribution provide exemption tax repatriate profit subject certain exception provision defer tax liability million million respect withholding taxation arise distribution profit certain overseas subsidiary unprovide defer tax unremitted earning december estimate million million relate taxis payable repatriation levy overseas tax jurisdiction provision ground group able control timing reversal remain temporary difference probable reverse foreseeable future movement defer tax asset liability pension share accelerate post option net capital contingent intragroup employment tax award temporary allowance intangible consideration profit benefit loss scheme difference total january exchange adjustment chargecredit income statement chargecredit equity creditcharge statement comprehensive income december recognise tax loss comprise million nil capital loss million million trading loss net temporary difference include accrue expense tax deduction available pay basis offset defer tax asset liability appropriate territory net defer tax asset comprise defer tax asset defer tax liability unrecognise tax loss trading loss expire year year available indefinitely december capital loss december defer tax asset recognise probable future taxable profit available utilise loss gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable pence paidpayable pence paidpayable penny interim july july july second interim october october october interim january january january fourth interim april april april total ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december gsk annual report strategic report governance remuneration financial statement investor information property plant equipment continue plant land equipment asset building vehicle construction total depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer fromto asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment million million net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment million million net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk value use calculation impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million million million million sga million million include nil million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale carrying value december asset impairment charge reverse year million million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue goodwill cost january exchange adjustment addition business combination note transfer asset hold sale movement contingent consideration balance cost december net book value january net book value december gsk complete acquisition business result recognition million goodwill majority goodwill relate acquisition okairos goodwill allocate europe emerge market japan pharmaceutical vaccine cash generating unit impairment testing purpose benefit acquire business split cash generating unit transfer asset hold sale arise anticipate sale gsk oncology business propose threepart transaction novartis carry value goodwill translate yearend exchange rate allocate follow cash generate unit cash generating unit pharmaceuticals vaccines europe pharmaceutical vaccine emerge market pharmaceutical vaccine establish product pharmaceutical vaccine consumer healthcare amount allocate japan pharmaceutical vaccines pharmaceutical vaccine viiv healthcare significant relative total balance gsk annual report strategic report governance remuneration financial statement investor information goodwill continue recoverable amount cash generating unit assess fair value cost disposal model value use model value use calculate net present value project riskadjuste posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate apply calculate net present value posttax cash flow discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk fair value cost disposal calculate similar discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis high fair value cost disposal value use key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical vaccines europe pharmaceutical vaccines emerge market pharmaceutical vaccine japan pharmaceuticals vaccines viiv healthcare establish product pharmaceutical vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market terminal growth rate fair value cost disposal calculation cash generating unit reflect impact future generic competition account new product launch case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill pharmaceutical vaccine cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise development cost addition business combination capitalise borrowing cost addition disposal asset writeoff transfer tofrom asset hold sale cost december exchange adjustment capitalise development cost capitalise borrowing cost addition reclassification disposal asset writeoff transfer asset hold sale cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software include million million internally generate cost charge impairment year include impairment lovaza reflect reassessment group expectation likelihood potential generic competition galapagos nanjing meirui retigabine bms middle east carrying value december intangible asset impairment charge reversed year follow impairment reversal million million gsk annual report strategic report governance remuneration financial statement investor information intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow dolutegravir benlysta flulavalfluviral selzentry arzerra okairos technology platform lovaza duac toctino indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow panadol sensodyne stiefel trade breathe right physiogel polident biotene corega poligrip brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate country currency specific risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal transfer investment distribution receive movement lossprofit tax recognise consolidated income statement december investment joint venture principally arise interest joint venture japan vaccine ltd daiichi sankyo ltd joint venture hold development commercial right exist preventative vaccine parent company supply vaccine include human papillomavirus hpv vaccine rotavirus vaccine seasonal flu vaccine mumps vaccine diphtheria pertussis dtp vaccine measle rubella vaccine mrv japan group hold significant associate december aspen pharmacare holding limit december group own million share aspen aspen list johannesburg stock exchange africa large pharmaceutical manufacturer major supplier brand generic pharmaceutical healthcare nutritional product southern african select international market investment market value million million group hold ownership interest voting control aspen group ability exercise significant influence shareholding nominate director active participation aspen board director summarise balance sheet information respect aspen set noncurrent asset current asset current liability noncurrent liability net asset summarise balance sheet information respect aspen base preliminary result information analyst forecast available december adjustment transaction gsk aspen reconciliation summarise financial information carry aspen investment set january profit year comprehensive income exchange adjustment dividend pay movement december interest associate undertaking goodwill carry value december gsk annual report strategic report governance remuneration financial statement investor information investment january exchange adjustment addition net fair value movement impairment loss transfer investment associate joint venture disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million decrease arise disposal fair value adjustment company group hold equity investment theravance inc theravance separate certain activity new biopharmaceutical company theravance biopharma inc theravance biopharma theravance ongoing activity focus maximise potential value respiratory asset partner group include relvarbreo ellipta anoro ellipta theravance eligible receive royalty revenue relvarbreo ellipta anoro ellipta approve commercialise vilanterol monotherapy theravance biopharma carry preseparation activity theravance include development pipeline development asset partner gsk marketing approve medicine december group hold common stock theravance common stock theravance biopharma account equity investment group power exert significant influence activity company group theravance enter governance agreement relate group investment company term governance agreement group right appoint director theravance board group hold theravance exceed certain limited exception vote share support recommendation independent director board proportion shareholder vote cast governance agreement theravance expire september creation theravance biopharma group theravance biopharma enter governance agreement similar term agreement place theravance expire agreement group right appoint director theravance biopharma board certain limited exception vote share support recommendation independent director board proportion shareholder vote cast net fair value movement include decrease value investment theravance million theravance biopharma million disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement carry value december investment impaired follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables net provision bad doubtful debt prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million provision bad doubtful debt million provision million state hospital authority greece ireland italy portugal spain trade receivables include million million associate joint venture receivables include million million associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale plant equipment vehicle goodwill intangible inventory noncurrent asset transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell discuss note propose novartis transaction gsk announce divest market oncology portfolio relate activity right akt inhibitor novartis subject approval threepart interconditional transaction asset associate oncology business divestment classify hold sale include asset hold sale asset write fair value cost sell million nil valuation methodology use significant input base observable market datum valuation classify level fair value hierarchy gsk annual report strategic report governance remuneration financial statement investor information trade payable trade payable wage salary social security payable defer income customer return rebate accrual contingent consideration accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group december payable include million respect maximum potential payable noncontrolle shareholder glaxosmithkline pharmaceuticals ltd groups pharmaceutical subsidiary india estimate prior year settle march million note trade payable include million million associate joint venture pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme net reduction postretirement healthcare scheme cost arise restructure postretirement medical obligation reduction pension scheme cost relate oneoff adjustment arise cap future pensionable salary increase change basis future discretionary pension increase rpi cpi certain legacy plan detail cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male females usa mortality rate calculate white collar table adjust reflect recent experience rate project scale bbd allow future improvement life expectancy average life expectancy assume individual age project apply individual age follow usa male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy plan asset allocation plan adjust approximately return seek asset liability match asset target asset allocation plan update return seek asset liability match asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix return seek asset generate future return liability match asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liability define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group restructure postretirement medical obligation active retired member age prior plan participant pay medical expense excess cover medicare prescription drug new arrangement participant instead eligible receive age health reimbursement account base year service subject inflation link maximum year retire age give option switch new arrangement impact change credit income statement million similar reduction postretirement obligation group change policy grant discretionary pension increase smithkline beecham define benefit scheme year group introduce limit define benefit scheme year rate pensionable pay increase group apply follow financial assumption assess define benefit liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service costcredit net interest creditcost gain settlement expense remeasurement record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service costcredit net interest cost expense remeasurement record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service creditcost net interest cost remeasurement record statement comprehensive income past service credit million include million relation restructure postretirement medical obligation past service credit million reflect adjustment million relate cap future pensionable salary increase change basis future discretionary pension increase rpi cpi certain legacy plan detail amount include past service cost include million nil million augmentation cost arise major restructuring programme note provision gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow usa rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset october scheme enter repurchase agreement gain exposure indexlinke gilt relate loan include asset value million illion nil usa rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue usa rest world group december equities list property unlisted corporate bond list government bond list insurance contract asset fair value asset present value scheme obligation recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit usa rest world group group movement fair value asset asset january exchange adjustment interest income remeasurement employer contribution scheme participant contribution benefit pay settlement curtailment asset december exchange adjustment interest income expense remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million million nil nil million scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation base funding agreement follow valuation additional contribution expect million contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue postretirement pension benefit usa rest world group group movement define benefit obligation obligation january exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost movement remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment movement remeasurement scheme participant contribution benefit pay obligation december define benefit scheme include define contribution section obligation total million december million million define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade postretirement healthcare scheme amend detail impact change oneoff reduction postretirement obligation million december postretirement healthcare scheme obligation million million million postretirement benefit unfunded gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue movement net define benefit liability follow present fair value value net asset obligation total january exchange adjustment service cost past service cost interest incomecost settlement curtailment remeasurement return plan asset exclude amount include interest gain change demographic assumption loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay december exchange adjustment service cost past service cost interest incomecost remeasurement return plan asset exclude amount include interest loss change demographic assumption loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay expensesother movement december exchange adjustment service cost past service cost interest incomecost settlement curtailment remeasurement return plan asset exclude amount include interest loss change demographic assumption loss change financial assumption experience loss employer contribution scheme participant contribution benefit pay expensesother movement december remeasurement include postretirement benefit detailed gainloss change demographic assumption lossgain change financial assumption experience gain gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost revision ias decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statement investor information provision legal major employee integration restructuring relate manufacturing dispute programme provision reorganisation provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute major restructuring programme group involve substantial number legal october group announce operational dispute include notification possible claim set excellence programme improve effectiveness note legal proceeding provision legal productivity operation note major restructuring dispute include amount relate product liability principally cost substantially complete end relate avandia paxil antitrust principally relate addition group initiate major change wellbutrin lamictal government investigation principally restructure programme focus opportunity simplify relate china settlement secdoj sfo relate supply chain process build group capability investigation contract termination self insurance environmental manufacturing restructure european cleanup property rental pharmaceutical business charge year million million net new pharmaceutical restructuring programme announce reversal estimate insurance recovery include october rescale commercial operation global support million fine pay chinese government provision function relevant rdmanufacturing operation product liability case paxil product pharmaceutical commercial dispute government investigation provision staff severance payment discount provision decrease nil management formal decision eliminate certain nil calculate riskadjuste project position communicate group cash flow riskfree rate return movement employee affect appropriate consultation procedure include increase million nil arise complete appropriate change discount rate year provision staff severance payment respect product liability claim relate certain product immediately sufficient history claim settlement enable pension augmentation arise staff redundancie management reliable estimate provision require million nil charge year cover unasserted claim ultimate liability matter transfer pension obligation provision show vary amount provide dependent note pension postemployment benefit outcome litigation proceeding investigation possible asset writedown recognise impairment settlement negotiation property plant equipment note property plant nature group business number equipment majority amount provide expect matter subject negotiation litigation utilise year year litigation proceeding include employee relate provision appeal procedure year reach resolution employee relate provision include obligation certain outofcourt settlement discussion protract medical benefit disabled employee spouse group potential settlement discussion number usa december provision benefit dispute amount provide base amount million million employee current assessment progress dispute benefit reflect variety provision severance cost jubilee estimate billion provide december award longservice benefit settle year december provision expect nil million provision include provision insurance provision legal dispute reimburse party insurer million million onerous property lease provision include receivables balance million million number note noncurrent asset note trade provision include vehicle insurance regulatory matter receivables discussion legal issue note legal proceeding gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncurrent liability accrual defer income contingent consideration payable contingent consideration primarily relate acquisition share shionogiviiv healthcare joint venture previously hold shionogi ltd contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december nil nil financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft obligation finance lease medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange longterm borrowing medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange obligation finance lease net debt gsk annual report strategic report governance remuneration financial statement investor information net debt continue current asset weight average interest rate current bank loan liquid investment classify availableforsale investment overdraft december december include treasury note weight average interest rate commercial paper government bond effective interest rate liquid borrowing december investment december approximately longterm borrowing approximately liquid investment balance yearend gsk longterm borrowing billion december earn interest float rate billion billion billion million million liquid investment balance fall year average effective preswap december earn interest fix rate immaterial interest rate note issue december million approximately approximately effective interest rate cash cash equivalent longterm borrowing repayable year carry interest december approximately approximately effective rate repayment cash cash equivalent december earn date range interest float fix rate million million respectively million million pledge asset group pledge investment treasury note gsk policy credit quality cash cash par value million million million equivalent refer note financial instrument million security irrevocable letter credit relate disclosure issue group behalf respect group self shortterm borrowing insurance activity provision respect selfinsurance gsk billion billion commercial paper include provision legal dispute programme billion billion issue discuss note provision addition million december billion billion gsk million asset include note billion year commit mediumterm facility noncurrent asset form net debt billion billion day commit facility pledge collateral future rental payment facility place september september operating lease arrangement enter human genome respectively undrawn december sciences inc prior acquisition group liquid investments cash cash equivalent show table finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme share capital cancel december issue employee share scheme share capital cancel december issue employee share scheme december december december number share issuable employee share scheme note number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million monthly purchase share follow average share price exclude number share commission stamp duty february june total detail substantial shareholding refer gsk annual report strategic report governance remuneration financial statement investor information movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset december exchange movement overseas net asset december exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial gain define benefit plan defer tax actuarial movement define benefit plan comprehensive incomeexpense year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive expenseincome year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust forward contract noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust writedown share hold esop trust december transfer income expense year disposal net fair value movement year ordinary share acquire esop trust writedown share hold esop trust forward contract noncontrolle interest december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report strategic report governance remuneration financial statement investor information relate party transaction gsk hold interest aspen pharmacare holding limit december gsk distribute million million product aspen extensive distribution network december balance gsk aspen million million balance payable gsk aspen million million addition million gsk relate consideration sale worldwide intellectual property right anticoagulant product business aspen group million december gsk hold interest japan vaccine ltd jvc subsidiary glaxosmithkline joint venture daiichi sankyo ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million million vaccine product joint venture december balance gsk jvc million balance payable gsk jvc nil aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance income net finance expense depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increasedecrease inventory decrease trade receivables decreaseincrease receivables increase trade payable increase payable decrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue reconciliation net cash flow movement net debt net debt begin year decreaseincrease cash bank overdraft decrease liquid investment net increase longterm loan net repayment shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year january reclass december exchange ification cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper european medium term note debt year european medium term note net debt information significant change net debt note net debt gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition acquisition acquisition integration cost million arise propose threepart interconditional transaction novartis discuss note propose novartis transaction expense million pay cash number acquisition previous year include contingent consideration payable future follow contingent consideration payable january addition remeasurement goodwill remeasurement income statement settlement december contingent consideration include trade payable noncurrent liability include contingent consideration million million payable acquisition shionogiviiv healthcare joint venture remeasurement income statement include million million respect increase liability consideration expect pay number year vary line sale dolutegravir disposal year million receive deferred consideration sale anticoagulent business complete million disposal associate gsk cash investment million associate business associate acquisition joint disposal venture total cash flow cash consideration pay transaction cost pay purchase business associate net cash proceed disposal acquisition gsk complete acquisition business cash include okairos european base biopharmaceutical company focus development specific vaccine technology prophylactic therapeutic field acquire total purchase price business million include million cash acquire million contingent consideration fair value book value adjustment fair value net asset acquire intangible property plant equipment inventory trade receivables asset include cash cash equivalent defer tax provision trade payable goodwill cash consideration pay contingent consideration total consideration gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue acquisition beginning year estimate group turnover increase approximately million year okairo fully integrate gsk business practicable separately identify impact group profit year acquisition occur shortly end year material impact group profit year goodwill arise acquisition reflect potential business synergy value workforce acquire majority goodwill expect deductible income tax purpose result acquisition report europe emerge market japan trade unallocated pharmaceutical vaccine consumer healthcare operating segment transaction account acquisition accounting method acquisition cost expense total million disposal lucozade ribena december gsk complete sale lucozade ribena business include manufacturing site relate inventory suntory beverage food ltd million cash recognise profit disposal operate income million lucozade ribena sale exclude retain market total million year end december cash consideration net asset sell inventory property plant equipment goodwill disposal cost profit disposal anticoagulant business december gsk complete sale anticoagulant business comprise worldwide intellectual property right exclude china india pakistan fraxiparine arixtra relate inventory manufacture site aspen group consideration million million receive cash million defer profit disposal million recognise operating income worldwide sale fraxiparine arixtra exclude retain market million year end december cash consideration cash consideration receivable net asset sell inventory property plant equipment intangible asset goodwill disposal cost total profit disposal deferral profit profit recognise year gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue investment associate joint venture november gsk sell shareholding aspen represent issue share capital company million cash december gsk hold aspen continue recognise investment aspen associate cash consideration net book value share reclassification exchange comprehensive income reclassification fair value movement comprehensive income profit disposal business associate acquisition joint disposal venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire contingent consideration cash consideration pay net cash acquire total cash proceed receivable cash proceed defer net cash proceed disposal acquisition human genome sciences inc august gsk complete acquisition issue share capital human genome sciences inc hgs base biopharmaceutical company focus development protein antibody drug treatment immuno inflammation disease cash goodwill arise acquisition business reflect potential business synergy realisation value benlysta albiglutide darapladib asset simplify optimise commercial manufacturing operation complete ownership asset goodwill recognise expect deductible income tax purpose result acquire business report europe emerge market japan trading unallocated cost operate segment transaction account acquisition accounting method proforma turnover hgs business year million gsk record turnover million hgs product hgs product fully integrate gsk business practicable separately identify impact acquisition group profit year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue acquisition cost expense arise acquisition amount million fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax asset trade liability goodwill cash consideration pay gain settlement preexisting collaboration total consideration shionogiviiv healthcare joint venture october gsk acquire share shionogiviiv healthcare joint venture previously hold shionogi ltd asset acquire include investigational medicine dolutegravir early stage integrase inhibitor compound development total consideration comprise equity stake viiv healthcare gsk exist investment joint venture contingent consideration payable cash future defer tax asset loss settlement preexist relationship contingent consideration payable base percentage future sale performance compound develop joint venture market product total payable unlimited result acquire business report viiv healthcare transaction account acquisition accounting method acquisition cost expense arise acquisition amount million fair value book value adjustment fair value net asset acquire intangible asset defer tax provision negative goodwill consideration settle share viiv healthcare contingent consideration defer tax contingent consideration fair value investment joint venture convert subsidiary loss settlement preexist relationship total consideration gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue acquisition gsk complete small acquisition cash total cash consideration pay million include million cash acquire fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax provision trade liability goodwill cash consideration pay contingent consideration fair value equity investment convert subsidiary gain settlement preexisting relationship total consideration acquisition beginning year estimate group turnover increase million year acquisition fully integrate gsk business practicable separately identify impact acquisition group profit year goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition market participant goodwill recognise expect deductible income tax purpose result acquisition report europe pharma research development reportable operating segment group recognise settlement gain million result measure fair value relationship exist prior acquisition date gain recognise operating income income statement acquisition cost expense arise acquisition total million investment associate joint venture gsk cash contribution million shionogiviiv healthcare joint venture prior acquisition subsidiary cash investment million new joint venture group hold share gsk cash investment million associates human shionogi total associate genome viiv joint business joint science venture acquisition acquisition venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire contingent consideration cash consideration pay net cash acquire gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncontrolle interest group subgroup material noncontrolle interest viiv healthcare limited subsidiary viiv healthcare group focus research development worldwide commercialisation hiv medicine summarise financial information respect viiv healthcare group set turnover lossprofit taxation comprehensive incomeexpense total comprehensive expenseincome total comprehensive expenseincome year attributable noncontrolle interest dividend pay noncontrolle interest noncurrent asset current asset total asset current liability noncurrent liability total liability net asset noncontrolle interest attributable subgroup net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment loss taxation million profit taxation million state charge million million remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line sale product contain dolutegravir acquisition noncontrolle interest march gsk increase shareholding glaxosmithkline pharmaceutical limited pharmaceuticals subsidiary india represent increase share hold price inr share million carrying noncontrolle interest acquire million february gsk increase shareholding glaxosmithkline consumer healthcare ltd india million gsk annual report strategic report governance remuneration financial statement investor information commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement include arrangement adaptimmune ltd new arrangement offset reduced commitment prior year transaction include amendment agreement prosensa gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million future payment base deficit position scheme maximum million table include commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease disclose million million provide commitment group balance sheet commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inancial instrument relate gsk longterm credit rating moodys investor service moodys stable outlook standard poor rate gsk disclosure stable outlook group shortterm credit rating gsk report sterling pay dividend sterling profit standard poor moodys respectively role corporate treasury monitor manage liquidity risk external internal funding requirement financial risk gsk policy borrow centrally order meet anticipate support strategic objective gsk operate global funding requirement cash flow forecast funding basis primarily subsidiary company manage requirement monitor tmg monthly basis capital ensure subsidiary able operate go strategy diversify liquidity source range concern optimise return shareholder facility maintain broad access funding market appropriate balance debt equity treasury activity govern policy approve board director december gsk billion borrowing recently july repayable year hold billion cash cash equivalent liquid investment billion hold treasury management group tmg meeting chair centrally gsk access shortterm finance chief financial officer take place monthly basis review billion billion commercial paper programme treasury activity member receive management information billion billion issue programme relate activity internal audit review treasury december gsk billion year commit internal control environment regularly mediumterm facility billion billion day gsk use variety financial instrument finance committed facility facility place operation derivative financial instrument manage september september respectively market risk operation derivative principally undrawn december gsk consider level comprise forward foreign currency contract foreign exchange commit facility adequate give current liquidity option interest rate swap swap borrowing requirement liquid asset currency require group purpose gsk billion european medium term note programme manage exposure financial risk change foreign december billion note issue exchange rate interest rate programme group shelf registration gsk hold issue derivative speculative purpose statement december billion treasury policy specifically prohibit activity billion note issue programme gsk transaction financial instrument undertake manage longterm borrowing mature date risk arise underlie business activity day gsk sweep cash number global subsidiary speculation central treasury account liquidity management purposes capital management market risk gsk financial strategy support group strategic priority interest rate risk management regularly review board gsk manage capital gsk objective minimise effective net interest cost structure group appropriate mix debt balance mix debt fix float interest rate equity gsk financial architecture design ensure time policy interest rate risk management limit maximise return sale key priority float interest payment prescribe percentage sustainable sale growth operate leverage financial efficiency operating profit convert earning cash free cash flow generate return shareholder reinveste gsk interest rate swap redenominate fix business return look attractive rate bond mature float interest rate duration swap match duration principal gsk capital allocation decision rigorously benchmarke instrument interest rate derivative instrument cash flow return investment framework account fair value hedge relevant liability free cash flow conversion improve earning exclude foreign exchange risk management aftertax legal charge legal settlement foreign currency transaction exposure arise internal free cash flow low billion external trade flow generally hedge group compare billion reflect impact objective minimise exposure overseas operating strength sterle low profit include impact subsidiary transaction risk match local currency income divestment consequence billion pay local currency cost possible gsk internal trading increase shareholde group indian pharmaceutical transaction match centrally intercompany payment subsidiary acquisition term manage reduce foreign currency risk foreign remain gsk indonesian consumer healthcare currency cash flow hedge selectively business hold party gsk net debt increase management treasury tmg include hedge billion december billion foreign exchange risk arise acquisition december disposal asset capital structure group consist net debt billion note net debt shareholder equity billion consolidated statement change equity total capital include provide noncontrolle interest billion gsk annual report strategic report governance remuneration financial statement investor information inancial instrument relate gsk actively manage exposure credit risk reduce surplus disclosure continue cash balance possible treasury strategy regionalise cash management concentrate cash possible gsk manage cash surplus borrow centrally possible gsk continue maintain requirement subsidiary company centrally forward conservative approach counterparty risk period contract hedge future repayment originating table set credit exposure counterpartie currency order reduce foreign currency translation exposure rating liquid investment cash cash equivalent group seek denominate borrowing currency derivative gross asset position derivative contract principal asset cash flow primarily denominate consider purpose table isda dollar euro sterle certain borrowing agreement risk net position swap currency require borrowing counterparty table set group financial denominate swap foreign currency match asset liability offset basis investment group overseas asset treat hedge billion bank balance deposit invest relevant asset forward contract major currency rate counterpartie december significantly reduce exposure group investment lower equivalent december result overseas asset net investment hedge section note disposal proceed receive end december details tmg review ratio borrowing compare year significantly high bank asset major currency monthly balance deposit hold rate counterpartie credit risk result gsk increase bank balance deposit hold group consider maximum credit risk december deutsche bank result introduce country million december million european cash pool downgrade total group financial asset exception million cash hold baabbb rate counterpartie investment comprise equity investment bear include bank balance deposit hdfc bank state bank equity risk credit risk detail india halk bank emirate bank counterpartie group total financial asset december gsk local cash management purpose local great concentration credit risk billion investment purpose gsk sole shareholder billion hsbc aaaa million hold babb rate counterparty relate treasuryrelate credit risk islandsbanki cash management purpose gsk set global counterparty limit gsk banking iceland million cash hold babb rate investment counterpartie base longterm credit rating counterparty relate gsk bank balance deposit hold moodys standard poor corporate treasury usage banque marocaine commerce extrieur limit monitor daily corporate compliance officer cco operate independently corporate treasury breach limit report cfo immediately cco monitor credit rating counterpartie change rating occur notifie corporate treasury change investment level authority limit appropriate addition relationship bank credit rating review regularly report present annually tmg approval aaaa aaaa aabaabbb baabbb babb babb total unrated bank balance deposit treasury treasury repo money market fund government security party financial derivative total aaaa aaaa aabaabbb baabbb babb babb total unrated bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating table assign moodys standard poor respectively opinion rating agency differ gsk assign low rating counterparty local rating agency datum source available rating convert global rating equivalent moodys standard poor publish conversion table gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inancial instrument relate follow method assumption estimate disclosure continue fair value cash cash equivalent approximate carry gsk centrally manage cash reserve amount billion december available month exclude liquid investment base quote market price billion centrally manage cash hold viiv healthcare calculate base observable input case marketable own subsidiary group invest centrally security base principal amount case non manage liquid asset bank deposit aaaaaa rate marketable security short repricing periods treasury treasury repo money market fund bear investment equity investment trade active credit exposure government aaaaa rate market determine reference relevant stock exchange wholesale retail credit risk quote bid price equity investment determine outside usa customer account reference current market value similar instrument group trade receivable balance reference discount cash flow underlie net asset usa line pharmaceutical company group sell product small number wholesaler shortterm loan overdraft commercial paper addition hospital pharmacie physician group approximate carry short sale large wholesaler approximately maturity instrument turnover pharmaceutical vaccine longterm loan base quote market price case segment element viiv healthcare european medium term note fix rate establish product segment december group borrowing level fair value measurement approximate trade receivable wholesaler total carrying case float rate bank loan million million group expose loan concentration credit risk respect wholesaler encounter financial difficulty contingent consideration business acquisition materially adversely affect group financial result january base present value expect future cash flow group credit risk monitoring activity relate wholesaler include review quarterly financial information interest rate swap foreign exchange forward contract standard poor credit rating development gsk internal option base present value contractual cash flow risk rating establishment periodic review credit limit option valuation model market source datum exchange group believe credit risk rate interest rate balance sheet date provision require excess normal provision bad receivables payable approximate carry doubtful debt note trade receivables fair value financial asset liability companyowne life insurance policy base cash table present carry amount surrender value fair value group financial asset liability december december lease obligation approximate carry fair value financial asset liability include fair value investment gsk share price receive sell asset pay transfer december employee share ownership plan liability orderly transaction market participant esop trust held gsk share carry value measurement date million million fair value million million base quote market price share represent purchase esop trust satisfy future exercise option award employee incentive scheme treasury share fair value million transfer esop trust satisfy future award shareholder approve performance share plan note employee share scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue carry fair carry fair value value value value note cash cash equivalent availableforsale investment liquid investment government bond total liquid investment investment loan receivables trade receivables certain noncurrent asset scope ia financial asset fair value profit loss noncurrent asset scope ias derivative designate fair value profit loss ade derivative classify held trading ia ade total financial asset financial liability measure amortise cost borrowing exclude obligation finance lease bond designate hedge relationship bond bank loan overdraft commercial paper total borrowing exclude obligation finance lease obligation finance lease total borrowing trade payable provision certain noncurrent liability scope ias financial liability fair value profit loss trade payable provision certain noncurrent liability scope ia derivative designate fair value profit loss ade derivative classify held trading ia ade total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability reconcile relevant note gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company trade payable noncurrent liability classify level comprise contingent consideration business acquisition level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss trade payable noncurrent liability derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss trade payable noncurrent liability derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income contingent consideration liability business acquire year payment contingent consideration liability addition disposal transfer level exchange december net loss million million attributable level financial instrument hold end year report operate income million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture net gain nil million report sell general administration net gain attributable level equity investment report comprehensive income fair value movement availableforsale investment include million nil respect equity investment hold end year gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue net liability position million million respect financial instrument measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line sale product contain dolutegravir regulatory approval product obtain usa canada european union table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation liability increasedecrease financial liability lossgain income statement change key input increase sale forecast decrease sale forecast increase market interest rate decrease market interest rate trade receivables noncurrent asset scope ias follow table reconcile financial instrument trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ias fair value non fair value non loan financial financial loan financial financial profit loss receivables instrument instrument total profit loss receivables instrument instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day amount past great day provision bad doubtful debt total million million balance million million relate receivable state hospital authority greece ireland italy portugal spain total receivable state hospital authority country current past net provision million million trade payable provision noncurrent liability scope ias follow table reconcile financial instrument trade payable provision noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ia fair value non fair value non financial financial financial financial profit loss liability instrument instrument total profit loss liability instrument instrument total trade payable note provision note noncurrent liability note gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie fair value hedge interest rate swap principal nil million net investment hedge foreign exchange contract principal million million cash flow hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument analyse current noncurrent total foreign exchange contract classify held trading ia principal foreign exchange contract absolute total outstanding position balance sheet date group foreign exchange contract period month december group hold outstanding foreign exchange contract net liability fair value million million asset million liability december fair value million net liability million asset million liability follow announcement propose novartis transaction gsk enter number forward exchange contract protect sterling value net dollar proceed group completion transaction december contract loss position result liability million recognition unrealised loss year million contract remain loss position maturity loss partly offset gain expect sterling value proceed receive group result favourable exchange movement inception forward contract maturity contract gain position gain partly offset loss sterling value proceed receive group result unfavourable exchange movement inception forward contract rest increase liability additional hedge intercompany loan deposit external debt legal provision designate accounting hedge fair value movement take income statement period offset exchange gain loss relate intercompany lending borrow external debt legal provision fair value hedge group designate series interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance expense bond swap mature april carry value bond designate fair value hedge relationship million net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro japanese yen foreign operation show table carry value bond designate hedge relationship include million million designate hedge instrument net investment hedge relationship cash flow hedge group continue enter forward foreign exchange contract designate cash flow hedge foreign exchange exposure arise euro dollar denominate coupon payment relate group european medium term note continuation initial hedging place addition group carry balance reserve arose prehedge fluctuation longterm interest rate pricing bond issue year disclose note hedging transaction nature carry balance reclassify finance cost life bond gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue offset financial asset liability follow table set financial asset financial liability subject offset enforceable master netting arrangement similar agreement amount set financial asset liability group balance sheet set trade receivables trade payable derivative financial asset derivative financial liability amount offset balance sheet offset certain circumstance set gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross financial asset liability set balance sheet primarily relate cash pooling arrangement bank amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing group long hold interest rate swap designate fair value hedge convert fix rate debt float million fix rate debt maturity year hedge manner sensitivity analysis foreign exchange interest rate sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation december financial instrument affect market risk include cash cash equivalent borrowing trade receivables payable derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change foreign exchange interest rate foreign exchange sensitivity table show indicative basis group sensitivity foreign exchange rate dollar euro yen financial instrument currency major foreign currency gsk financial instrument denominate gsk consider movement currency conclude cent yen movement rate sterling reasonable analysis financial instrument consider sensitive foreign exchange rate functional currency entity hold obligation finance lease intercompany loan fully hedge maturity certain nonderivative financial instrument net debt exclude present material exposure foreign exchange sensitivity group asset liability financial instrument include calculation dollar denominate financial instrument movement income statement table relate primarily hedge foreign exchange risk acquisition disposal cash cash equivalent intercompany loan deposit intercompany trading balance hedge instrument legal provision trade receivables payable denominate functional currency entity hold impact spot rate change whilst hedging instrument provide economic hedge relate remeasurement legal provision include calculation increasedecrease increase income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow increasedecrease income million million nil million dollar euro yen exchange rate respectively decrease income million million million gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue movement equity table relate hedge instrument foreign exchange derivative external debt designate net investment hedge hedge group asset denominate euro yen cash flow hedge increasedecrease decrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow increasedecrease equity million million million dollar euro yen exchange rate respectively nil million million table present group sensitivity foreign exchange rate base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency follow impact net debt million million million dollar euro yen exchange rate respectively million million million interest rate sensitivity table show indicative basis group sensitivity interest rate float rate sterling dollar euro financial instrument issue debt bank borrowing cash cash equivalent liquid investment gsk consider movement interest rate year conclude basis point increase reasonable benchmark debt bank borrowing maturity year float rate calculation interest rate movement derivative financial instrument designate fair value hedge deem immaterial effect group income statement compensating amount carry value debt hedge hedge bond mature basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate interest rate decrease currently maximum increasedecrease income limit million million million sterling dollar euro interest rate respectively million nil million decrease interest income low level cash balance sheet date euro net investment hedging activity foreign exchange forward contract contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis impact interest rate swap exclude purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december contractual cash flow respect operating lease vacant space provision exclude table include commitment noncancellable operating lease table note commitment finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow increase contractual cash flow nonderivative financial liability billion year result principally increase billion forecast future cash flow respect contingent consideration payable acquisition shionogiviiv healthcare joint venture table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year increase compare december high level hedge intercompany loan hedge acquisition disposal denominate foreign currency external debt reflect increase principal amount show table contractual cash flow derivative instrument year receivables payable receivables payable gross contractual cash flow year employee share scheme group operate share option scheme option grant employee acquire share ad glaxosmithkline plc grant price savingsrelate share option scheme share award scheme addition gsk operate performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period grant restrict share award replace grant option employee cost scheme readily equate potential gain employee grant share option scheme normally exercisable year date grant grant restrict share share award normally exercisable end year vestingperformance period grant savingsrelate share option scheme normally exercisable year save grant share option scheme award performance share plan normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash option share option scheme grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant option pricing purpose value option arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life savingsrelate share option share award scheme year year year weight average share price grant year share plan dividend reinveste gsk annual report strategic report governance remuneration financial statement investor information employee share scheme continue volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option lapse december option grant option exercise option lapse december option grant option exercise option lapse december range exercise price option outstanding year end weight average market price exercise weight average remain contractual life year year year option outstanding share option share option savingsrelate december scheme share scheme ad share option scheme weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year option exercisable share option share option savingsrelate scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december december december gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant director member cet performance condition base equally weight measure year performance period measure base achievement adjust free cash flow target second measure base relative tsr performance comparator group remain measure base business specific performance measure business diversification new product performance detail calculation measure remuneration report page award grant onwards performance condition base equally weight measure year performance period adjust free cashflow tsr new product performance award eligible employee performance condition base gsk ep growth increase retail price index year measurement period adjust free cashflow addition business element award base strategic operational business measure year measurement period specific employee business area fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant share weight ad weight number share ad issuable number fair value number fair value january award grant dividend reinveste award exercise award cancel december award grant dividend reinveste award exercise award cancel december award grant dividend reinveste award exercise award cancel december share value plan group operate share value plan award grant form share certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december gsk annual report strategic report governance remuneration financial statement investor information employee share scheme continue employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution treasury share fair value million transfer esop trust satisfy future award shareholder approve performance share plan cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value propose novartis transaction april gsk announce threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business propose transaction gsk novartis create new consumer healthcare business gsk majority control equity interest addition gsk acquire novartis global vaccine business exclude influenza vaccine initial cash consideration billion subsequent potential milestone payment billion ongoing royalty gsk divest market oncology portfolio relate activity right akt inhibitor grant commercialisation partner right future oncology product novartis aggregate cash consideration billion term transaction billion purchase price return novartis certain condition relate combid trial meet follow positive outcome study announce february gsk believe condition satisfied transaction expect complete week commence march gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue principal group company follow represent principal subsidiary associate glaxosmithkline group december detail give principal country operation location headquarters business sector business activity equity share capital entity wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline mercury limit brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc phch brentford smithkline beecham limited phch brentford wellcome limited phch brentford glaxo group limit brentford glaxo operation limit brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline limit brentford setfirst limited phch brentford glaxosmithkline trading service limit brentford viiv healthcare limit brentford viiv healthcare limit austria vienna glaxosmithkline pharma gmbh belgium wavre glaxosmithkline pharmaceuticals rixensart glaxosmithkline biological czech republic prague glaxosmithkline sro phch finland espoo glaxosmithkline france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxosmithkline sante grand public sas marly roi viiv healthcare sas amand les eaux glaxosmithkline biological sas germany buehl glaxosmithkline consumer healthcare gmbh munich glaxosmithkline gmbh greece athens glaxosmithkline aebe phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa netherlands zeist glaxosmithkline zeist glaxosmithkline far east phch poland poznan gsk services spz republic carrigaline smithkline beecham cork limit ireland dublin glaxosmithkline consumer healthcare ireland limited dublin glaxosmithkline ireland limit dungarvan stafford miller ireland limited dungarvan glaxosmithkline dungarvan limited sligo stiefel laboratory ireland limit romania brasov europharm hold phch russian moscow glaxosmithkline trading zao federation spain madrid glaxosmithkline switzerland muenchenbuchsee glaxosmithkline usa usa research triangle park stiefel laboratory inc marietta corixa corporation philadelphia glaxosmithkline llc phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline holdings americas inc phch wilmington glaxosmithkline capital inc phch research triangle park viiv healthcare company rockville human genome sciences inc gsk annual report strategic report governance remuneration financial statement investor information principal group company continue america location subsidiary sector activity canada mississauga glaxosmithkline inc mississauga glaxosmithkline consumer healthcare inc laval biomedical corporation quebec mexico mexico city glaxosmithkline mexico phch asia pacific australia boronia glaxosmithkline australia pty ltd phch china beijing glaxosmithkline china investment ltd phch hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceutical limit gurgaon glaxosmithkline consumer healthcare limited malaysia selangor glaxosmithkline consumer healthcare sdn bhd pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch brazil rio janeiro glaxosmithkline brasil limitada phch colombia bogota glaxosmithkline colombia phch venezuela caracas glaxosmithkline venezuela phch middle east africa nigeria lagos glaxosmithkline consumer nigeria plc phch saudi arabia jeddah glaxo saudi arabia limit south africa johannesburg glaxosmithkline south africa pty limited phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa location associate sector activity south africa johannesburg aspen pharmacare holding limited iii phch xempt provision section company amendment act ireland addition subsidiary company schedule table stiefel distributor ireland limited smithkline beecham manufacturing limited glaxosmithkline consumer healthcare investment ireland limited glaxosmithkline consumer healthcare investment ireland glaxosmithkline investments ireland limited glaxosmithkline consumer healthcare ireland limited exempt provision consolidate group financial statement onsolidate subsidiary accordance section company act ground dominant influence iii quity account ground significant influence ncorporated ireland directly hold wholly own subsidiary glaxosmithkline plc key business sector pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production research service subsidiary associate list principally affect figure group financial statement detail group subsidiary associate attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding december anchen notify group file anda jalyn paragraph certification allege group involve significant legal administrative patent invalid unenforceable infringe jalyn proceeding principally product liability intellectual property combination dutasteride tamsulosin cover tax antitrust governmental investigation relate patent cover avodart subsequently group private litigation group make provision proceeding receive similar notice impax laboratories inc impax regular basis summarise note accounting principle watson challenge patent cover jalyn policy note provision group involved significant legal proceeding respect group file suit anchen banner impax mylan possible reliable estimate expect roxane watson united states district court financial effect result ultimate resolution district delaware infringement avodart jalyn proceeding case appropriate disclosure patent applicable case consolidate trial case include provision august group file separate suit apotex court infringement patent case respect legal proceeding describe consolidated original case provision group generic defendant court order unable reliable estimate expect financial apotex case stay pende entry judgment effect stage group believe information banner case apotex subsequently agree bind seek plaintiff know outcome consolidated case january meaningful respect legal proceeding group anchen settle litigation term number factor include limited stage allow anchen enter market jalyn fourth quarter proceeding entitlement party appeal decision early certain circumstance group previously clarity theory liability damage govern law settle early patent challenge avodart teva intellectual property claim include challenge validity pharmaceutical teva term allow teva launch enforceability group patent product generic dutasteride product fourth quarter early process assertion noninfringement certain circumstance tevas generic dutasteride product patent loss case result loss patent approve fda december protection product issue consequence loss significant decrease sale product trial consolidated case generic defendant materially affect future result operation group hold january august district court uphold validity patent banner impax mylan legal expense incur provision relate legal claim roxane watson appeal decision favour group charge sell general administration cost provision united states court appeal federal circuit take appropriate legal specialist august february federal circuit advice outflow resource consider probable enter decision favour group affirm decision reliable estimate likely outcome district court concluding matter dispute certain product liability claim group benlysta provision sufficient history claim settlement enable management reliable estimate human genome sciences inc hgs group company hold provision require cover unasserted claim december european patent cover country include group aggregate provision legal dispute cover antibodie bind bly define functional term include tax matter describe note taxation eli lilly company eli lilly previously challenge billion ultimate liability legal claim vary validity patent patent uphold amount provide dependent outcome litigation european patent office court validity proceeding investigation possible settlement negotiation challenge conclude group position change time eli lilly request declaration supplementary assurance loss result protection certificate spc file hgs extend term outcome legal proceeding exceed material patent year base eli lillys future marketing provision report group authorisation antiblys antibody invalid financial statement happen material high court deny lillys motion july october adverse impact result operation group eli lilly announce cease development reporting period judgment incur antibly antibody hgs apply appeal dismiss settlement enter significant matter november eli lilly consent appeal describe court decision end litigation intellectual property epzicomtrizivirkivexa avodartjalyn november group affiliate viiv healthcare november banner pharmacaps inc banner notify receive notice teva pharmaceuticals usa inc teva group file abbreviate new drug application file anda paragraph certification epzicom anda market generic version avodart dutasteride combination lamivudine abacavir certification usa banners notification contain paragraph certification challenge patent cover hemisulfate salt abacavir allege patent expire patent expiring expire viiv healthcare sue teva patent cover compound dutasteride patent june viiv healthcare receive notice teva invalid infringe banner propose generic dutasteride amend anda epzicom contain paragraph product group subsequently receive similar notice certification additional patent list orange book anchen pharmaceuticals anchen apotex apotex roxane allege patent invalid unenforceable infringe laboratory roxane watson laboratories inc watson patent challenge new certification relate method mylan pharmaceuticals inc mylan variously treat hiv combination expire certain challenge patent patent crystal form lamivudine expire august viiv healthcare file suit teva combination patent united states district court district delaware gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue challenging validity underlie patent teva challenge spc basis invalid viiv healthcare receive notice lupin ltd failure comply requirement article lupin file anda contain paragraph certification regulation spc regulation tevas trizivir triple combination lamivudine abacavir article contention case pende germany zidovudine allege patent list orange oral hearing set france oral book trizivir invalid unenforceable infringe hearing set december final hearing patent relate method treat hiv triple date set italy combination expire hemisulfate salt abacavir expire certain crystal form lamivudine november viiv healthcare commence action expire june viiv healthcare file suit teva declaration tevas article lupin patent cover triple combination contention concern kivexa spc incorrect interim united states district court district delaware hearing schedule march determine district court consolidated case relate epzicom question spc regulation refer case relate trizivir court justice european union december united states district court lexiva district delaware uphold validity patent april ranbaxy laboratory limit ranbaxy expiry date march cover combination notify viiv healthcare file paragraph certification lamivudine abacavir epzicom triple combination allege patent claim polymorphic form fosamprenavir lamivudine abacavir zidovudine trizivir separate calcium active ingredient lexiva invalid infringe component decision judge rule lupin generic patent expire viiv healthcare sue version trizivir infringe patent lupin subsequently patent launch generic version trizivir teva early stipulate july mylan pharmaceuticals inc mylan notify generic version epzicom infringe patent viiv healthcare file anda lexiva district court enjoin teva launch generic version paragraph certification assert patent claim epzicom expiration patent party appeal active ingredient expire polymorphic form judgment february united states court active ingredient expire invalid unenforceable appeal federal circuit affirm decision infringe mylan second generic company file district court anda lexiva generic company challenge february viiv healthcare receive notice lupin basic compound patent active ingredient august file anda contain paragraph certification viiv healthcare licensor vertex pharmaceutical epzicom allege patent list orange incorporate file patent infringement suit mylan book epzicom invalid unenforceable infringe patent claim active ingredient patent claim viiv healthcare file suit lupin march allege polymorph united states district court district infringement patent cover combination delaware party settle case lamivudine abacavir patent cover hemisulfate term confidential salt abacavir trial date set april october ranbaxy file petition inter parte june apotex file petition request inter parte review ipr allege patent claim active ingredient review ipr combination patent cover epzicom lexiva invalid march uspto grant trizivir united states patent trademark office uspto ranbaxys petition ipr settle october term grant petition december initiate ipr confidential patent uspto january teva file december lupin limited file petition petition uspto join proceeding uspto ipr allege compound patent cover teva canada apotex challenge patent active ingredient lexiva invalid uspto kivexa lamivudineabacavir list canadian patent rule petition ipr grant register viiv healthcare file suit infringement product liability party patent cover combination lamivudine preclinical clinical trial conduct abacavir patent cover hemisulfate salt abacavir development potential product determine safety rule hemisulfate salt patent improperly list efficacy product use human follow approval result delist patent canadian patent regulatory body notwithstanding effort drug register viiv healthcare appeal rule notwithstanding vaccine introduce marketplace unanticipated rule infringement case teva canada safety issue claim evident apotex relate validity combination hemisulfate group currently defendant number product liability salt patent proceed hear infringement case lawsuit relate group pharmaceutical vaccine teva canada schedule april consumer healthcare product significant hearing infringement case apotex matter describe schedule december group able reliable estimate addition teva challenge claim combination expect financial effect matter discuss category patent cover kivexa germany france italy include provision appropriate matter relate litigation ongoing united kingdom combination provision legal dispute matter patent litigation involve viiv healthcare teva commence group provision note note germany december france june provisions italy september combination patent expire europe addition viiv healthcare correspond supplementary protection certificate spc kivexa trizivir expire late gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue june group inform legal aid agency laa legal service commission avandia consider discharge public funding certificate group name product liability lawsuit behalf follow recommendation special case review panel individual assert personal injury claim arise use case poor prospect success january avandia federal case file group laa discharge public certificate effectively multidistrict litigation proceed pende united states end group action district court eastern district pennsylvania mdl court case file number state court poligrip begin number product liability lawsuit claim february group reach agreement file group state federal court settle substantial majority federal state case pende usa include purport class action allege zinc purport class action avandia pende super poligrip cause copper depletion permanent neurologic canada group reach agreement principle injury federal case consolidate denture cream resolve single purport consumer class action israel adhesive multidistrict litigation mdl united states district approve court litigation court southern district florida establish group end follow formal discontinuance june original putative class action mdl claim majority claimant court order strike dismiss putative class action file puerto claim remain claimant rico remove federal court transfer purport class action seek economic damage mdl remain pende february behalf party payer assert claim arise current exception state court case state federal law include racketeer influence pennsylvania state court case small claim court corrupt organization act rico state unfair trade practice tennessee state court case consolidate andor consumer protection law mdl court deny philadelphia state court mass tort program mtp february group motion dismiss party payer action case currently pende gsk fourth action stay group appeal philadelphia mtp vast majority individual case decision united states court appeal dismiss seven active individual case putative circuit consumer class action bring behalf missouri class action mdl state court case pende resident remain pende mdl court humana medical group usa group humana bring separate subrogation action purport class action mdl court mdl canada individual lawsuit purport class action court deny class certification united health group inc assert consumer fraud claim file bring separate subrogation action group individual lawsuit putative class action dismiss addition file unfiled claim paxilseroxat paxil turkey group voluntarily withdraw group receive numerous lawsuit claim allege zinccontaine formulation super poligrip market use paxil paroxetine cause variety injury early lawsuit recent year allege use paxil pregnancy result birth child birth sale marketing regulation defect health issue lawsuit claim allege group able reliable estimate expect patient take paxil commit attempt commit financial effect matter discuss category suicide act violence patient suffer symptom include provision matter provision legal discontinuing treatment paxil dispute note matter group provision note note provision pregnancy china investigation group reach agreement settle substantial majority claim relate use paxil september group announce changsha pregnancy february number claim relate intermediate people court hunan province china rule use pregnancy pende court accord chinese law gsk china investment ltd matter dismiss payment currently gskci offer money property nongovernment trial schedule personnel order obtain improper commercial gain find guilty bribing nongovernment personnel propose certify class action verdict follow investigation initiate chinas ministry canada action certify national class public security june result court verdict action british columbia relate cardiovascular defect gskci pay fine rmb billion million appeal certification decision dismiss chinese government october case schedule try october secdoj sfo anticorruption enquirie securities exchange commission sec act violence department justice doj initiate industrywide enquiry february pende matter include pharmaceutical company engage lawsuit appeal pende united states court violation foreign corrupt practice act fcpa appeals ninth circuit concern allegation patient relate sale pharmaceutical include argentina take paxil commit attempt commit suicide act brazil canada china germany italy poland russia saudi violence currently trial schedule arabia group company ask discontinuation respond enquiry cooperate sec doj late public funding withdraw group inform doj sec investigation claimant receive funding pursue litigation allege china operation chinese government paxilseroxat cause suffer withdrawal initiate outcome investigation reaction dependency majority claimant discontinue claim gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue august group removed case united states district court eastern district pennsylvania group advise fraud office sfo move dismiss complaint oral argument motion investigation china operation chinese dismiss hold february case government outcome investigation sfo stay pende decision united states court appeal request information group commercial circuit overlap potentially dispositive operation number country issue group thirdparty payer litigation avandia sfo informed group formally open criminal group provision matter investigation group practice group respond sfos request group unable reliable manufacturing issue group plant cidra estimate expect financial effect investigation subject federal state claim group resolve provision federal government group compliance obligation corporate integrity agreement state sale marketing investigation government group conclude agreement united paxilseroxat state government multiple states district columbia conclude group significant ongoing united states group settle lawsuit file new york state federal government investigation group notify attorney general office allege group fail disclose consortium state attorney general datum use paxil child adolescent investigate conduct underlie group federal group class settlement lawsuit bring state settlement relate product avandia consumer thirdparty payer respectively economic determine group violate state unfair deceptive trade damage allegedly result prescription paxil child practice statute group resolve allegation adolescent group deny liability settlement state district columbia civil settlement plaintiff voluntarily dismiss similar purport class agreement state attorney general action pende action file behalf governmental entity pay related matter prescription paxil minor avandia remain similar purport class action canada group defend action county santa clara seek economic damage behalf individual california bring californias consumer purchase paxil use patient age protection law seek civil penalty restitution result certification application purport class action group marketing avandia pretrial activity adjourn permit filing evidence continue case proceed trial mdl court likely resume send case california federal court bench trial antitrustcompetition seven lawsuit file behalf native american tribe group able reliable estimate relate sale marketing avandia group expect financial effect matter discuss category product group resolve claim include provision matter provision group december legal dispute note matter group provision note note average wholesale price provision number state respective attorney general county new york state file civil lawsuit sector enquiry state federal court group european commission launch enquiry pharmaceutical company claim damage restitution investigate possible anticompetitive condition average wholesale price awp andor wholesale acquisition pharmaceutical sector final report pharmaceutical cost wac price report pharmaceutical product cover sector inquiry publish july announce state medicaid programme case allege final report commission decide continue monitoring group report caused report false awp wac patent settlement agreement originator generic price turn allegedly cause state medicaid agency company relate market result group reimburse provider money cover medicine provide input report publish agency intend state seek recovery behalf provision matter state payer case behalf instate competition market authority investigation patient consumer group resolve awp claim august office fair trading know state medicaid programme state competition market authority cma launch formal group settlement agreement federal government investigation group pharmaceutical company announce september multiple additional potential infringement competition act investigation settlement litigation concern awp issue focus litigation settlement group continue state illinois wisconsin trial potential supplier generic paroxetine formulation enter involve group schedule object effect cidra thirdparty payer litigation prevention restriction distortion competition july number major healthcare insurers group infringe dominant position make file suit group philadelphia pennsylvania payment potential supplier generic paroxetine aim county court common plea seek compensation restrict development generic competition reimbursement medicine manufacture group terminate agreement issue cma group cidra plant puerto rico insurer claim investigation cover issue investigate group knowingly illegally market sell european commission respect paroxetine adulterate drug manufacture condition noncompliant european union european cgmp thirdparty insurer unlawfully commission pharmaceutical sector enquiry induce pay suit allege federal state law cause action gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue complaint allege stiefel officer director violate employee retirement income security act erisa march commission announce formally federal state security law induce stiefel employee conclude enquiry action march sell share employee stock plan stiefel cma decide focus investigation potential anticompetitive greatly undervalue price disclose employee aspect paroxetine settlement agreement drop stiefel sell group july investigation relation potential abuse dominance district court deny plaintiff motion class certification february cma decide reopen dominance aspect matter october district court grant defendant motion summary judgment dismiss group cooperate cma investigation remain plaintiff litigation trial claim outset april cma issue statement plaintiff timothy finnerty take place resulted objection set decision cma million jury verdict favour finnerty security propose allow affected party claim separately group settle finnertys erisa claim representation propose decision cma group appeal verdict court appeal state propose fine group detail eleventh circuit affirm verdict june petition provide fine calculate august certiorari file supreme court group submit response rebut additionally stiefel complete defence verdict fry cmas argument october cma issue case try federal court florida october plaintiff secondary statement objection amending theory appeal verdict eleventh circuit decision harm group respond december state court pende stiefel case pende florida play meeting january cma informed dismiss bacon case settle group group final decision january mackay summary judgment continue investigation cma website indicates grant favour group ruling later uphold final decision late spring cma circuit remain case florida martinolich decide fine group cma decision appeal schedule trial august discovery continue competition appeal tribunal georgia new york suit lawsuit involve claim lamictal similar bring finnerty purport direct indirect purchaser class action file addition private litigant suit december united states district court district new jersey securities exchange commission sec file formal alleging group teva pharmaceuticals unlawfully complaint stiefel charles stiefel united states conspire delay generic competition lamictal result district court district florida allege stiefel overcharge separate count accuse group principal violate federal security law induce stiefel monopolising market district court deny motion employee sell share employee stock plan purport direct purchaser class reconsideration company greatly undervalue price disclose order grant group motion dismiss december employee company sell matter plaintiff appeal decision united states stay pende final rule finnerty appeal court appeal circuit oral argument hear group provision stiefel litigation november await decision circuit environmental matter action purport indirect purchase class suspend pende decision direct purchaser appeal group notify potential responsibility relate past operation past waste disposal practice certain wellbutrin site primarily usa matter subject action file biovail corporation biovail litigation include proceeding initiate federal group united states district court eastern state government waste disposal site remediation cost district pennsylvania purport class direct indirect tort action bring private party purchaser allege unlawful monopolisation anti trust violation relate enforcement biovail patent group advise responsible party wellbutrin file biovail citizen petition approximately site appear national direct indirect purchaser class certify priority list create comprehensive environmental motion decertify indirect purchaser class remain pende response compensation liability act superfund district court grant group motion partial summary proceeding seek require operator hazardous waste judgment primarily immunity ground facility transporter waste site generator hazardous waste dispose site clean site sole remain claim relate plaintiff allegation reimburse government cleanup cost group enter anticompetitive reverse payment settlement instance group involve allege generator resolve patent infringement litigation dispositive motion hazardous waste connection remain issue case march superfund provide defendant jointly severally liable clean cost proceeding commercial corporate frequently resolve basis nature quantity waste group able reliable estimate dispose generator site group proportionate expect financial effect matter discuss liability cleanup cost substantially determined category include provision respect matter site refer provision legal dispute set note provision group potential liability vary greatly site site cost investigation study remediation site securitieserisa class action stiefel time significant group routinely accrue amount july class action suit bring behalf current relate share liability matter employee stiefel laboratories inc stiefel group company file united states district court southern district florida gsk annual report strategic report governance remuneration financial statement investor information financial statement glaxosmithkline plc prepare gaap director statement responsibility disclosure information auditor relation company financial director office date annual report confirm statement far aware relevant audit information director responsible prepare parent company company auditor unaware glaxosmithkline plc financial statement remuneration take step ought report accordance applicable law regulation take director aware company law require director prepare financial relevant audit information establish companys statement financial year law director auditor aware information elect prepare parent company financial statement confirmation give interpret accordance accordance united kingdom accounting standard provision section company act applicable law united kingdom generally accept accounting practice company law director approve go concern basis parent company financial statement satisfied making enquiry director reasonable true fair view state affair company expectation company adequate resource continue period operational existence foreseeable future reason continue adopt go concern basis prepare prepare financial statement director require financial statement corporate governance code select suitable accounting policy apply board consider glaxosmithkline plc apply consistently principle provision corporate governance judgement accounting estimate reasonable code maintain financial reporting council describe prudent corporate governance section page comply provision board consider state regard parent company financial statement annual report take fair balanced applicable accounting standard follow understandable provide information necessary subject material departure disclose explain shareholder assess group performance business parent company financial statement model strategy prepare financial statement go concern basis require financial conduct authority list rule inappropriate presume group continue auditor consider director statement business compliance relation point corporate director responsible keep adequate accounting governance code specify review record sufficient explain companys transaction disclose reasonable accuracy time financial position company enable ensure parent company financial statement remuneration report comply company act responsible sir christopher gent safeguard asset company take chairman reasonable step prevention detection fraud february irregularitie parent company financial statement year end december comprise balance sheet year end december support note set page report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end december include annual report publish print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different strategic report risk section annual report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement investor information independent auditor report members glaxosmithkline plc report parent company financial responsibility financial statement statement audit opinion responsibility director opinion parent company financial statement define explain fully director statement responsibility set director responsible true fair view state parent company preparation financial statement affair december satisfied true fair view properly prepare accordance united responsibility audit express opinion kingdom generally accept accounting practice financial statement accordance applicable law isa prepare accordance requirement ireland standard require comply company act auditing practice board ethical standard auditor audit report include opinion prepare glaxosmithkline plcs financial statement comprise company member body accordance chapter company balance sheet december company act purpose give opinion accept assume note company balance sheet include responsibility purpose person summary significant accounting policy explanatory report show hand come save information expressly agree prior consent write financial reporting framework apply preparation financial statement applicable law audit financial statement involve united kingdom accounting standard united kingdom conduct audit accordance isas ireland generally accept accounting practice audit involve obtain evidence amount disclosure financial statement sufficient reasonable require reporting assurance financial statement free material consistency information misstatement cause fraud error include company act opinion assessment opinion information give strategic report accounting policy appropriate parent director report financial year company circumstance consistently apply financial statement prepare consistent adequately disclose financial statement reasonableness significant accounting estimate isa ireland report director international standard audit ireland isas ireland require report overall presentation financial statement opinion information annual report primarily focus work area assess materially inconsistent information audit director judgement available evidence form financial statement judgement evaluate disclosure financial apparently materially incorrect base materially statement inconsistent knowledge company acquire test examine information sampling course perform audit audit technique extent consider necessary misleading provide reasonable basis draw conclusion obtain exception report arise responsibility audit evidence testing effectiveness control substantive procedure combination adequacy accounting record information explanation receive addition read financial nonfinancial information company act require report annual report identify material inconsistency opinion audit financial statement identify information apparently materially incorrect base materially inconsistent receive information explanation knowledge acquire course perform require audit audit aware apparent material misstatement adequate accounting record keep parent inconsistency consider implication report company return adequate audit receive branch visit matter financial statement director report separately group financial statement remuneration report audit agreement glaxosmithkline plc year end december accounting record return company pass resolution accordance section exception report arise responsibility company act senior statutory auditor director remuneration state director remuneration report company act opinion opinion director remuneration report pricewaterhousecooper llp audit properly prepare accordance charter accountant statutory auditor companies act london february company act report company act require report opinion certain disclosure director remuneration specify law exception report arise responsibility gsk annual report strategic report governance remuneration financial statement investor information company balance sheet gaap december note fix asset investment debtor cash bank current asset creditor amount year net current asset total asset current liability provision liability net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund financial statement page approve board february sign behalf sir christopher gent chairman glaxosmithkline plc register number gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet expenditure gaap expenditure recognise respect good service receive supply accordance contractual term presentation financial statement provision obligation exist future liability description business respect past event obligation glaxosmithkline plc parent company gsk major global reliably estimate healthcare group engage creation discovery investment subsidiary company development manufacture marketing pharmaceutical investment subsidiary company hold cost product include vaccine overthecounter otc medicine provision impairment healthrelate consumer product impairment investment preparation financial statement carry value investment review impairment financial statement prepare go concern indication investment impair basis draw accordance generally accept provision result impairment review charge accounting practice gaap accounting income statement year concern presentation december comparative figure december appropriate comparative figure share base payment reclassify ensure consistent presentation current issuance company subsidiary grant year information company share represent additional capital contribution company subsidiarie additional investment permit section company act subsidiary result correspond increase shareholder profit loss account company present equity additional capital contribution base fair value annual report grant issue allocate underlying grant vest company include group financial statement period glaxosmithkline plc publicly available advantage taxation take exemption provide frs cash flow current tax provide amount expect pay statement revise prepare cash flow apply tax rate enact substantively statement exemption provide frs relate enact balance sheet date party disclosure disclose related party transaction group company account taxation defer accelerate reason timing difference originate accounting convention standard reverse balance sheet date defer tax asset balance sheet prepare historical recognise extent consider cost convention complie applicable accounting recoverable future taxable profit standard defer tax measure average tax rate expect accounting principle policy apply period time difference expect preparation balance sheet conformity generally reverse defer tax liability asset discount accept accounting principle require management estimate assumption affect report amount financial guarantee asset liability disclosure contingent asset liability relate guarantee issue company behalf liability date balance sheet actual amount subsidiary initially recognise fair value differ estimate amortise life guarantee balance sheet prepare accordance legal dispute company accounting policy approve board company provide anticipate settlement cost describe note outflow resource consider probable reliable estimate likely outcome dispute accounting policy legal expense arise claim company foreign currency transaction foreign currency transaction record exchange rate operating profit ruling date transaction forward rate hedge fee relate audit forward exchange contract foreign currency asset company charge operating profit liability translate rate exchange rule balance dividend sheet date forward rate director declare interim dividend result dividend pay receive dividend year pence pence increase dividend pay receive include financial dividend detail note group statement period relate dividend financial statement dividend actually pay receive gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap continue fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment debtor amount year corporation tax recoverable receivables defer tax recoverable amount owe group undertaking amount year amount owe group undertaking defer tax asset arise result recognition defer tax tax loss expect completion novartis transaction creditor amount year bank overdraft creditor amount owe group undertaking company guarantee debt issue subsidiary company receive annual fee subsidiary aggregate company outstanding guarantee billion debt instrument amount subsidiary company relation guarantee fee recover life bond disclose debtor note provision liability january charge year utilise movement december provision liability relate number legal dispute company currently involve gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap continue call share capital share premium account share premium ordinary share account number share capital authorise december december share capital issue fully pay january issue employee share scheme share capital cancel december issue employee share scheme december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million reserve profit reserve loss account total january profit attributable shareholder dividend shareholder share purchase cancel hold treasury share capital contribution relate share base payment december profit attributable shareholder dividend shareholder share purchase hold treasury share treasury share transfer esot hold subsidiary company december profit glaxosmithkline plc year million million loss dividend million million give retain profit million million loss cost share purchase hold treasury share million million effect million treasury share transfer subsidiary company nil profit loss account reserve december stand million million million unrealise million adoption financial reporting standard frs reduce disclosure framework follow publication frs application financial reporting requirement glaxosmithkline plc require change accounting framework entity financial statement currently gaap financial year commencing january consider good interest group glaxosmithkline plc adopt frs disclosure current financial statement omitted adoption frs gsk annual report strategic report governance remuneration financial statement investor information investor information section quarterly trend year record product development pipeline product competition intellectual property risk factor share capital share price dividend tax information shareholder annual general meeting law regulation shareholder service contact glossary term index ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statement investor information financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation core result describe gsk annual report strategic report governance remuneration financial statement investor information quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating income operating profit net finance cost profit disposal interest associate joint venture share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation core result describe gsk annual report strategic report governance remuneration financial statement investor information financial record continue pharmaceutical vaccine turnover therapeutic area total usa europe emerge market japan therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin oncology arzerra mekinist promacta tafinlar tyverbtykerb votrient cardiovascular metabolic urology cvmu avodart immuno inflammation benlysta pharmaceutical dermatology augmentin antibacterial rare disease innovative pharmaceutical vaccine boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix innovative pharmaceutical vaccine viiv healthcare hiv combivir epzicomkivexa lexivaagenerase selzentry tivicay trizivir establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix table include sale product report trade unallocated pharmaceutical segment include canada puerto rico australasia central vaccine tender sale contract manufacturing sale total column cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine turnover therapeutic area total usa europe emerge market japan therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin oncology arzerra mekinist promacta tafinlar tyverbtykerb votrient cardiovascular metabolic urology cvmu avodart immuno inflammation benlysta pharmaceutical dermatology augmentin antibacterial rare disease innovative pharmaceutical vaccine boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix innovative pharmaceutical vaccine viiv healthcare hiv combivir epzicomkivexa lexivaagenerase selzentry tivicay trizivir establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix table include sale product report trade unallocated pharmaceutical segment include canada puerto rico australasia central vaccine tender sale contract manufacturing sale total column cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board establish product segment create certain product reclassification principally otc dermatology brand acquire stiefel business pharmaceutical vaccine segment consumer healthcare segment effect january comparative turnover information year restate accordingly addition core result restate exclude divestment complete comparative information report include effect divestment complete restate restate restate restate restate turnover division pharmaceutical vaccine pharmaceutical vaccine consumer healthcare divestment total turnover include divestment group turnover geographic region usa europe emerge market japan divestment total turnover include divestment group turnover segment usa europe emerge market japan viiv healthcare hiv establish product trade unallocated pharmaceutical pharmaceutical vaccine consumer healthcare divestment total turnover include divestment pharmaceutical vaccine turnover restate restate restate restate restate therapeutic area respiratory oncology emesis cardiovascular metabolic urogenital immunoinflammation pharmaceutical establish product vaccine viiv healthcare hiv gsk annual report strategic report governance remuneration financial statement investor information year record continue restate restate restate restate restate consumer healthcare turnover wellness oral care nutrition skin health financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence pence basic earning share dilute earning share million million million million million million weight average number share issue basic dilute restate restate financial result core turnover operate profit profit taxation profit taxation pence pence pence pence pence pence core earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee usa europe emerge market japan manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england buy rate average average rate year calculate average buy rate day year feb jan dec nov oct sep high low buying rate february gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key inlicence alliance relationship party develop indication therapeutic area phase evaluation clinical pharmacology usually conduct volunteer month submission phase determination dose initial evaluation efficacy conduct month regulatory approval maa small number patient approval letter phase iii large comparative study compound versus placebo andor establish bla biological licence application treatment patient establish clinical benefit safety maa marketing authorisation application europe nda new drug application usa maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla respiratory phosphoinositide kinase pik inhibitor idiopathic pulmonary fibrosis soluble epoxide hydrolase seh inhibitor chronic obstructive pulmonary disease copd tumour necrosis factor receptor tnfr acute lung injury domain antibody muscarinic acetylcholine antagonist beta agonist copd fluticasone furoate maba glucocorticoid agonist maba copd tolllike receptor agonist asthma pik inhibitor asthma copd recombinant human angiotensin convert acute lung injury enzyme danirixin cxcr chemokine receptor antagonist copd fluticasone furoate glucocorticoid agonist muscarinic acetylcholine asthma copd overlap syndrome umeclidinium antagonist losmapimod kinase inhibitor oral copd mepolizumab monoclonal antibody nasal polyposis fluticasone furoate glucocorticoid agonist longacting beta copd iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab monoclonal antibody copd iii relvarbreo ellipta longacte beta agonist glucocorticoid agonist copd mortality outcomes iii vilanterol fluticasone furoate vilanterol longacte beta agonist copd iii mepolizumab monoclonal antibody severe eosinophilic asthma submit nov nov anoro ellipta muscarinic acetylcholine antagonist longacte copd approve dec umeclidinium beta agonist vilanterol arnuity ellipta glucocorticoid agonist asthma approve aug fluticasone furoate incruse ellipta muscarinic acetylcholine antagonist copd approve apr aapr umeclidinium relvarbreo ellipta longacte beta agonist glucocorticoid agonist asthma approve nov jun vilanterol fluticasone furoate paediatric vaccine rsv recombinant respiratory syncytial virus prophylaxis maternal immunisation rsv recombinant viral vector respiratory syncytial virus prophylaxis pneumoniae recombinant conjugate streptococcus pneumoniae disease prophylaxis generation mmr live attenuate measle mump rubella prophylaxis iii mosquirix recombinant malaria prophylaxis plasmodium falciparum submit jun malaria rtss dtpahbvipvhib conjugate diphtheria tetanus pertussis poliomyelitis approve hepatitis haemophilus influenza nimenrix conjugate neisseria meningitis group approve apr menacwytt disease prophylaxis gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla vaccines malaria generation recombinant malaria prophylaxis plasmodium falciparum nthi recombinant nontypeable haemophilus influenzae prophylaxis tuberculosis recombinant tuberculosis prophylaxis hepatitis recombinant viral vector hepatitis virus prophylaxis ebola recombinant viral vector prevention filovirus haemorrhagic fever cause iii ebola zaire virus zoster recombinant herpe zoster prophylaxis iii antigenspecific cancer immunotherapeutic magea recombinant treatment melanoma iii immunotherapeutic hiv viiv healthcare cabotegravir hiv integrase inhibitor hiv infections longacte parenteral formulation cabotegravir hiv integrase inhibitor hiv preexposure prophylaxis longacte parenteral formulation triumeq dolutegravir hiv integrase inhibitor hiv infection fix dose combination approve sep aug abacavir sulphate reverse transcriptase inhibitor lamivudine fix dose combination oncology bromodomain inhibitor cancer focal adhesion kinase inhibitor cancer pik inhibitor cancer enhancer zeste homologue ezh cancer inhibitor erbb monoclonal antibody cancer beta cell maturation antigen antibody multiple myeloma drug conjugate lysinespecific demethylase lsd cancer inhibitor fibroblast growth factor ligand trap cancer afuresertib akt protein kinase inhibitor multiple myeloma votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer monoclonal antibody afuresertib akt protein kinase inhibitor ovarian cancer mekinist trametinib mek inhibitor braf protein nonsmall cell lung cancer tafinlar dabrafenib kinase inhibitor mekinist trametinib mek inhibitor braf protein rare cancers tafinlar dabrafenib kinase inhibitor mekinist trametinib mek inhibitor braf protein colorectal cancer tafinlar dabrafenib kinase inhibitor human antiegfr panitumumab monoclonal antibody revoladepromacta thrombopoietin receptor agonist acute myeloid leukaemia eltrombopag arzerra ofatumumab human monoclonal antibody chronic lymphocytic leukaemia use relapse patient iii arzerra ofatumumab human monoclonal antibody follicular lymphoma refractory relapse patient iii mekinist trametinib mek inhibitor braf protein metastatic melanoma adjuvant therapy iii tafinlar dabrafenib kinase inhibitor revoladepromacta thrombopoietin receptor agonist myelodysplastic syndrome iii eltrombopag votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii arzerra ofatumumab human monoclonal antibody chronic lymphocytic leukaemia line therapy approve jun apr mekinist trametinib mek inhibitor metastatic melanoma approve jul mekinist trametinib mek inhibitor braf protein metastatic melanoma approve jan tafinlar dabrafenib kinase inhibitor revoladepromacta thrombopoietin receptor agonist aplastic anaemia approve nov aug eltrombopag gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla cardiovascular metabolic prolyl hydroxylase inhibitor topical wound healing transient receptor potential cation heart failure channel trpv antagonist selective androgen receptor modulator muscle waste prolyl hydroxylase inhibitor anaemia associated chronic renal disease ileal bile acid transport inhibitor type diabete cholestatic pruritus camicinal motilin receptor agonist delay gastric empty eperzantanzeum glp agonist type diabete albiglutide losmapimod kinase inhibitor focal segmental glomerular sclerosis otelixizumab monoclonal antibody new onset type diabete losmapimod kinase inhibitor acute coronary syndrome iii retosiban oxytocin antagonist threaten preterm labour iii eperzantanzeum glp agonist type diabetes approve mar aapr albiglutide immunoinflammation receptor monoclonal antibody autoimmune disease spleen tyrosine kinase syk inhibitor chronic urticaria topical lag monoclonal antibody autoimmune disease rip kinase inhibitor autoimmune disease ccl monoclonal antibody autoimmune disease macrophage target histone rheumatoid arthritis deacetylase inhibitor mor granulocyte macrophage colony rheumatoid arthritis stimulate factor monoclonal antibody benlysta belimumab lymphocyte stimulator monoclonal transplant rejection antibody benlysta belimumab lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody benlysta belimumab lymphocyte stimulator monoclonal vasculitis iii antibody sirukumab human monoclonal antibody rheumatoid arthritis iii rare disease sap monoclonal antibody amyloidosis sap depleter cphpc exvivo stem cell gene therapy metachromatic leukodystrophy exvivo stem cell gene therapy wiscottaldrich syndrome ozanezumab neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis monoclonal antibody exvivo stem cell gene therapy adenosine deaminase severe combine immune iii deficiency adascid mepolizumab monoclonal antibody eosinophilic granulomatosis polyangiitis iii volibris ambrisentan endothelin antagonist chronic thromboembolic pulmonary hypertension iii infectious disease antiviral maturation inhibitor hiv infections nsb polymerase inhibitor hepatitis type topoisomerase inhibitor bacterial infection tafenoquine aminoquinoline plasmodium vivax malaria iii relenza zanamivir neuraminidase inhibitor influenza iii neuroscience ofatumumab human monoclonal antibody neuromyelitis optica benlysta belimumab lymphocyte stimulator monoclonal myaesthenia gravis antibody ofatumumab human monoclonal antibody multiple sclerosis rilapladib lppla inhibitor alzheimer disease gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla ophthalmology beta amyloid monoclonal antibody geographic retinal atrophy dermatology stearoyl coa desaturase inhibitor topical acne vulgaris umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis nonsteroidal antiinflammatory atopic dermatitis psoriasis chlorhexidine cationic polybiguanide topical umbilical cord care iii ofatumumab human monoclonal antibody pemphigus vulgaris iii toctino alitretinoin retinoic acid receptor modulator chronic hand eczema iii brand name appear italic trade mark own andor license gsk associate company optionbase alliance party include asset phase phase iii development company disease area phase adaptimmune cancer cancer research cancer isis pharmaceutical hepatitis transthyretinmediate amyloidosis iii oncome pharmaceutical oncology oncology shionogi bacterial infection gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brands usa respiratory anoro ellipta umeclidinium bromide copd spiriva onbrez nce nce vilanterol terfenatate device device formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex nce nce alvesco device device formulation formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva seebri nce nce device device formulation formulation relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate copd flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expire onbrez disku device diskus device hfadevice ventolin hfa albuterol sulphate asthmacopd generic company hfadevice hfadevice antiviral relenza zanamivir influenza tamiflu expire expire valtrex valaciclovir genital herpe coldsore famvir expire expire shingles zeffixepivirhbv lamivudine chronic hepatitis hepsera expire expire central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire requip ropinirole parkinson disease mirapex expired expire seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabete victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post lovaza omega acid ethyl ester high triglyceride tricor expire risk factor detail uncertainty time followon competition note financial statement legal proceeding generic competition possible generic competition possible gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brands usa antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection oncology arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia imbruvica mekinist trametinib braf metastatic yervoy opdivo melanoma keytruda promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura hepatitis mabtherarituxan associate thrombocytopenia tafinlar dabrafenib braf metastatic yervoy zelboraf grant melanoma opdivo keytruda tykerbtyverb lapatanib advance metastatic herceptin breast cancer kadcyla positive patient votrient pazopanib soft tissue sarcoma yondelis sutent metastatic renal cell nexavar afinitor carcinoma temsirolimus rare disease volibris ambrisentan pulmonary hypertension tracleer revatio immunoinflammation benlysta belimumab systemic lupus erythematosus vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis polio hepatitis pentaxim pentavac haemophilus influenzae haemophilus influenzae hexaxim type type cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtype fluzone influvac subtype antigen aggripal fluad intenza flumist fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtype vaxigrip qiv subtype antigen fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtype fluzone influvac subtype antigen aggripal fluad intenza flumist pandemrix derive split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis adjuvant prepandrix derive split inactivated pandemic aflunov vepacel grant influenza virus antigen influenza prophylaxis adjuvant synflorix conjugate pneumococcal invasive pneumococcal prevenar prevnar polysaccharide disease pneumonia acute otitis medium gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brands usa hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexivatelzir fosamprenavir hivaid prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaid isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir stribild compleraeviplera trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera note financial statement legal proceeding generic competition commence include supplementary protection certificate patent term extension grant consumer healthcare product competition brand product application market competition wellness panadol tablet caplet infant drop paracetamolbase treatment global reckittbenckiser nurofen panadol cold headache joint pain bayers aspirin flu fever cold symptom johnson johnsons tylenol retailer label eno effervescent immediate relief antacid global hypermarcas estomazil pfizer gelusil tum chewable tablet immediate relief antacid sanofis rolaids bayers alkaseltzer retailer label nicorette lozenge gum treatment nicotine global novartiss nicotinell nicoderm transdermal patch withdrawal aid johnson johnsons nicorette niquitin smoking reduction nicabate cessation retailer label oral health sensodyne toothpaste toothbrush treat prevent dental global colgatepalmolive mouth rinse sensitivity acid erosion colgate sensitive pro relief proctor gamble crest sensirelief crest sensistop strip polident denture adhesive denture improve comfort global procter gamble fixodent poligrip cleanser fit denture reckittbenckiser kukident corega clean denture steradent aquafresh toothpastes toothbrushe prevention carie gum global colgatepalmolive colgate mouthwash disease bad breath procter gamble crest oralb nutrition horlick malt drink food nutritional indian sub continent mondelezs bournvita beverage food ireland nestle milo skin health physiogel moisturise cream face body care dry germany france italy loreal roche posay lotion cleanser sensitive irritated skin poland spain beiersdorf eucerin pierre fabre avene zovirax topical cream lip care treat prevent global johnson johnsons compeed abreva onset cold sores carma labs carmex blistex incorporated blistex retailer label gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor principal risk discuss risk uncertaintie healthcare product affect cost product relevant business financial condition result operation development time require reach market affect performance ability achieve objective uncertainty successfully factor believe cause actual rule regulation change governmental result differ materially expect historical result interpretation rule regulation evolve nature operate global basis industry highly particular risk change change certain regulatory regime competitive highly regulate competitor substantial change failure comply significant product innovation technical advance applicable law regulation materially adversely affect intensify price competition light competitive environment financial result continue development commercially viable new product similarly business expose litigation government development additional use exist product critical investigation include limited product liability litigation ability maintain increase overall sale patent antitrust litigation sale marketing litigation litigation develop new pharmaceutical vaccine consumer healthcare government investigation include related provision product costly lengthy uncertain process unfavourable outcome increase related cost product candidate fail stage include significant insurance premium materially adversely affect financial group economic human resource invest result detail status uncertainty involve competitor product pricing strategy failure significant unresolved dispute potential litigation set develop commercially successful product develop note legal proceeding additional use exist product materially adversely regulation require discussion mitigating activity affect financial result company take address principal risk uncertainty adapt comply broad range law summary activity group take manage regulation requirement apply research principal risk accompany description principal development manufacturing testing approval distribution risk principal risk factor uncertaintie list sale marketing pharmaceutical vaccine consumer order significance patient safety risk definition paramount importance cmo authoritative role failure appropriately collect review follow report adverse event evaluate addressing matter human safety individual potential source act relevant finding timely medical officer group substantial global safety manner pharmacovigilance organisation track adverse issue report product course clinical study risk impact impact risk potentially compromise ability conduct group product approve marketing group robust safety signal detection interpretation ensure extensive postmarkete surveillance signal detection system appropriate decision take respect riskbenefit profile information possible effect medicine receive product include completeness accuracy product label source include unsolicited report health professional pursuit additional studiesanalyse appropriate patient regulatory authority medical scientific literature lead potential harm patient reputational damage product liability medium policy employee require report immediately claim litigation governmental investigation regulatory action issue relate safety quality medicine fine penalty loss product authorisation country manager responsible monitoring exception tracking training help assure collection safety information context report information relevant central safety department preclinical clinical trial conduct development accordance group policy legal requirement investigational pharmaceutical vaccine consumer healthcare product determine safety efficacy product use information change benefitrisk profile group human notwithstanding effort determine safety medicine result certain action characterise communicate product appropriate preclinical clinical trial minimise risk propose action discuss regulatory unanticipated effect evident product authority include modify prescribing information widely introduce marketplace question raise communication physicians healthcare provider ongoing safety surveillance postmarkete study restriction product prescribingavailability help assure safe use governmental agency thirdpartie analyse publicly carry clinical trial certain case available clinical trial result appropriate stop clinical trial withdraw medicine market group global safety board gsb comprise senior group currently defendant number product liability physician representative support function integral lawsuit include class action involve significant claim component system gsb include subsidiary board damage relate product litigation particularly dedicated consumer healthcare product vaccine review inherently unpredictable class action seek sweep safety investigational market product group person prescribe product increase potential liability authority stop clinical trial continue conduct claim pain suffer punitive damage frequently trial ethically scientifically justify light information assert product liability action allow represent emerge start trial potentially openende exposure materially adversely affect group financial result addition medical governance framework group describe group use mechanism foster early mitigate activity evaluation mitigation resolution dispute arise chief medical officer cmo responsible medical governance potential claim arise goal programme group global policy policy safeguarding create culture early identification evaluation risk claim human subject clinical trial patient product actual potential order minimise liability litigation gsk annual report strategic report governance remuneration financial statement investor information intellectual property risk definition depend certain key product significant portion failure appropriately secure protect intellectual property sale product respiratory pharmaceutical product right seretideadvair account group sale worldwide timing impact entry generic product risk impact contain combination active substance seretide failure obtain subsequent loss patent protection advair uncertain patent composition contain include reduce availability scope patent right combination active substance seretideadvair expire compulsory licensing government force manufacturer patent component advair diskus license patent specific product competitor device continue august generic product contain materially adversely affect financial result market combination active substance seretideadvair absence adequate patent datum exclusivity protection limit meter dose inhaler dry powder inhaler launch opportunity rely market future sale growth manufacturer number european market product materially adversely affect time impact entry major market europe financial result followon product seretideadvair uncertain context generic drug manufacturer exhibit readiness innovative pharmaceutical vaccine consumer healthcare market generic version important product product company seek obtain appropriate intellectual prior expiration patent effort involve property protection product ability obtain enforce challenge validity enforceability patent assertion patent proprietary right regard product generic product infringe patent result critical business strategy success pharmaceutical continue involve legal proceeding vaccine product usually protect copy involve patent challenge materially adversely generic manufacturer period exclusivity provide affect financial result issue patent relate intellectual property right increasingly common patent infringement action prompt regulatory data protection orphan drug status follow claim antitrust law violate prosecution expiration certain intellectual property right generic patent litigation involve defence patent manufacturer lawfully produce generic version product claim direct indirect purchaser payer operate market intellectual property law patent typically file class action relief seek include treble office develop government unwilling damage restitution claim similarly antitrust claim grant enforce intellectual property right fashion similar bring government entity private party follow develop region japan settlement patent litigation allege settlement develop country limit threatened limit effective anticompetitive violation antitrust law successful patent protection pharmaceutical product generally antitrust claim private party government entity particular therapeutic area order facilitate early competition materially adversely affect financial result market generic manufacturer expiration date patent major product face competition manufacturer proprietary generic affect date generic version product pharmaceutical product major market introduction introduce set page legal proceeding generic product particularly highest involve patent challenge set note financial turnover margin typically lead rapid dramatic loss statement legal proceeding sale reduce revenue margin proprietary mitigating activity product pharmaceutical vaccine global patent group focus secure protect product million annual global sale certain patent right global group maintain internal process product generic competition design help ensure successful procurement enforcement market europe experience impact sale defence patent goal maintain exclusive right product expiry loss patent protection market product product market competitor similar product class treatment similar disease condition global patent group monitor new development international patent law help ensure appropriate protection asset act trade association work local government seek secure effective balanced intellectual property protection design meet need patient payer support longterm investment innovation gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue product quality risk definition adopt single quality management system qms failure comply current good manufacturing practice define quality standard system business cgmp requirement commercial manufacture associated pharmaceutical vaccine consumer distribution chain gsk contractor supplier healthcare product investigational material qms inadequate control governance quality product broad scope cover endtoend supply chain development support regulated activity start material distribute product applicable complete lifecycle product risk impact mature commercial supply failure ensure product quality far reach implication term patient consumer safety delay qms periodically update base experience evolve launch new product drug shortage product recall potential regulatory agency expectation requirement improve damage reputation relevant product scientific understanding help ensure operation comply regulatory legal financial consequence cgmp requirement globally support delivery materially adversely affect reputation financial result consistent reliable product large network quality compliance professional align business unit context provide oversight assist delivery quality performance patient consumer healthcare professional trust quality operational compliance management oversight product failure ensure product quality enterprise activity accomplish hierarchy quality council risk applicable business activity meeting staff train help ensure standard product quality influence factor include expect behaviour base value follow product process understand supply chain security refresher training cgmp issue include focus consistency manufacturing component compliance gmp issue raise inspectional trend accuracy labeling reliability external supply chain embodiment overarching quality culture internal implement riskbase approach assess external environment continue evolve new product new manage thirdparty supplier provide material market new legislation introduce particularly finish product contract manufacturer make product security supply good distribution practice product expect comply standard identify group standard inspectional trend national authority audit help provide assurance expect standard meet highlight focus issue relate data integrity chief product quality officer oversee activity contamination robustness quality investigation gsk quality council serve forum escalate mitigating activity emerge risk share experience handle quality issue medicine development scientist adopt principle quality business help ensure lesson learn design new product devise control strategy assess deploy globally preparation deploy product lifecycle help ensure implementation new legislation regularly review gsk consistency reliability performance supply quality council advocacy communication programme maintain awareness external environment convey consistent message group emphasis quality performance metric culture right time gsk annual report strategic report governance remuneration financial statement investor information supply chain continuity risk definition failure small number singlesource thirdparty supplier failure deliver continuous supply compliant finished product service provider fulfill contractual obligation timely manner result regulatory noncompliance physical risk impact disruption logistic manufacturing site result delay material interruption supply exclusion healthcare service interruption programme impact patient access product expose litigation regulatory action materially adversely mitigate activity affect financial result particular incur fine supply chain model design help ensure supply disgorgement result noncompliance manufacture quality security product globally closely monitor practice regulation materially adversely affect supply chain governance committee inventory group financial result result reputational damage status delivery product help ensure customer medicine vaccine product need context safety stock backup supply arrangement high revenue supply chain operation subject review approval medicallycritical product place practical regulatory agency effectively provide licence help mitigate risk addition compliance manufacture operate failure manufacture distribution facility external supplier routinely monitor order identify supplier key service material lead litigation manage supply base risk regulatory action product recall seizure interruption supply delay approval new product suspension practical dependency single source critical item manufacture operation pende resolution manufacturing remove reliance single source component logistic issue consumer healthcare business reduce key product qualification particularly smoker health product alli bactroban alternative material help improve supply chain robustness impact supply issue vaccine case dual source possible inventory strategy business particularly hepatitis vaccine boostrix develop protect supply chain unanticipate impact supply constraint disruption material service provide thirdparty supplier continue implement anticounterfeit system necessary commercial production product include product serialization accordance emerge requirement active pharmaceutical ingredient api antigen intermediate mitigate risk commodity component necessary manufacture supply chain operating model improve package pharmaceutical vaccine consumer strengthen link commercial forecasting healthcare product thirdparty service procure manufacturing implementation core commercial service provide contract manufacturing organization cycle methodology action time decrease risk clinical research organisation support development key associate demand fluctuation impact ability supply product important ensure continuous operation writeoff associate product exceed expiry date business undertake business continuity plan new model node supply chain optimise single source certain component bulk api finished product help ensure adequate safety stock balance working service create risk failure supply event capital associate endtoend supply chain regulatory noncompliance physical disruption manufacturing site logistic system financial reporting disclosure risk definition mitigate activity failure report accurate financial information material event group maintain control environment design identify compliance accounting standard applicable legislation material error financial reporting disclosure design operating effectiveness key financial reporting control risk impact periodically test provide assurance noncompliance exist new financial reporting control key financial reporting disclosure process disclosure requirement change recognition income operate effectively expense expose litigation regulatory action materially adversely affect financial result uptodate late development financial reporting requirement work external auditor context legal advisor help ensure adherence relevant report new revise accounting standard rule interpretation disclosure requirement issue time time international accounting standard board result change recognition income share accountability financial result expense materially adversely affect financial result business financial result review approve regional management review financial group require law jurisdiction controller chief financial officer cfo allow disclose publicly financial result event materially financial controller cfo assess evolution affect financial result group regulator routinely review business time evaluate performance plan significant financial statement list company compliance judgment review confirm senior management accounting regulatory requirement group believe complie appropriate regulatory requirement concern group maintain disclosure committee report financial statement disclosure material information board review group quarterly result annual subject investigation potential report determine year consultation noncompliance accounting disclosure requirement legal advisor necessary disclose publicly potential restatement previously report result information group stock exchange subject significant penalty announcement gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue tax treasury risk definition liquidity risk manage diversify liquidity source failure comply current tax law react rapidly range facility maintain broad access funding evolve tax environment incur significant loss market order meet anticipate future funding requirement treasury activity hold significant amount cash investment invest line strict investment guideline risk impact change tax law application respect matter interest rate risk manage limiting float rate transfer pricing foreign dividend control company interest payment prescribe percentage operating profit tax credit taxation intellectual property restriction mix debt fix float interest rate monitor tax relief allow interest intragroup debt impact regularly tmg effective tax rate significant loss arise treasury foreign currency transaction risk arise internal external activity inconsistent application treasury policy trade flow generally hedge internal trading deal settlement error counterparty default transaction match centrally manage intercompany change tax law application failure comply tax payment term reduce foreign currency risk foreign currency law significant loss treasury activity materially cash flow hedge selectively management adversely affect financial result treasury tmg possible manage cash context surplus borrowing requirement subsidiary company treasury group deal high value transaction foreign centrally order reduce foreign currency translation exposure exchange cash management transaction daily basis seek denominate borrowing currency group effective tax rate drive rate tax principal asset cash flow tmg review ratio jurisdiction higher low borrowing asset major currency monthly addition jurisdiction currently offer regime encourage counterparty risk manage set global counterparty limit innovation investment science provide tax incentive banking investment counterpartie base tax credit low tax rate income derive longterm credit rating moodys standard poor patent furthermore international business face treasury usage limit monitor daily corporate risk associate intragroup transfer pricing compliance officer cco operate independently tax charge include financial statement good corporate treasury cco monitor credit rating estimate tax liability pende audits tax authority submit counterpartie change rating occur tax return accord statutory time limit engage tax notifie treasury change investment authority help ensure tax affair current exceptional level authority limit appropriate case matter settle agreement tax detail mitigation treasury risk find authority resolve dispute formal note financial instrument relate disclosure appeal proceeding international business subject range duty taxis carry monitor government debate tax policy key similar type risk jurisdiction deal proactively potential future change tax law tax risk manage set policy procedure increase focus tax position multinational help ensure consistency compliance tax legislation business consequence challenge economic engage advisor legal counsel review tax legislation environment priority place address applicability business allegation unlawful tax avoidance see increase audits government seek raise revenue attempt mitigate risk aggressive tax authority corporate taxis line taxis custom duty audits date possible tax affair audits regardless merit outcome costly work proactively tax authority possible divert management attention adversely impact move centralised simplified reputation addition increase number change intellectual property ownership trading model model international tax framework lead increase centralise pharmaceutical intellectual property decrease tax cost reduce complexity intercompany arrangement enable drive bilateral advance pricing agreement mitigate activity apa jurisdiction operate group treasury function operate profit centre apa great certainty application transfer pricing enter financial derivative transaction direct tax affair reduce risk centralise speculative purpose transaction financial instrument team dedicate specialist responsible manage undertaken manage risk arise underlie business transactional tax reporting compliance activity treasury activity govern policy approve board director compliance regularly review treasury management group tmg chair cfo gsk annual report strategic report governance remuneration financial statement investor information antibribery corruption risk definition mitigate activity risk gsk personnel party act code conduct value behaviour commitment behalf seek induce improper performance someone role zero tolerance integral mitigate risk light order gain retain gsk business advantage complexity geographic breadth risk offer promise give bribe go ethical constantly enhance oversight activity datum reinforce standard contrary law bind employee contractor clear expectation acceptable behaviour maintain ongoing communication risk impact group centre headquarters local market failure mitigate risk expose group associate persons governmental investigation regulatory action civil group enterprisewide abac programme design criminal liability damage group reputation respond threat risk bribery corruption shareholder value licence operate particular build group value exist standard form jurisdiction materially adversely affect comprehensive practical approach compliance abac financial result programme support toplevel commitment group board director leadership business context ongoing risk assessment global policy control document expose bribery corruption risk global address commercial practice rise abac business operation market government structure risk diligence high risk party ongoing training rule law develop bearing communication confidential reporting line monitor bribery corruption risk exposure addition global compliance investigation team addition programme nature business healthcare sector highly competitive mandate enhance control interaction government subject regulation increase instance official undertake business development expose activity interaction bribery transaction programme governance provide group corruption risk abac oversight committee include representation previously disclose group key functional area business unit subject regulatory action medium focus regard bribery additionally dedicated abac team responsible investigation china market september implementation evolution programme response group announce changsha intermediate people development internal external environment court hunan province china rule accord chinese complement abac investigation abac audit team law gsk china investment ltd gskci offer money separate reporting line property nongovernment personnel order obtain improper commercial gain find guilty bribe continually benchmark abac programme nongovernment personnel verdict follow investigation large multinational company use external expertise review initiate chinas ministry public security june help improve element abac programme result result court verdict gskci pay fine china country investigation group rmb billion million chinese government increase resource centrally locate abac team regional abac team authority lead extraterritorial abac inquire certain group operation investigation discuss note legal proceeding gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue commercial practice scientific engagement risk definition time researcher hcp healthcare organisation hco failure engage commercial andor scientific activity external expert engage compensate consistent letter spirit legal industry service expertise provide payment group requirement relate marketing communication excessive perceive medicine associate therapeutic area inducement reward prescribing product consistent appropriate interaction healthcare professional hcp abac policy comply market patient legitimate transparent transfer value abac law recipient payment government official risk impact mitigate activity failure comply applicable law rule regulation take action level group enhance result governmental investigation regulatory action legal improve standard procedure scientific engagement proceeding bring group governmental promotional interaction base value transparency private plaintiff failure provide accurate complete respect integrity patient focus policy information relate product result incomplete standard govern promotional activity scientific awareness benefitrisk profile medicine possibly engagement undertake group behalf suboptimal treatment patient consequence activity conduct worldwide conform high ethical materially adversely affect financial result medical scientific standard local standard differ practice find misaligned value global standard stringent applie result reputational damage dilute trust establish group harmonize policy procedure guide key stakeholder pay billion resolve country commercial practice scientific engagement government investigation focus large process clarify applicable standard promotional practice engage market specific accountability authorisation context scientific engagement reside medical governance commit legitimate scientific engagement framework oversee medical governance executive ethical responsible commercialisation medicine support committee mgec accountable chief medical officer mission improve quality human life enable people mgec responsible oversight applicable policy feel well live long accomplish mission ensure high level integrity continuous development engage healthcare community way advance scientific engagement gsk commercial practice activity scientific knowledge provide important oversight business unit risk management information medicine compliance board rmcbs country executive board cebs manage risk incountry business activity group disseminate information product nonpromotional scientific engagement promotional promotional material activity review activity interaction exchange information approve accord group policy standard group partner external community conduct accordance local law regulation order advance scientific medical understanding include help ensure material activity fairly represent appropriate development use product product service group necessary management disease patient care distinct discipline include termination employee promotional activity place authorisation engage misconduct broaden ability claw new product indication conduct strictly remuneration senior management event accordance promotional law code group policy misconduct promotion approve medicine helps ensure hcp globally take proactive risk mitigation step access information need patient access assure operation reflect value gsk publicly commit medicine need medicine prescribe stop payment hcp healthcare manner provide maximum healthcare benefit organisation hcos gsk commit extended step patient commit communicate information relate take change sale compensation model approve product responsible legal ethical globally base sale target approach manner individually reward sale force quality interaction healthcare professional end result gsk annual report strategic report governance remuneration financial statement investor information research practice risk definition mitigate activity failure adequately protect inform patient involve human establish office animal welfare ethic strategy clinical trial research conduct objective ethical preclinical oawe lead chief animal welfare ethic strategy clinical trial sound scientific principle guarantee integrity help ensure humane responsible care animal discovery preclinical clinical development datum manage increase knowledge application nonanimal alternative human biological sample accord establish ethical group oawes embeds framework animal welfare standard regulatory expectation treat animal ethically governance promote application replacement refinement practice good animal welfare appropriately disclose human subject reduction animal research explore opportunitie research medicinal product ensure integrity crossindustry datum sharing conduct quality assessment regulatory filing datum publish report result human subject research risk impact medicine vaccine publicly accessible clinical study impact risk include harm patient reputational register website governmentrequire repository damage failure obtain necessary regulatory approval submit human research result manuscript publication product governmental investigation legal proceeding peer review scientific journal disclose product liability suit claim damage regulatory clinical study report market terminate medicine action fine penalty loss product authorisation research result publish scientific literature materially adversely affect financial result register early gsk online system allow researcher request access anonymise patientlevel datum context group clinical trial reconfigure multisponsor research relate animal raise ethical concern request site wwwclinicalstudydatarequestcom include study attempt proactively address animal study remain vital conduct sponsor end list research case method gsk trial available request investigate effect potential new medicine living body test human generally mandate global human biological sample management hbsm regulator ethically imperative animal research provide governance framework place oversee ethical lawful critical information cause disease acquisition management human biological sample develop country require additional animal testing global hbsm network champion hbsm activity provide medicine approve use experienced group support internal sample custodian well practice clinical trial healthy volunteer patient assess demonstrate investigational product efficacy safety remain important priority enhance datum integrity evaluate product approve control establish plan develop new write marketing work human biological sample standard ensure integrity datum research sample fundamental discovery development safety development datum integrity committee establish monitoring product provide oversight datum integrity quality assurance team create provide independent business monitor internal integrity datum essential success stage control activity research datum lifecycle design generation record management analysis report storage retrieval chief regulatory officer oversee activity research datum govern legislation regulatory regulatory governance board include promote requirement compliance regulatory requirement groupwide standard make regulatory service efficient agile research datum support document core component align regulatory capability international stage pipeline progression decisionmake business need enterprise local level form content regulatory submission poor datum integrity compromise research effort innate complexity interdependency require regulatory filing particularly give global research development footprint rapid change submission requirement develop country continue increase complexity worldwide product registration gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue environment health safety sustainability risk definition mitigate activity failure manage environment health safety sustainability corporate executive team responsible ehss ehss risk consistent group ethic objective governance group global policy policy policy relevant law regulation cet ensure system place manage risk impact legal compliance issue relate ehss risk impact assign responsibility senior manager provide failure manage ehss risk lead significant harm maintain system individual manager responsible people environment community operate make sure ehss management system effective fine failure meet stakeholder expectation regulatory implement respective business area fully requirement litigation regulatory action damage compliant applicable law regulation adequately group reputation materially adversely affect resource maintain communicate monitored financial result additionally employee personally responsible ensure context applicable local standard operating procedure group subject health safety environmental law follow expect responsibility ehss matter jurisdiction law impose duty protect people riskbase proactive approach articulate global environment community operate ehs standard support ehss policy objective potential obligation remediate contaminate site discover develop manufacture supply sell product identify potentially responsible party harm people environment addition comprehensive environmental response compensation design provision safe facility plant equipment liability act number site remediation cost relate operate rigorous procedure help eliminate hazard use ownership site failure manage practicable protect employee health wellbee environmental risk properly result litigation regulatory employment practice design create work place culture action additional remedial cost materially employee feel value respect empower adversely affect financial result note financial inspire achieve goal statement legal proceeding discussion environmental relate proceeding involve continue effort improve environmental routinely accrue amount relate liability matter sustainability reduce water consumption hazardous waste energy consumption actively manage environmental remediation obligation help ensure practice environmentally sustainable compliant ehss performance result share public year responsible business supplement information protection risk definition mitigate activity risk group business activity critical sensitive group global information protection policy computer system information available need support dedicated programme activity increase access authorise deliberately change focus information security group establish corrupted information protection privacy function provide strategy direction oversight enhance global information risk impact security capability failure adequately protect critical sensitive system information result inability maintain patent right assess change information protection risk environment loss commercial strategic advantage damage briefing government agency subscription reputation business disruption include litigation regulatory commercial threat intelligence service knowledge sharing sanction fine materially adversely affect pharmaceutical crossindustry company financial result aim use industry good practice information context security policy process technology invest rely critical sensitive system datum strategy commensurate change nature corporate strategic plan sensitive personally identifiable security threat landscape information intellectual property manufacturing system trade subject law govern process secret potential malicious careless action personally identifiable information pll help ensure compliance expose computer system information misuse crossborder pii transfer requirement group bind unauthorised disclosure corporate rule bcrs approve information commissioner office human resource research activity datum bcrs possible transfer pii internationally group entity individual privacy agreement european union country gsk annual report strategic report governance remuneration financial statement investor information crisis continuity management risk definition mitigate activity inability recover sustain critical operation follow ccm governance group set forth global policy disruption respond crisis incident timely manner policy business unit functional area head ensure effective crisis management business risk impact continuity plan place include authorise response failure manage crisis continuity management ccm recovery strategy key area responsibility clear effectively lead prolonged business disruption great communication route business disruption occur damage group asset risk supply disruption additionally represent ccm governance board patient medicine materially adversely perform risk oversight provide vital information affect financial result delay operational activity ccm programme team new threat acquisition delivery product consumer patient rely significant business organisational change expose litigation regulatory action materially adversely affect financial result lead dedicated team ccm expert support business reputational damage responsibility include chairing governance board coordinate crisis management business continuity training context facilitate exercise monitor provide global group international operation partner consistency alignment centrally store monitoring maintain vast global footprint expose workforce facility update plan support critical business process operation information technology potential disruption activity help ensure appropriate level readiness result natural event storm earthquake man response capability maintained develop maintain event civil unrest terrorism global emergency partnership external body like business continuity ebola outbreak flu pandemic effective crisis institute international strategy disaster risk management business continuity planning commit reduction helps improve business continuity initiative provide health safety people minimise disaster prone area support development damage impact group maintain functional community resilience disaster operation follow natural manmade disaster public health emergency continually improve ccm risk management programme tool base learn plan activation example group implement global disaster monitoring tool monitor disruption support local crisis team guidance central support need regularly evaluate introduce new tool improve ccm practice thirdparty oversight risk definition mitigate activity failure maintain adequate governance oversight thirdparty responsibility activity perform safely relationship failure thirdpartie meet contractual compliance applicable law gsk value standard regulatory confidentiality obligation failure thirdpartie code conduct business unit leadership team retain comply law appropriately manage respective ultimate accountability manage party interaction operation mitigate principal risk group outline risk appropriately govern interaction work party gsk employee expect risk impact manage external interaction commitment responsibly failure adequately manage thirdparty relationship result expectation embed value code conduct business interruption exposure risk range sub optimal contractual term condition severe business help guide enforce global principle interaction sanction andor significant reputational damage thirdpartie place policy framework applicable consequence materially adversely affect business buying good service manage external spend operation financial result pay work thirdpartie policy framework apply employee complementary worker worldwide context framework complement technical local standard party critical business delivery integral design help ensure alignment nature party solution improve productivity quality service interaction good manufacturing practice adherence innovation rely thirdpartie include supplier distributor local law regulation independent business monitor individual contractor license pharmaceutical key financial operational control place biotechnology collaboration partner discovery manufacture supplement periodic check company marketing product important business process independent audit assurance function business relationship present material risk help enhance continuous monitoring performance example share critical sensitive information party interaction establish party oversight marketing plan clinical datum employee datum specific programme global programme take enterprise view party conduct relevant outsource business party relate risk help strengthen diligence operation inadequate protection misuse information effort party improve overall management party significant business impact similarly party risk lifecycle thirdparty use distributor agent range activity engagement oversight programme provide promotion tender inherent risk gsk global ethic compliance group inappropriate promotion corruption insufficient internal compliance control distributor affect reputation risk increase complexity work large number party gsk annual report strategic report governance remuneration financial statement investor information shareholder information share capital control share buyback programme board authorise issue allot ordinary share detail issue share capital number share article company article association hold treasury december find note power article authority company financial statement share capital share premium purchase share subject shareholder authority account seek annual basis annual general ordinary share list london stock exchange meeting agm share purchase company quote new york stock exchange nyse cancel hold treasury share satisfy share form american depositary share ad ad option grant group employee share plan represent ordinary share detail list debt continue longterm buyback programme list refer note financial statement million share purchase total cost million net debt date final share purchase june holder ordinary share ad entitle receive share purchase period june dividend declare company annual report february annual summary attend speak general meeting programme cover purchase share cancellation company appoint proxy exercise voting right hold treasury share accordance authority restriction transfer limitation renew shareholder agm hold ordinary share ad requirement company authorise purchase maximum obtain approval prior transfer ordinary share ad million share detail share purchase cancel carry special right regard control company hold treasury share disclose note restriction vote right major shareholder financial statement share capital share premium account voting right share shareholder determine specific share repurchase level company know arrangement financial right hold consider development free cash flow year give person holder share know impact sustain strength sterle free cash flow agreement restriction share transfer voting right company suspend share repurchase programme share acquire share scheme plan rank follow completion novartis transaction gsk equally share issue special right intend return shareholder billion net proceed trustee employee share ownership plan trust company expect ordinary share waive right dividend share hold trust repurchase exchange control limitation market capitalisation affect security holder market capitalisation base share issue exclude certain economic sanction force treasury share gsk december time time currently applicable law decree billion regulation restrict import export capital affect date gsk fourth large company market remittance dividend payment holder capitalisation ftse index company share nonresident similarly certain economic sanction force time share price time limitation relate nonresident english law company article association january right holder vote respect company december share decreaseincrease interest voting right high year state far aware low year person significant direct indirect holding company table set middle market closing price information provide company pursuant financial company share price decrease conduct authoritys fca disclosure transparency rule compares decrease ftse index dtrs publish regulatory information service year share price february company website february company receive notification accordance fca dtrs follow notifiable interest voting right company issue share capital percentage issue share capital blackrock inc legal general group plc ercentage ordinary share issue exclude treasury share acquire disposed interest share period review connection share buyback programme share price ad price gsk annual report strategic report governance remuneration financial statement investor information nature trading market follow table set period indicate high low middle market closing quotation pence share london stock exchange high low closing price dollar ad nyse ordinary share ad pence share dollar share high low high low february january december november october september august quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december february analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bny mellon depositary company adss list nyse ordinary share represent company adr programme manage depositary register bny nominees limited february bny nominees limit hold ordinary share represent issue share capital exclude treasury share date february number holder ordinary share usa holdings ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue dividend shareholder summary apply resident shareholder hold company pay dividend quarterly continue return share capital asset cash shareholder dividend policy dividend remain essential component total shareholder return taxation dividend company commit increase dividend long resident shareholder generally subject income term detail dividend declare amount tax dividend pay gross payment date give note financial statement tax credit tax credit set individual dividend income tax liability respect gross dividend repayable shareholder tax liability dividend share associate tax credit tax year subsequent tax table set dividend share ad year additional rate income tax dividend impose year dividend ad translate dollar taxpayer income resident applicable exchange rate shareholder corporation taxpayer note dividend generally entitle exemption corporation tax year dividend pence taxation capital gain shareholder liable tax gain disposal share adr disposal individual subject availability exemption relief annual exempt taxable capital gain accrue disposal share supplemental adr tax allowable deduction shareholder taxable income tax year exceed basic supplemental dividend relate disposal certain rate income tax limit case taxable capital gain accrue noncore otc brand north america pay fourth disposal share adr tax quarter ordinary dividend combination rate corporation taxpayer entitle indexation allowance apply reduce capital gain dividend calendar extent gain arise inflation indexation ad exdividend exdividend allowance reduce chargeable gain create quarter date date record date payment date allowable loss february february february april july inheritance tax august august august october individual shareholder liable inheritance tax transfer share adr tax charge november november november january value shareholders estate reduce result transfer way gift disposal tax information shareholder market value gift disposal subject summary certain tax federal income tax inheritance tax estate gift tax estate gift consequence holder share adr citizens tax convention generally provide tax pay usa usa set complete analysis credit tax payable possible tax consequence purchase ownership stamp duty sale security intend general guide stamp duty stamp duty reserve tax sdrt subject holder advise consult adviser respect certain exemption payable transfer share rate tax consequence purchase ownership sale consideration transfer share adr consequence state local tax law usa implications current ukus tax convention holder adr generally treat owner underlie share purpose current usauk double taxation convention relate income gain income tax convention estate gift taxis estate gift tax convention purpose internal revenue code amend code gsk annual report strategic report governance remuneration financial statement investor information shareholder stamp duty summary apply shareholder citizen stamp duty sdrt subject certain exemption resident usa domestic corporation person payable transfer share adr custodian subject federal income tax net income basis depository rate consideration respect share adr hold share adr provide transfer sale value transfer capital asset resident tax purpose consideration hold share purpose trade profession sdrt payable transfer agreement vocation carry branch agency transfer adr stamp duty payable summary address tax treatment holder transfer adr provide instrument transfer subject special tax rule bank taxexempt execute remain time outside stamp duty entity insurance company dealer security currency transfer adr payable rate person hold share adr integrate consideration transfer sale underlie share investment include straddle comprise share adr subject certain exception result liability stamp position person directly duty case sdrt rate indirectly vote stock company annual general meeting taxation dividend gross dividend receive treat foreign time thursday source dividend income tax purpose eligible queen elizabeth conference centre broad sanctuary dividend receive deduction allow corporation westminster london swp dividend adr payable dollar dividend share payable pound sterling dividend pay pound sterling agm company principal forum communication include income dollar calculate private shareholder addition formal business reference exchange rate day dividend presentation ceo performance receive holder subject certain exception shortterm group future development opportunity hedge position individual eligible holder subject question ask board chairman board taxation maximum rate respect qualified committee question relate committee dividend investor hold share nominee service arrange taxation capital gain nominee service appoint proxy respect generally holder subject capital gain tax shareholding order attend vote meeting subject tax capital gain realise sale adr holder wish attend meeting obtain proxy disposal share adr gain longterm bny mellon depositary notifying request capital gain subject reduce rate taxation individual enable attend vote business holder share adr hold year transact adr holder instruct bny mellon information report backup withholding way share represent adr vote dividend payment proceed sale share complete return voting card provide adr pay usa certain usrelated financial depositary intermediary subject information reporting document display subject backup withholding holder articles association company directors service corporation exempt recipient provide taxpayer contract applicable letter appointment identification number certifie loss exemption director company subsidiary occur nonus holder generally subject information letter relate severance term pension arrangement report backup withholding require provide available inspection company register office certification nonus status connection payment available inspection agm receive amount withhold allow refund credit holder federal income tax liability provide require information furnish internal revenue service estate gift taxis estate gift tax convention shareholder generally subject inheritance tax gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue financial calendar definition political donation political expenditure political organisation legislation wide event date particular definition political organisation extend quarter result announcement aprilmay body concern policy review law reform annual general meeting representation business community special interest quarter result announcement july groups concern environment quarter result announcement october company subsidiary wish support result preliminaryquarter result announcement february definition cover legitimate business activity ordinary sense consider political donation political annual report announcement februarymarch expenditure annual reportsummary distribution march activity design support political party information company include share price available independent election candidate authority board website wwwgskcom information available seek annually precautionary measure ensure website constitute annual report company subsidiary inadvertently breach result announcement legislation result announcement issue london stock exchange director available news service send securities exchange commission nyse issue director power determine legislation medium available website article association available website article amend special resolution member financial report director exercise company power provide company publish annual report shareholder article applicable legislation stipulate need detail annual report summary power exercise member document available website date rule appointment replacement director publication summary send shareholder shareholder contain article provide director elect receive annual report contact registrar appoint ordinary resolution member resolution alternatively shareholder elect receive notification director provide instance director email publication financial report register appoint way retire agm follow wwwshareviewcouk appointment copy previous financial report available website article provide director normally subject print copy obtain registrar reelection agm interval year annually gsk response center usa page hold office continuous period year contact detail board agree director wish continue member board seek reelection donation political organisation annually accordance corporate governance code political expenditure member remove director pass ordinary resolution special notice give pass special effect january ensure consistent approach resolution political contribution group introduce global policy stop voluntarily corporate political contribution director automatically cease director period january december bankrupt compound group political donation noneu creditor generally organisation cease director virtue company notwithstanding introduction policy accordance act article federal election campaign act usa continue suffer mental physical ill health support employeeoperate political action committee pac board resolve shall cease director facilitate voluntary political donation eligible gsk employee miss director meeting continuous period month permission board pac control gsk decision amount resolve shall cease director recipient contribution participate employee exercise legal right pool resource prohibit director law political contribution subject strict limitation resign total donate political organisation gsk employee pac offer resign board accept offer agm shareholder authorise director number require company donation political organisation resign incur political expenditure provision political party election referendum act year authority renew annually company act require company continue obtain shareholder approval donation political organisation incur political expenditure intend donation political party independent election candidate donation political organisation incur political expenditure gsk annual report strategic report governance remuneration financial statement investor information director conflict interest law regulation director duty company act avoid number provision law regulation apply situation direct indirect company share quote new york stock conflict interest possible conflict company duty exchange nyse form adss apply particular exploitation property information opportunity company advantage nyse rule article provide general power board authorise general nyse rules permit company follow conflict corporate governance practice instead apply usa provide explain significant variation nomination committee authorise board explanation contain form access grant periodically event annually review security exchange commission sec edgar potential actual conflict authorisation director database website nyse rule come effect count quorum authorisation actual require file annual interim write affirmation potential conflict authorisation grant record concern audit risk committee statement company secretary register note board significant difference corporate governance ongoing basis director responsible informing sarbanesoxley act company secretary new actual potential conflict follow number corporate accounting scandal arise change circumstance usa congress pass sarbanesoxley act affect authorisation previously give provide sarbanesoxley wideranging piece legislation concern authorisation director absolve largely financial report corporate governance statutory duty promote success company actual conflict arise postauthorisation board choose recommend sec company establish exclude director receipt relevant information disclosure committee committee report ceo participation debate suspend director cfo audit risk committee chair board resort require director resign company secretary member consist senior manager finance legal corporate communication investor nomination committee review register potential relation conflict authorisation october report board conflict appropriately authorise external legal counsel external auditor internal expert process authorisation continue operate effectively invite attend meeting periodically responsibility describe note financial statement relate party consider materiality information timely basis transaction end financial year director determine disclosure information responsibility connect person material interest contract timely filing report sec formal review significance group company annual report form committee meet time independent advice board recognise occasion sarbanesoxley require annual report form director feel necessary independent legal contain statement member audit risk andor financial advice company expense committee arc audit committee financial expert define agree procedure set website enable sarbanesoxley statement relevant member arc stacey cartwright judy lewent tom swaan include audit risk committee report indemnification director biography page additional qualifying party indemnity provision define disclosure requirement arise section section company act force benefit director sarbanesoxley respect disclosure control director hold office signing procedure internal control financial report annual report change control essential contract contract arrangement individually fundamental ability business operate effectively company party material agreement effect altered terminate change control follow takeover bid agreement director provide compensation loss office employment result takeover provision company share plan cause option award grant plan vest takeover detail termination provision company framework contract executive director give page gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue section corporate responsibility financial report management conduct evaluation effectiveness sarbanesoxley introduce requirement ceo internal control financial reporting base framework cfo complete formal certification confirm internal control integrate framework issue committee sponsor organisation treadway review annual report form commission coso base knowledge annual report form change group internal control contain material misstatement omission financial reporting materially affect base knowledge financial statement reasonably likely affect materially group internal financial information fairly present material respect control financial report financial condition result operation cash flow management assess effectiveness internal control date period present annual report financial reporting december form conclusion file group form responsible establish maintain disclosure pricewaterhousecooper llp audit consolidated control procedure ensure material information financial statement group year end december known evaluated effectiveness assess effectiveness group internal control procedure yearend result control financial reporting auditing standard evaluation contain annual report public company accounting oversight board united states form audit report file group form responsible establish maintain internal section securities exchange act control financial reporting provide reasonable section securities exchange act assurance reliability financial reporting amend require issuer specific disclosure annual preparation financial statement external purpose report certain type dealing iran include transaction accordance generally accept accounting principle dealing governmentowne entity dealing entity sanction activity relate terrorism proliferation disclose annual report form weapons mass destruction activity change internal control financial reporting prohibit law involve person group period cover annual report form legal entity base iran export certain materially affect reasonably likely affect materially pharmaceutical vaccine product iran sale nonus company internal control financial reporting entity privately hold iranian distributor group disclose base recent evaluation internal business nonus entity jurisdiction target control financial report external auditor sanction law include syria crimea north korea sudan arc significant deficiency material weakness believe group direct dealing iran design operation internal control financial reporting require specific disclosure requirement group reasonably likely affect adversely company limit sale iran north korea syria sudan cuba essential ability record process summarise report financial medicine determine criterion set world health information fraud regardless materiality involve organization group direct knowledge identity person significant role company internal distributor downstream customer iran possible control financial reporting customer include entity governmentowne group carry evaluation supervision hospital pharmacy own control directly participation management include ceo indirectly iranian government person entity cfo effectiveness design operation sanction connection terrorism proliferation activity group disclosure control procedure group direct knowledge distributor december customer establish proportion gross revenue sale potentially attributable entity affiliate iranian inherent limitation effectiveness system government party sanction disclosable activity disclosure control procedure include possibility result group report entire gross revenue million human error circumvention override control net loss million group sale iran procedure accordingly effective disclosure control procedure provide reasonable assurance group aware hospital medical achieve control objective facility lebanon affiliate control hezbollah designate united states terrorist organization ceo cfo expect complete certification group deal directly facility sell report conclusion effectiveness disclosure control distributor group unable identify procedure february follow certificate certainty degree nature affiliation end customer file sec group form hezbollah group unable establish proportion section management annual report internal control gross revenue sale potentially attributable reportable financial reporting entity result group report entire gross revenue accordance requirement section sarbane million net profit million group sale oxley follow report provide management respect lebanon company internal control financial reporting define rule securities exchange act management responsible establish maintain adequate internal control financial reporting group internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance ifrs gsk annual report strategic report governance remuneration financial statement investor information shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance wwwshareviewcouk tel tel outside equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend drip election form drip choose reinvest dividend buy gsk download share wwwshareviewcouk request telephone equiniti dividend payment direct bank currently receive dividend cheque dividend bank mandate form account bank mandate post instead pay directly download bank building society account quick wwwshareviewcouk secure avoid risk cheque go astray request telephone equiniti dividend payment direct instead wait sterling cheque arrive post details service bank account overseas shareholder equiniti convert dividend local currency cost involve contact equiniti send direct local bank account service available country worldwide electronic communication shareholder elect receive electronic notification register company communication include annual report wwwshareviewcouk dividend payment pay way bank mandate access electronic tax voucher availability online vote general meeting time gsk mail hard copy shareholder document receive email contain link document relevant website shareview service enable create free online portfolio view register share balance movement update address wwwshareviewcouk dividend payment instruction register vote agm duplicate publication mailing receive duplicate copy report contact equiniti mailing contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificated internet transaction log note market trading hour form hold corporate sponsor nominee wwwshareviewcoukdeale time internet telephone postal dealing service provide telephone transaction monday friday exclude public equiniti financial services limit holiday outside postal transaction request deal form corporate sponsor nominee account convenient way manage share application form download require share certificate service provide facility hold share nominee company wwwshareviewcouk sponsor company continue receive request telephone equiniti dividend payment annual report attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service detail available limited provide gsk corporate isa hold gsk wwwshareviewcouk ordinary share request telephone equiniti line open monday friday public holiday call number charge minute plus network extras provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue adr depositary contact investor relation adr programme administer bank new york mellon investor relation contact follow bny mellon shareowner services great west road box brentford middlesex college station tel overnight correspondence send usa bny mellon shareowner service crescent drive quality circle suite philadelphia college station tel toll free wwwmybnymdrcom tel outside usa tel toll free tel outside usa gsk response center email shrrelationscpushareownerservicescom tel toll free depositary provide global buydirect direct ad share scam alert purchasesale dividend reinvestment plan adr holder receive unsolicited telephone offering sell buy detail enrol visit wwwmybnymdrcom share extra care caller helpline number obtain enrolment pack highly organise financial scam glaxo wellcome smithkline beecham shareholder contact financial conduct corporate pep authority information similar activity share centre limit wwwfcaorgukconsumer consumer helpline oxford house oxford road aylesbury buck tel tel line open time wwwsharecom monday friday public holiday donate share save child responsible business supplement gsk embark ambitious global partnership publish responsible business supplement save child share expertise resource online outline gsk approach performance aim help save live million child key responsible business area health behaviour people planet shareholder small number share value make uneconomical sell wish consider donate save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidence title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc corporate integrity agreement cia company enter settlement federal government relate past sale marketing practice settlement company enter corporate integrity agreement department health human service improvement build exist compliance programme currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance code gsk annual report strategic report governance remuneration financial statement investor information index accounting principle policy latestage pipeline summary acquisition disposal legal proceeding adjustment reconcile profit tax operating longterm incentive plan cash flow major restructuring cost annual general meeting movement equity asset hold sale net debt associate joint venture new accounting requirement cash cash equivalent nonexecutive director fee ceos statement note financial statement chairman statement operate profit commitment intangible asset committee report investment competition noncurrent asset consolidate balance sheet noncurrent liability consolidate cash flow statement operating income consolidate income statement provision consolidate statement change equity board consolidate statement comprehensive income business consumer healthcare product competition people contingent liability strategy priority corporate executive team outlook corporate governance pension postemployment benefit critical accounting policy pharmaceutical product competition director senior management intellectual property director interest share pipeline director statement responsibility presentation financial statement dividend principal group company donation political organisation property plant equipment political expenditure propose novartis transaction earning share quarterly trend employee cost reconciliation net cash flow movement net debt employee share scheme registrar exchange rate relate party transaction executive director remuneration relation shareholder finance expense remuneration policy report finance income remuneration report financial instrument relate disclosure research development financial position resource responsible business financial statement glaxosmithkline plc prepare risk factor gaap segment information year record share capital control glossary term share capital share premium account goodwill share price group financial review shareholder information independent auditor report taxation inventory tax information shareholder investment associate joint ventures remuneration committee investor relation trade payable key accounting judgement estimate trade receivable key performance indicator law regulation gsk annual report gsk annual report strategic report governance remuneration financial statement investor information gsk glaxosmithkline plc incorporate notice limitation director liability english law english public limited company december company act safe harbour limit liability director respect statement form merger omission director report strategic report remuneration report glaxo wellcome plc smithkline beecham english law director liable company party plc gsk acquire english company report contain error result recklessness know misstatement dishonest concealment december merger material fact liable page inclusive comprise arrangement director report page inclusive comprise strategic report page inclusive comprise remuneration report draw present accordance reliance english company law liabilitie director share list london stock connection report shall subject limitation restriction provide law exchange new york stock exchange website gsk website wwwgskcom give additional information group notwithstanding reference read wwwgskcom annual report gsk website information available website constitute annual report shall deem incorporate reference cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future find downloadable pdfs operate financial performance particular include statement relate future action prospective annual report product product approval future performance result current anticipate product sale effort annual summary expense outcome contingency legal proceeding financial result accordance legal regulatory obligation include form list rule disclosure transparency rule financial conduct authority group responsible business supplement undertake obligation update forwardlooke statement result new information future event reader consult additional disclosure group document publish andor file sec reader locate note disclosure accordingly assurance give particular expectation meet shareholder caution place undue reliance forward look statement forwardlooke statement subject assumption inherent risk uncertaintie relate brand name factor group control precise brand name appear italic report estimate group caution investor number trade mark own andor license gsk important factor include document associate company exception boniva cause actual result differ materially express bonviva trade mark roche nicoderm trade imply forwardlooke statement factor mark johnson johnson merrell novartis sanofi include limited discuss risk glaxosmithkline potiga trade mark valeant prolia factor page annual report xgeva trade mark amgen vesicare trade mark forwardlooke statement behalf astella pharmaceutical country group speak date yamanouchi pharmaceutical certain country volibris base knowledge information available trade mark gilead xyzal trade mark ucb gsk director date annual report zyrtec trade mark ucb gsk certain country licence group number adjust measure report performance business measure define acknowledgement reconciliation core result total result set design salterbaxter information document constitute offer sell invitation buy share glaxosmithkline printing plc invitation inducement engage print pureprint group iso investment activity past performance rely fsc certify carbonneutral guide future performance annual report construe profit forecast paper annual report print amadeus silk recycle paper fsc certification pulp deinked postconsumer waste elemental chlorine free manufacturing mill hold iso ecolabel certificate environmental management gsk annual report doctor like kaali picture frontline malaria work ghana treat child malaria educates family prevent disease partner commit fight malaria front improve access medicine encourage use preventative tool like bed net search new treatment develop potential vaccine head office register office wwwgskcom glaxosmithkline plc great west road brentford middlesex search united kingdom tel register number